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The anaplastic lymphoma kinase (ALK) is a single chain transmembrane receptor tyrosine 
kinase that belongs to the insulin receptor superfamily. Other members of this superfamily 
include the insulin receptor (IR), type I insulin-like growth factor receptor (IGF-IR), and the 
leukocyte tyrosine kinase. The common structural finding among these tyrosine kinases is the 
YXXXYY motif present within their respective tyrosine kinase domains. Binding of its 
ligands causes ALK receptor homodimerization and protein kinase activation. ALK has been 
previously shown to play a significant role during early developmental stages. In human 
embryos, the expression of ALK is mainly seen in the nervous system but it decreases at 
birth. A variety of structural rearrangements have been identified in the ALK gene, such as 
mutations, overexpression, and translocations, often leading to the production of oncogenic 
proteins found in several different types of human cancers, such as nucleophosmin-anaplastic 
lymphoma kinase-expressing anaplastic large-cell lymphoma (NPM-ALK+ ALCL). The 
oncogenic potential of NPM-ALK has been demonstrated by several studies using in vitro 
assays as well as transgenic mouse models. 
NPM-ALK+ ALCL is an aggressive subset of T-cell lymphoma that predominantly occurs 
in children and young adults. It comprises approximately 85% of ALK+ ALCL cases and is 
characterized by the translocation t(2;5)(p23;q35) that leads to the fusion between the NPM 
gene on chromosome 5q35 and the ALK gene on chromosome 2p23 generating the NPM-
ALK oncogene, which encodes the expression of NPM-ALK chimeric tyrosine kinase. NPM-
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ALK induces lymphomagenic effects through the formation of the constitutively activated 
NPM-ALK/NPM-ALK homodimers, which phosphorylate/activate downstream survival-
promoting proteins including JAK/STAT, PI3K/AKT, and MAP kinase. NPM-ALK resides 
in the cytoplasm; nonetheless, it is also capable of forming the wild type NPM/NPM-ALK 
heterodimers that translocate to the nucleus through the nuclear localization signal site 
present in wild type NPM.  
IGF-IR is a homodimeric protein that is composed of two extracellular α and two 
transmembranous β subunits connected by disulfide bonds. Similar to ALK, its expression 
plays an important role during early developmental stages. Mouse models have confirmed 
the importance of IGF-IR in prenatal and postnatal growth through its interactions with the 
growth hormone. The result of activation of IGF-IR during these stages is survival and 
proliferation of cells resulting in developmental growth of tissues such as skeletal and cardiac 
muscles. It also plays a critical role during growth of the mammary gland during pregnancy 
and lactation. It has been previously shown that Igf1r null mice develop generalized organ 
hypoplasia, such as developmental delays in bone ossification, abnormalities in the central 
nervous system, and they prematurely die because of underdevelopment of their lungs that 
leads to respiratory failure. Recently, it has been shown that IGF-IR overexpression 
significantly contributes to the establishment and progression of different types of cancer and 
to the emergence of therapeutic resistance. These effects have been extensively investigated 
in solid tumors including breast, prostate, lung, ovary, skin, and soft tissue cancers.  
We have recently demonstrated that, compared with normal human T lymphocytes and 
reactive lymphoid tissues, the expression and activation of IGF-IR are remarkably 
upregulated in NPM-ALK+ ALCL. We also demonstrated that IGF-IR physically associates 
and directly interacts with NPM-ALK. Nonetheless, the exact mechanisms for the up-
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regulation of IGF-IR and NPM-ALK in this lymphoma are not fully characterized. We 
hypothesized that multilevel deregulation of survival mechanisms contributes to aberrant 
NPM-ALK and IGF-IR expression, which supports the survival and progression of NPM-
ALK+ ALCL.  
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1.1. NPM-ALK+ T-cell anaplastic large cell lymphoma  
Anaplastic large cell lymphoma (ALCL) is a high-grade non-Hodgkin’s T-cell lymphoma 
that was originally described as universally expressing the tumor necrosis factor receptor 
CD30/Ki-1 [1, 2]. Morphological features typically include large anaplastic cells with 
abundant cytoplasm and distinct, often “horse-shoe” shaped, nuclei [3]. However, it is agreed 
now that ALCL is a misnomer as it is not unusual for this lymphoma to represent in the form 
of small lymphoma cells without notable anaplastic features. ALCL constitutes 3 to 5% of 
adult malignant lymphomas and comprises 10 to 30% of malignant lymphomas in children 
and young adults [3, 4]. The lymphoma is slightly more predominant in males. ALCL usually 
presents as a widespread stage III/IV neoplasm, with a rapidly progressive course. It is 
considered an aggressive type of lymphoma because patients typically present with B 
symptoms (fever, weight loss, and night sweats), generalized lymphadenopathy, and frequent 
extranodal involvement [1].  
Approximately 60-80% of ALCL cases harbor an aberration involving the anaplastic 
lymphoma kinase (ALK) gene that encodes the expression of the ALK protein (ALK+ 
ALCL). The expression of ALK holds prognostic significance as ALK- ALCL patients show 
a much reduced 5-year survival rate compared to ALK+ ALCL patients [5, 6]. Although 
several chromosomal translocations involving ALK have been identified in ALK+ ALCL, 
approximately 85% of these lymphomas are characterized by the translocation 
t(2;5)(p23;q35) that generates the fusion between the NPM gene on chromosome 5q35 to the 
ALK gene on 2p23 that forms the oncogenic fusion protein NPM-ALK, which is the defining 
feature of NPM-ALK+ ALCL [1, 5-8]. Because NPM-ALK expression is the most common 
and because cell lines have been developed only from the NPM-ALK+ variant, in this work 
we will refer to this lymphoma as NPM-ALK+ ALCL. 
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First-line treatment using doxorubicin-based polychemotherapy is encouraging in some 
cases, in which 60-80% of NPM-ALK+ ALCL patients initially respond favorably, with a 5-
year relapse-free survival of 60%, and a 5-year overall survival of 70% [9, 10]. 
Anthracycline-based chemotherapy regimens, including CHOP (cyclophosphamide, 
doxorubicin, vincristine, and prednisone), have also provided favorable results. Radiation or 
stem cell transplantation in combination with CHOP is oftentimes utilized in more advanced 
cases, in which large localized masses are found [9, 10]. However, as many as 40% of these 
patients relapse, develop resistance, and eventually die, suggesting the need for specific and 
more effective therapeutics. Recently, selective ALK inhibitors have been developed; 
nonetheless, most of these inhibitors have been tested in solid tumors, with the majority 
being in lung cancer patients [11-14]. Notably, mutations of ALK have quickly developed in 
some of the NPM-ALK+ ALCL patients that were treated with such inhibitors, indicating that 
the battle against this aggressive lymphoma is far from over [15, 16]. 
1.2. NPM   
1.2.1. Roles of NPM: NPM is a ubiquitously expressed RNA-binding nucleolar 
phosphoprotein that is encoded by chromosome 5q35. It is believed to be involved in 
regulating numerous processes that leads to maintaining cellular homeostasis. For instance, it 
is involved in the transport of pre-ribosomal particles during ribosome biogenesis, response 
to stress stimuli such as UV irradiation and hypoxia, the maintenance of genomic stability 
through the control of chromosome segregation, and DNA-repair processes. Furthermore, it 
is highly involved in gene transcription where it regulates chromatin condensation and 
decondensation events [17]. 
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1.2.2. Structure of NPM:  NPM protein has a molecular weight of approximately 38 kDa. The 
numerous functions of NPM are largely attributed to the diversity of its structural 
characteristics (Figure 1). The N-terminus contains a hydrophobic segment that is essential 
for oligomerization and chaperone activity. Immediately following this segment are two 
acidic stretches that are important for binding histones during DNA transcription processes 
[17-19]. The ribonuclease activity stems from the middle portion of NPM, the region 
between the two acidic domains. Finally, the C-terminal domain contains segments 
comprising basic amino acids that are important for nucleic-acid binding. These basic regions 
are followed by aromatic stretches, which house two tryptophan residues (288 and 290) 
located within the nuclear-localization signal (NLS) that are required for nuclear localization 
of the protein [17, 20]. In addition, NPM includes a nuclear-export signal (NES) that 
mediates NPM’s ability to shuttle from the nucleus [21].  
 
 
 
 
 
 
 
 
 
5 
 
 
 
 
 
 
 
 
 
 
 
6 
 
 
 
 
 
 
FIGURE 1. Structure of NPM. Starting from the N-terminus, the protein contains one 
hydrophobic segment that is involved in oligomerization as well as chaperone activity, 
followed by two acidic stretches that are important for binding to histones. The central 
portion between the two acidic domains is required for ribonuclease activity, together with 
the C-terminus domain, which contains basic regions involved in nucleic-acid binding. The 
basic clusters are followed by an aromatic stretch, which contains two tryptophan residues 
(288 and 290) that are required for nucleolar localization of the protein. In addition, NPM 
includes a nuclear-localization signal (NLS) and a nuclear-export signal (NES). Adapted 
with permission from Macmillan Publishers Ltd on behalf of Cancer Research UK: 
[Nature Reviews Cancer] (Grisendi S, Mecucci C, Falini B, Pandolfi PP. 
Nucleophosmin and cancer. Nat Rev Cancer. 2006 Jul;6(7):493-505.), copyright 2006. 
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1.3. ALK 
1.3.1. Role of ALK: Physiologically, the expression of ALK is largely restricted to neuronal 
tissues at early developmental stages, as indicated by the high expression of ALK mRNA in 
the central nervous system (CNS) during mouse embryogenesis [22-24]. ALK expression 
diminishes after birth, reaching minimal levels at 3 weeks of age, and subsequently 
maintained at low levels during adult stages [22]. Based on these observations, it is believed 
that ALK is a critical regulator of neuronal development and function of the CNS. For 
example, it has been demonstrated that the ALK–IgG Fc hybrid protein, in which the 
extracellular region of ALK is substituted with the mouse IgG Fc domain, induces neurite 
differentiation and outgrowth of PC12 cells, mediated through the MAPK pathway [25]. In 
addition, it has also been demonstrated that specific antibody-mediated inhibition of ALK 
leads to prevention of the binding of the Src homology and collagen domain protein (Shc) to 
ALK, which causes subsequent MAPK inactivation and decreased neuronal differentiation. 
Similarly, inhibition of the ALK-activated MAPK pathway decreases neurite outgrowth, 
further strengthening the idea that neuronal differentiation induced by ALK is mediated via 
the MAPK pathway [26, 27]. In addition to Shc, the fibroblast growth factor receptor 
substrate 2 (FRS2) has also been reported to be recruited to a novel non-consensus 
phosphotyrosine site within ALK and contributes to ALK-induced neuronal differentiation 
[27].  
1.3.2. Structure of ALK: ALK is a receptor tyrosine kinase whose structure is highly 
conserved within species, as well as within members of the insulin receptor superfamily, 
especially in regards to their kinase domains. The common structural finding among these 
tyrosine kinases is the YXXXYY (indicating a tyrosine (Y), followed by 3 non-tyrosine 
amino acid residues, and then 2 additional tyrosine residues) motif present within their 
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respective tyrosine kinase domains. It has been reported that the first tyrosine residue 
(Tyr1278) within the YXXXYY motif is the principal site to become phosphorylated during the 
autoactivation process of ALK [28, 29]. 
The ALK gene is located on chromosome 2p23 that encodes for a single chain 
transmembrane receptor tyrosine kinase of 180 kDa (Figure 2). The extracellular portion of 
ALK contains an N-terminal signal peptide followed by two MAM domains (meprin, A5 
protein and receptor tyrosine phosphatase mu) that flank one LDLa domain (low-density 
lipoprotein class A), followed by a glycine rich (G-rich) region. The N-terminus region is 
capable of undergoing N-linked glycosylation, which increases the molecular weight of ALK 
by 20kDa. Although the precise function of the LDLa domain is unknown, it has been 
proposed as the ligand binding domain. Similarly, the function of the MAM domains remains 
to be identified, however, they are thought to be involved in cell-to-cell interactions [30]. In 
addition, the G-rich domains are believed to be required for ALK function, as point 
mutations within this region render loss of ALK function [31]. The intracellular domain 
(ICD) consists of a transmembrane (TM)-spanning segment that essentially connects the 
extracellular region to the PTK domain; the ICD also contains ATP binding sites and putative 
binding sites for various interacting proteins including insulin receptor substrate 1 (IRS-1), 
Shc, phosphoinositide 3-kinase (PI3K) and phosphoinositide phospholipase C-gamma (PLC-
γ) distributed throughout [22, 23, 32].  
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FIGURE 2. Structure of human ALK. The N-terminal region of ALK comprises two 
MAM domains (amino acids 264–427 and 480–626), one LDLa domain (amino acids 453–
471), and a glycine rich (G-rich) region (amino acids 816–940). A transmembrane (TM)-
spanning segment connects the extracellular region with the protein tyrosine kinase domain -
containing intracellular region (amino acids 1116–1383). Adapted with permission from 
PMC [Biochemical Journal] (Palmer RH, Vernersson E, Grabbe C, Hallberg B. 
Anaplastic lymphoma kinase:signalling in development and disease. Biochem J. 2009 
May 27;420(3):345-61.), copyright 2009.  
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1.3.3. ALK and disease: Alterations involving ALK have been implicated in various diseases, 
with the initial discovery of the NPM-ALK fusion protein in NPM-ALK+ ALCL in 1994 [33, 
34]. In addition to NPM-ALK, other ALK fusion proteins have been identified in ALCL, 
inflammatory myofibroblastic tumors, non-small cell lung cancer, diffuse large B-cell 
lymphoma, and squamous cell carcinoma [35-38]. Recently, overexpression of ALK has 
been reported to play a role in malignant transformation of cell lines and tumors, as well as 
activating point mutations in ALK, as in the case of neuroblastoma [39-49]. 
1.4. NPM-ALK  
1.4.1. NPM-ALK structure and function: The most distinguishable feature in NPM-ALK+ 
ALCL is the presence of the translocation t(2;5)(p23;q35) that generates the fusion between 
the NPM gene on chromosome 5q35 to the ALK gene on 2p23 to form the chimeric oncogene 
NPM-ALK, that encodes for NPM-ALK fusion protein [7] (Figure 3; upper panel). The 
t(2;5)(p23;q35) translocation juxtaposes the N-terminal domain of the NPM gene (amino 
acids 1-117) to the C-terminal domain of the ALK gene that codes for the entire cytoplasmic 
region of the ALK protein. As a consequence, the ALK gene is under the control of the highly 
active NPM promoter, which induces continual transcription of NPM-ALK gene and results 
in the silencing of the ALK regulatory and promoter regions that normally suppress ALK 
expression in normal lymphocytes. This leads to the constitutive activation of the NPM-ALK 
protein because the oligomerization domain of NPM and activation of the kinase catalytic 
domain of ALK are preserved.  
Because the truncation of NPM during the translocation does not conserve its C-terminal 
domain, the nuclear localization signals are absent in the chimeric protein. Similarly, the 
extracellular and transmembrane regions of ALK are also not present, thereby rendering 
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ALK entirely cytoplasmic. The NPM-ALK protein is able to form homodimers with other 
NPM-ALK moieties or heterodimers by cross-linking with wild-type NPM. The formation of 
homodimers results in the constitutive activation of the ALK tyrosine kinase domain 
contained in the NPM-ALK fusion protein and the induction of downstream signaling via the 
JAK/STAT3, MEK/ERK1/2, or the PI3K/AKT pathways (detailed in section 1.4.2). The 
NPM/NPM-ALK heterodimers, on the other hand, translocate to the nucleus, primarily from 
the ability of wild type NPM to translocate to the nucleus (Figure 3; lower panel). There is 
considerable evidence suggesting that the nuclear localization of NPM-ALK is not required 
for the development of lymphoma, and therefore, the biological consequences of nuclear 
localization of NPM-ALK are not known [50, 51]. However, the importance of NPM in the 
transforming abilities of NPM-ALK has been demonstrated through experiments in which 
deletion of the NPM portion of the fusion protein abolishes transformation events; the 
process of dimerization through NPM oligomerization domain essentially mimics ligand 
binding and therefore, gives NPM-ALK its transforming abilities [52].  
The oncogenic properties of NPM-ALK have been demonstrated in vitro in a variety of 
cell types, such as mouse NIH-3T3 and Fr3T3, as well as Rat-1 cells, and several 
hematopoietic cell lines such as the myeloid line 32Dcl3 and the lymphocytic cell line Ba/F3 
[50-54]. Transformation occurs in primary mouse bone marrow cells retrovirally transduced 
with NPM-ALK, which was reversed upon treatment with PI3K inhibitors [54]. In addition, 
cells transfected with NPM-ALK are able to grow colonies in soft-agar, providing further 
support for the transforming abilities of NPM-ALK. These properties have also been 
demonstrated in vivo. For example, bone marrow expressing human NPM-ALK is able to 
induce lymphoid malignancies in lethally irradiated mice [53, 55]. Furthermore, transgenic 
mice expressing NPM-ALK under the control of the CD4 promoter develop CD30+ NPM-
13 
 
ALK+ T-cell lymphoma [56]. Of important note is that in all NPM-ALK transgenic mouse 
models, significant numbers of tumors were plasma cell or B-cell neoplasms, strongly 
suggesting that NPM-ALK is not the only factor contributing to the immunophenotypic, 
pathophysiological, and clinical features as known in humans. 
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FIGURE 3. The t(2;5)(p23;q35) translocation resulting in NPM-ALK fusion protein. 
Upper panel, the t(2;5)(p23;q35) translocation juxtaposes the N-terminal domain of the NPM 
gene (amino acids 1-117) to the C-terminal domain of the ALK gene that encodes the entire 
cytoplasmic region of the ALK protein. The NPM-ALK fusion protein retains the 
oligomerization domain with the metal binding region of NPM and the tyrosine kinase 
domain and the cytoplasmic tail of ALK. Reprinted from Anaplastic Lymphoma Kinase: 
Role in specific tumours, and development of small molecule inhibitors for cancer 
therapy: Ardini E, Magnaghi P, Orsini P, Galvani A, Menichincheri M. Anaplastic 
Lymphoma Kinase: role in specific tumours, and development of small molecule 
inhibitors for cancer therapy. Cancer Lett. 2010 Dec 28;299(2):81-94., with permission 
from Elsevier. Lower panel, NPM-ALK is able to form homodimers with other NPM-ALK 
moieties in the cytoplasm as well as heterodimers with wild type NPM that allow ALK to 
translocate to the nucleus. 
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1.4.2. NPM-ALK signaling: The predominant signaling system in the cell survival 
mechanisms maintained by NPM-ALK is the signal transducer and activator of transcription 
3 (STAT3) pathway either through Janus kinase-3 (JAK3)-dependent or independent 
mechanisms [57-59]. NPM-ALK can directly phosphorylate STAT3 [60, 61] and/or activate 
JAK3, which subsequently activates STAT3 [62] (Figure 4). Under normal circumstances, 
the SH2-containing ubiquitously expressed tyrosine-specific protein phosphatase-1 (SHP1) 
functions to inhibit ALK-mediated signaling by dephosphorylating ALK or its interacting 
proteins, namely Src and JAK. In NPM-ALK+ ALCL, SHP1 is methylated, and therefore 
loses its expression, resulting in the enhancement of STAT3 signaling. Phosphorylated 
STAT3, in turn, translocates to the nucleus and up-regulates the expression of molecules 
involved in anti-apoptotic mechanisms such as B cell leukemia/lymphoma 2 (Bcl-2), Bcl-xL, 
and myeloid cell leukemia sequence 1 (Mcl-1), or key cell cycle regulators such as survivin, 
cyclin D3, and C/EBPβ [58, 63, 64]. We have also demonstrated previously that STAT3 
plays a direct role in upregulating the tissue inhibitor of metalloproteinase-1 (TIMP1) in 
ALK+ ALCL, and that expression of TIMP1 is associated with high level of STAT3 
activation in this disease [65]. Also, there has been evidence that STAT5, particularly 
STAT5b, may act promote survival in NPM-ALK+ ALCL through the activation of JAK2 
[66, 67]. In vitro and in vivo studies using anti-STAT5b inhibitors resulted in impairment of 
NPM-ALK-induced cell transformation by inducing apoptosis. In contrast, it has also been 
shown that STAT5a is epigenetically silenced in this lymphoma [68]. In this regard, STAT5a 
acts as a tumor suppressor by reciprocally inhibiting NPM-ALK expression. 
NPM-ALK also exerts proliferation signals through the activation of Ras, Raf-1, 
MEK1/2, and ERK1/2 by the direct binding of IRS-1, Src, and Shc to the autophosphorylated 
tyrosine residues located in the substrate-binding domain of ALK [7, 52] (Figure 4). This 
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induces the interaction between the SHP2-Grb2 (growth factor receptor-bound protein 2) and 
the ALK/Shc complex, which in turn enhances the phosphorylation of ERK1 and ERK2 
through Src. Phosphorylation of ERK1 and ERK2 leads to the phosphorylation of the 
mammalian target of rapamycin (mTOR), which stimulates protein translation, ribosome 
biogenesis, and cap-dependent translation of mRNA [69]. In addition, NPM-ALK 
phosphorylates JUN N-terminal kinase (JNK) that up-regulates the activity of certain 
oncogenic transcription factors, such as AP1, which leads to uncontrolled proliferation due to 
repression of p21 and subsequent upregulation of cyclins [70]. Lastly, PLC-γ directly binds 
to ALK, catalyzes the conversion of diacylglycerol and inositol triphosphate, triggering the 
release of Ca2+ from the endoplasmic reticulum (ER) to activate protein kinase C, leading to 
cell cycle progression [54].  
Survival signaling can also occur through the PI3K/AKT pathway primarily by eliciting 
anti-apoptotic signals by NPM-ALK (Figure 4). NPM-ALK activates PI3K, which in turn 
activates the serine/threonine kinase, AKT, and results in the enhancement of survival signals 
by phosphorylating the cyclin-dependent kinase inhibitor p27 and increasing its proteosomal 
degradation [71]. Activation of AKT also results in inhibition of the function of pro-apoptotic 
proteins such as Bcl-2 antagonist of cell death (BAD) [72]. Concurrently, activated AKT 
phosphorylates and deactivates the FOXO3a transcription factor, which sustains FOXO3a in 
the cytoplasm, preventing its translocation to the nucleus and subsequent transcription of pro-
apoptotic and cell cycle inhibitory genes [73]. This also leads to upregulation of cyclin D2, 
which is involved in G1-S cell cycle progression. Furthermore, mTOR is also activated by 
PI3K/AKT signaling through the induction of sonic hedgehog (SHH) expression. Binding of 
SHH to its receptor, Patched (PTCH), activates Smoothened (SMO) co-receptor by Patched, 
which results in activation of the GLI1 transcription factor and subsequently cyclin D2 [74]. 
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FIGURE 4. NPM-ALK and its downstream signaling pathways. The NPM-ALK fusion 
protein is aberrantly expressed and activates canonical signaling pathways, including 
Ras/Mek/Erk and PI3K/Akt cascades. The STAT3 signaling pathway has a central role in 
NPM-ALK–mediated transformation. Adapted from Pathobiology of ALK+ anaplastic 
large-cell lymphoma: Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell 
lymphoma. Blood.2007 Oct 1;110(7):2259-67., Copyright 2007, with direct permission 
from BLOOD. 
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1.5. Overview of the insulin-like growth factor system 
The insulin–like growth factor (IGF) system plays significant roles in both embryonic and 
postnatal development as well as important functions in normal adult physiology. The IGF 
system includes 4 receptors: insulin receptor (IR), type I insulin-like growth factor receptor 
(IGF-IR), IGF-IIR, and the hybrid receptors (HR) consisting of one-half IR and one-half 
IGF-IR. These receptors interact with at least three ligands: insulin, IGF-I, and IGF-II 
(Figure 5). The IR, IGF-IR, and IGF-IIR have strongest binding affinity for their respective 
ligand, whereas binding of insulin to IGF-IR and IGF-I to IR are approximately 100-fold 
less. IGF-I and IGF-II signaling is mediated through IGF-IR; however, IGF-I has a 4-5-fold 
higher binding affinity. The IGF system also includes 6 regulatory proteins known as IGF 
binding proteins that regulate IGF signaling [75].  
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FIGURE 5. Overview of IGF system. The IGF system consists of 4 receptors: IR, IGF-IR, 
IGF-IIR, and HR. These receptors interact with at least three ligands: insulin, IGF-1, and 
IGF-II. In addition, the IGF system also includes 6 regulatory proteins called IGF binding 
proteins that regulate IGF signaling. 
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1.6. IGF-I 
IGF-I is a single chain peptide that shares 62% homology with IGF-II and 40% homology 
with proinsulin [75]. Evidence shows that IGF-I is synthesized in a variety of tissues and 
cultured cell types, suggesting that the protein may have autocrine and paracrine effector 
functions, unlike insulin, which is stored within cells of a particular tissue (pancreas) and has 
mainly autocrine effects [76-80]. Liver secretion of IGF-I is regulated by the growth 
hormone (GH), which signals peripheral tissues to grow, whereas insulin is tightly regulated 
by glucose uptake [79, 81, 82]. Therefore, insulin is primarily associated with inducing 
metabolic effects, whereas IGF-I is essentially a growth factor and an anabolic agent.  
IGF-I is the primary ligand for IGF-IR. There is increasing evidence that IGF-I might 
provide a major link between IGF-IR and the development of cancers through its regulatory 
effects on normal cell proliferation, differentiation, and apoptosis. Although most cancers do 
not secrete IGF-I, high concentrations of circulating IGF-I in serum appear to contribute to 
the growth, maintenance, and progression of cancers of the breast, lung, and colon [83-87]. 
For example, previous studies have demonstrated that colonic epithelium in acromegalic 
patients is characterized by increased proliferation that is proportional to serum IGF-I levels 
[88]. Also, in vitro and in vivo experiments showed that prostate cancer is mitogenically 
responsive to IGF-I [84]. Several mouse models have shown reduced proliferation of 
androgen-dependent prostate cancer cells in IGF-I deficient hosts relative to control hosts, 
testifying to the strong mitogenic properties of IGF-I [89].  
IGF-I appears to tightly control both positive and negative regulators of the cell cycle 
primarily through the interaction with IGF-IR. It has been previously documented that IGF-I 
increases cell proliferation by amplifying DNA synthesis and upregulating cyclin D1 mRNA 
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expression, which allows entry into the S phase of the cell cycle. Using skeletal myoblasts, it 
was demonstrated that the early effects of IGF-I during cell cycle progression are associated 
with the stabilization of Rb1 phosphorylation, which is typical of proliferating cells. 
Subsequently, upregulation of CDK4 and cyclin D1 gene expression further maintains Rb1 
phosphorylation [83]. In another study using neocortical neural progenitor cells, in vitro 
addition of IGF-I induced rapid increase in cyclin D1 and cyclin D3. This led to a further 
increase in cyclin E, which also assists in the G1/S phase transition. Simultaneously, 
observed decrease in CDK inhibitors p27 and p57 suggested that downregulation of negative 
regulators of cell cycle also contributes to the mitogenesis induced by IGF-I. These effects 
were further demonstrated in vivo, where injection of IGF-I led to increased DNA synthesis 
and number of S phase cells, with simultaneous increase in phosphorylated/activated AKT, 
cyclin D1, and cyclin E [90]. Endogenous blockade of IGF-I with an anti-IGF-I antibody led 
to decreased DNA synthesis, upregulation of p27 and p57, as well as prevention of cyclin E 
mRNA expression. Interestingly, it has been demonstrated that the effects exerted by IGF-I 
are primarily induced through the PI3K/Akt pathway. Blocking this pathway, but not the 
MAPK/Erk pathway, inhibited the mitogenic potential of IGF-I [90]. These data suggest that 
the strong mitogenic potential of IGF-I is essentially mediated through IGF-IR.  
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1.7. IGF-IR  
1.7.1. IGF-IR structure and signaling: IGF-IR is a receptor tyrosine kinase consisting of two 
identical α subunits and two identical β subunits that are connected by disulfide bonds to 
form the functional homodimeric receptor complex. The α subunit is entirely extracellular 
and contains a cysteine rich domain that forms the primary binding site for its ligands IGF-I 
and, to a lesser affinity, IGF-II and insulin. The β subunit includes an extracellular domain, a 
24-residue hydrophobic transmembrane domain, and a larger cytoplasmic region that shares 
84% homology with the IR [91, 92]. Tyrosine 950 is the binding site for its substrates, IRS-1 
and Shc, among others. The intracellular region of the β subunit contains an ATP binding site 
at lysine 1003. It also contains a kinase domain encompassing the activation loop made up of 
three critical tyrosine residues at positions 1131, 1135, and 1136 (form part of the YXXXYY 
moiety), which become phosphorylated upon ligand binding. Residue 1136 is particularly 
important in that it maintains the conformational stability of the β subunit. The C-terminus 
domain contains several tyrosine and serine residues that are phosphorylated to probably 
induce mitogenic effects, but how they actually contribute to normal and malignant IGF-IR 
signaling is still not fully understood [92] (Figure 6). 
Binding of IGF-IR to its ligands causes the phosphorylation of tyrosine residues located 
in the intracellular portion of its β subunit. Once phosphorylated, tyrosine 950 provides a 
docking site for its substrates IRS-1-4 and Shc proteins. Upon substrate binding, downstream 
signaling is activated through PI3K/AKT, MAPK or STAT pathways and may stimulate 
cancer cell growth in an autocrine/paracrine manner [93-95] (Figure 7). 
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FIGURE 6. Structure of IGF-IR. IGF-IR is a transmembrane homodimeric receptor 
tyrosine kinase that is composed of two identical extracellular α subunits and two identical 
transmembranous β subunits connected by disulfide bridges. The α subunit contains a 
cysteine rich domain where the ligand binds. The cytoplasmic regions of the β subunits 
contain residues involved in the activation of IGF-IR. Y950 is the binding site for its primary 
substrates IRS-1 and Shc; K1003 is the ATP binding domain; and Y1131, Y1135, and Y1136 
make up the activation loop of the kinase domain, which is followed by the C-terminus.  
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FIGURE 7. IGF-IR signaling. Binding of IGF-IR to its ligands causes the phosphorylation 
of tyrosine residues present in the intracellular portion of its β subunit. Once phosphorylated, 
Y950 provides a docking site for its substrates IRS-1-4 and Shc domain protein. Upon 
substrate binding, downstream signaling is activated through PI3K/AKT, MAPK, or 
JAK/STAT pathways. Adapted from Kojima S, Inahara M, Suzuki H, Ichikawa T, 
Furuya Y. Implications of insulin-like growth factor-I for prostate cancer therapies. Int 
J Urol. 2009 Feb;16(2):161-7.  Copyright 2008 by JOHN WILEY AND SONS. 
Reproduced with permission of JOHN WILEY AND SONS in the format Dissertation 
via Copyright Clearance Center.  
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1.7.2. Physiological and pathological roles of IGF-IR: Mouse models have signified the 
importance of IGF-IR in prenatal and postnatal growth, especially in regards to genetic 
imprinting. The outcome of activation of IGF-IR during these stages is survival and 
proliferation of mitosis-competent cells resulting in growth of tissues such as skeletal and 
cardiac muscles [76, 80, 96-99]. IGF-IR also plays roles related to the growth of mammary 
gland during pregnancy and lactation. It has been previously shown that Igf1r null mice 
develop generalized organ hypoplasia, including developmental delays in bone ossification 
and abnormalities in the central nervous system [76, 80, 100-103]. During embryonic 
development, the IGF-IR pathway is also involved in the development of limb buds. Mice 
lacking the entire Igf1r gene typically exhibit dramatic reduction in body mass, testifying to 
the strong growth-promoting effect of this receptor, and they die at birth due to severe 
respiratory failure [100]. Mice carrying only one functional copy of Igf1r are normal, but 
demonstrate ~45% decrease in their body mass [100].  
Aberrant activation of the IGF-IR pathway is also strongly associated with initiating 
cancer growth [86, 93, 96, 104-115]. Evidence in the last 20 years has emerged to support 
that IGF-IR overexpression plays a significant role in the development and progression of 
tumors, metastatic potential, and resistance to therapies. Studies have shown that IGF-IR 
induces its oncogenic effects through the inhibition of apoptosis and induction of 
transformation, metastasis, and angiogenesis. Moreso, it has been documented that IGF-IR 
can induce ligand-independent tumor cell progression, a process that is highly reliant on the 
level of expression of IGF-IR that deems it as constitutively active. In other words, exceeding 
a certain threshold for IGF-IR expression results in the lack of need for exogenous ligand 
stimulation. For example, treatment of RM11A cells (a murine breast cancer cell line with 
high levels of IGF-IR) with exogenous IGF-I, IGF-II or serum did not enhance the 
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proliferative/survival advantage [116]. On the other hand, the ability of RM11A cells 
expressing low levels of IGF-IR to respond to IGF stimulation was found to be robust, most 
likely to be due to the activation of the endogenous murine IGF-IR. Therefore, it was 
proposed that high expression of IGF-IR results in constitutive activation of the IGF-IR 
independent of the presence of ligands [116]. In addition, autoactivation of IGF-IR, when 
expressed at sufficient levels, has previously been shown in cells lacking IGF-IR that have 
been transfected with different levels of IGF-IR [117]. Furthermore, IGF-IR regulates 
properties that cause the malignant cells to overcome anchorage-independent growth, 
allowing them to acquire characteristics directly relevant to enduring detachment and 
migration that are essential attributes for metastasis [118].  
It has been shown that the number of IGF-IR molecules present in cells plays a key role 
in its transforming properties [117, 119]. In fibroblasts, IGF-IR number needs to be greater 
than 20,000 receptors per cell to enable mitogenesis after stimulation with IGF-I. Similarly, 
in a pancreatic cell line, the observed increase in receptor number from 40,000 to 100,000 
receptors/cell is in the range required to enable IGF-I-stimulated growth and therefore may 
be of central importance for pancreatic tumor growth. Based on these findings, it is 
concluded that only a small increment in the number of receptors per cell can induce the 
transforming properties of IGF-IR in different types of tumors [117, 119].  
In solid tumors, some studies for the role of the IGF system have been performed using 
breast cancer cell lines, and found that one of the mechanisms that IGF-IR was activated both 
in vitro and in vivo was through IGF-I: 1) serum IGF-I may act as a stimulatory molecule to 
induce the proliferation of breast cancer cells in an endocrine manner and/or 2) stromal cells 
that surround the tumorigenic cells serve as a paracrine stimulator of the mitogenic signal 
[110, 120-123]. It has been demonstrated that there is hindrance of cell proliferation by 
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cancer cells when IGF-IR activation is inhibited. One possible mechanism is the lack of 
interaction of IGF-I with IGF-IR, which results in interrupting the signaling pathway. In 
prostate cancer, IGF-I is believed to directly stimulate the androgen receptor (AR) via 
crosstalk with IGF-IR on prostatic epithelial cells to induce its pathogenesis, progression, and 
metastasis [124]. Similarly, the oncogenic effects of IGF-IR are documented in colon cancer. 
IGF-IR is overexpressed in colon cancer, compared to normal colonic mucosa and IGFs in 
colonic malignant mucosa are shown to exert their effects via the IGF-IR only [88, 114].  
In contrast to the widely studied solid tumors, not many studies have been performed to 
examine the role of IGF-IR in hematological neoplasms, and most of the studies have 
focused on plasma cell myeloma [125, 126]. In addition, our lab has demonstrated the 
contributions of IGF-IR signaling to the pathogenesis of other hematological neoplasms 
including mantle cell lymphoma and chronic myeloid leukemia [127-130].  
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Rationale, Hypothesis, and Specific Aims 
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The scope of this project is to further current understanding of the pathobiology of NPM-
ALK+ ALCL. Our findings may provide a framework that could be useful to tailor novel 
selective and specific therapeutic strategies for NPM-ALK+ ALCL.  
There has been substantial evidence supporting the importance of NPM-ALK in the 
pathogenesis of NPM-ALK+ ALCL, highlighted in section 1.4.1. Oncogeneic effects are 
induced by NPM-ALK interaction with several proteins that regulate cell survival and growth 
[131]. Notably, the mechanisms leading to NPM-ALK overexpression and activation in this 
neoplasm are still unclear. In this regard, we have recently shown that NPM-ALK is post-
transcriptionally regulated by microRNA-96 [132]. 
Previous experiments performed in our lab demonstrated that IGF-IR is overexpressed in 
NPM-ALK+ ALCL cell lines and primary tumors than normal human T lymphocytes and 
reactive lymphoid tissues, which provide preliminary findings for this project [128] (Figure 
8). Moreover, we found that novel reciprocal functional interactions exist between IGF-IR 
and NPM-ALK. Our previous results suggest that the two kinases physically associate to 
maintain their tyrosine phosphorylation and kinase activation levels. We demonstrated that 
IGF-IR and NPM-ALK directly interact through a positive feedback loop that appears to 
exist between NPM-ALK and IGF-IR through specific tyrosine (Y) residues, Y644 or Y664, 
located within the C terminus of NPM-ALK that maintains NPM-ALK phosphorylation 
status. A single mutation within Y644 or Y664 that changes these residues to phenylalanine 
decreased substantially the association between IGF-IR and NPM-ALK and phosphorylation 
levels, although not entirely [128] (Figure 9). Generation of a double mutation, NPM-
ALKY644,664F, completely eliminated the association between IGF-IR and NPM-ALK, which 
provides strong evidence to support a direct role of IGF-IR in maintaining the 
phosphorylation status of NPM-ALK for the latter to subsequently activate/phosphorylate 
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downstream proteins [113]. In addition, we have shown that IGF-IR can also maintain NPM-
ALK protein stability; because specific targeting of IGF-IR by siRNA significantly decreased 
NPM-ALK basal protein levels [127]. Based on its dual influence on NPM-ALK 
phosphorylation and stability, IGF-IR most likely represents an important survival entity in 
this lymphoma.  
Reciprocally, NPM-ALK appears to play a crucial role in maintaining the 
phosphorylation of IGF-IR at Y1131, and thereby sustains its downstream signaling. In 
support of this idea, specific targeting of NPM-ALK by siRNA decreased IGF-IR 
phosphorylation significantly [128]. However, NPM-ALK does not appear to contribute to 
IGF-IR protein stability. Specific targeting of NPM-ALK by siRNA resulted in substantial 
decrease of NPM-ALK protein, but changes in IGF-IR mRNA or protein expressions were 
not observed, even over prolonged periods of time. These important observations suggest that 
NPM-ALK does not contribute to IGF-IR overexpression, but mainly to its phosphorylation 
and downstream signaling process [113] (Figure 10). 
Because the mechanisms underlying the survival of NPM-ALK+ ALCL are not 
completely understood, we hypothesized that multilevel deregulated mechanisms contribute 
to aberrant expression of IGF-IR and NPM-ALK, which enhances the survival potential of 
this aggressive lymphoma. To test this hypothesis, the following set of specific aims were 
performed: 
Specific Aim 1: Transcriptional regulation of IGF-IR.  
a. Transcription factors: We identified novel transcription factors that regulate the 
expression of IGF-IR and test their biological significance in NPM-ALK+ ALCL. 
b. Gene amplification: IGF-IR gene amplification has been observed in different 
types of cancers including malignant melanoma and breast and pancreatic 
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cancers. We examined whether IGF-IR gene amplification exists in NPM-ALK+ 
ALCL. 
Specific Aim 2: Posttranscriptional regulation of IGF-IR.  
a. MicroRNA: We identified potential deregulated microRNAs that contribute to 
IGF-IR upregulation and test their biological significance in NPM-ALK+ ALCL. 
b. RNA stability: We tested whether IGF-IR mRNA decay rate contributes to up-
regulation of IGF-IR expression in NPM-ALK+ ALCL. 
Specific Aim 3: Posttranslational regulation of NPM-ALK and IGF-IR.  
a. SUMOylation: We examined whether SUMOylation contributes to 
posttranslational stabilization of IGF-IR and NPM-ALK in NPM-ALK+ ALCL. 
b. Deregulation of IGF-I: We examined whether NPM-ALK potentiates IGF-IR 
signaling via upregulation of IGF-I expression. 
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FIGURE 8. Expression of IGF-IR in NPM-ALK+ ALCL cell lines. Upper panel, WB 
studies showed overexpression of IGF-IR protein in NPM-ALK+ ALCL cell lines. R− and P6 
cell lines were used as negative and positive controls for the expression of IGF-IR, 
respectively. It is important to note that the overexpression of IGF-IR in P6 cells has been 
artificially over-induced and does not represent a physiologic level. RT-PCR shows the 
presence of IGF-IR mRNA in the NPM-ALK+ ALCL cell lines as well as in the P6 cell line. 
Although IGF-IRα mRNA is not detectable in R− cells, these cells appear to express very low 
levels of IGF-IRβ mRNA. Quantitative flow cytometric analysis shows that the NPM-
ALK+ ALCL cell lines express significantly higher levels of IGF-IR compared with normal 
human T lymphocytes. Using flow cytometry, the estimated numbers of IGF-IR 
molecules/cell are shown to be much more abundant in NPM-ALK+ ALCL cell lines 
compared with normal human T-cells. Lower panel, immunohistochemical staining of ALK+ 
ALCL patient specimens illustrates that 89% and 86% of patient samples were positive for 
IGF-IR and pIGF-IR expression, respectively. Patients 1 and 2 represent positive cases, and 
patient 3 represents a negative case. Karpas 299 and R- were used as positive and negative 
controls, respectively. Adapted by direct permission from BLOOD (Shi P, Lai R, Lin Q, 
Iqbal AS, Young LC, Kwak LW, Ford RJ, Amin HM. IGF-IR tyrosine kinase interacts 
with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell 
lymphoma cells. Blood. 2009 Jul 9;114(2):360-70.), copyright 2009.  
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FIGURE 9. Association and functional interactions between NPM-ALK and IGF-IR. 
Upper panel, NPM-ALK and IGF-IR are physically associated through Y644 and Y664 of 
NPM-ALK and Y950 of IGF-IR. Through this association, the phosphorylation and tyrosine 
kinase activity of the two oncogenic proteins are maintained at high levels, and this leads to 
up-regulation of the phosphorylation of the common downstream targets including STAT3, 
AKT, and ERK. Such effects enhance the transformation, proliferation, and migration of 
NPM-ALK+ T-cell lymphoma cells. In addition, the physical association between NPM-ALK 
and IGF-IR, in the presence of Hsp90 (not shown), appears to sustain the stability of NPM-
ALK protein. Lower panel, specific targeting of IGF-IR by siRNA significantly decreased 
NPM-ALK protein expression levels over prolonged time; densitometric analysis of the IGF-
IR:β-actin and NPM-ALK:β-actin ratios are shown below the WB. Adapted with 
permission from PMC [Neoplasia] (Shi B, Vishwamitra D, Granda JG, Whitton T, Shi 
P, Amin HM. Molecular and functional characterizations of the association and 
interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-
like growth factor receptor. Neoplasia. 2013 Jun;15(6):669-83.), copyright 2013.  
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FIGURE 10. NPM-ALK does not regulate IGF-IR expression. Upper panel, specific 
targeting of NPM-ALK by siRNA significantly decreased NPM-ALK protein expression, but 
changes in IGF-IR protein expression were not observed even after 96 h. Lower panel, no 
change in IGF-IR mRNA expression was observed after sufficient knockdown of NPM-ALK 
by siRNA. 
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3.1. Transcriptional Regulation of IGF-IR 
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3.1.1. Introduction 
Deregulated expression, activation or inactivation of transcription factors plays critical roles 
in tumorigenesis. Additionally, signaling via major oncogenic pathways is tightly controlled 
through transcription factors that have the ability to regulate the expression of target genes 
that are directly relevant to the corresponding oncogenic pathways, resulting in either 
induction or inhibition of tumor formation and progression. Under physiological conditions, 
genes are regulated by specific upstream transcriptional regulators, whereas in cancer cells, 
aberrant activation or inactivation of these transcription factors leads to deregulated 
expression of oncogenes or tumor suppressor genes that affect tumor development and 
progression. Only a few transcription factors have been shown to bind the IGF-IR gene 
promoter (15q26.3) and modulate its activity through stimulation or inhibition. These 
transcription factors include Sp1, WT1, E2F1, STAT1, and EGR-1 [26-34].  
Gene amplification is indicative of a copy number increase of a particular segment on a 
chromosome. It is prevalent in some tumors and is associated with overexpression of the 
amplified genes. The presence of IGF-IR gene amplification and its clinical relevance has 
been investigated in a limited number of solid cancers including breast, lung, and 
gastrointestinal stromal tumors (GISTs) [133-139]. Of these cancers, gene amplification was 
detected only in small subgroups of patients with non-small cell lung cancer and GISTs 
[134]. IGF-IR amplification correlated positively with high IGF-IR protein expression and 
lymph node metastasis. 
In this aim, we examined whether increased IGF-IR expression in NPM-ALK+ ALCL 
may be explained by transcriptional aberrancies, such as deregulated transcription factors 
and/or IGF-IR gene amplification. 
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GE, Kaseb AO, Shi P, Amin HM. The transcription factors Ik-1 and MZF1 downregulate 
IGF-IR expression in NPM-ALK(+) T-cell lymphoma. Mol Cancer. [accepted]. 
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3.1.2.1. Materials and Methods 
Web-based transcription factor search algorithms – To identify transcription factors that 
potentially bind the human IGF-IR gene promoter, 3 web-based transcription factor search 
algorithms were searched: Genomatix (www.genomatix.de/), and MATCH 
(http://www.gene-regulation.com/pub/programs.html), and TFSearch (we used this 
transcription factor search algorithm when we initiated the study, but we noticed that now it 
has been removed and the website is not available for online support. Importantly, the 
findings we obtained from TFSearch matched exactly the findings gathered from Genomatix 
and MATCH). 
Cell lines – Five NPM-ALK+ ALCL cell lines were used in this study: Karpas 299, SUP-M2, 
SR-786, DEL, and SU-DHL-1 (DSMZ, Braunschweig, Germany). The R- cell line (mouse 
3T3-like fibroblasts with targeted ablation of Igf1r gene; gift from Dr. Renato Baserga, 
Thomas Jefferson University, Philadelphia, PA) was used as the host cell line for luciferase 
assay studies (8). Normal human peripheral blood CD3+ pan-T lymphocytes were used in 
some experiments (catalog number: PB009-1F; StemCell Technologies, Vancouver, BC, 
Canada). In addition, Jurkat cells (ATCC, Manassas, VA) were used as a positive control for 
the expression of Ik-1 and MZF1 [140, 141]. The T lymphocytes as well as the Jurkat and 
NPM-ALK+ ALCL cell lines were maintained in Roswell Park Memorial Institute (RPMI) 
1640 medium supplemented with 10% fetal bovine serum (FBS) (Sigma, St. Louis, MO), 
glutamine (2 mM), penicillin (100 U/mL), and streptomycin (100 μg/mL) at 37°C in 
humidified air with 5% CO2. Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented 
with 10% FBS was used to culture the R- under the same conditions. 
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Antibodies – The following antibodies were used: pIGF-IRY1131 (3021), pALKY1604 (Y664 in 
NPM-ALK; 3341), pAKTS473 (4051), and Ikaros (5443) (Cell Signaling Technology, 
Danvers, MA); IRS-1 (ab40777), AKT (ab8805), NPM (ab52644), and MZF1 (ab64866) 
(Abcam, Cambridge, MA); IGF-IR (396700; Life Technologies, Grand Island, NY); pIRS-
1S639 (sc-22300; Santa Cruz Biotechnology, Santa Cruz, CA); ALK (M719501-2; Dako, 
Carpinteria, CA); c-Myc (631206, Clontech Laboratories, Mountain View, CA); IGF-I (05-
172; Millipore, Billerica, MA); and β-actin (A-5316; Sigma). 
Western blotting – Cells were lysed using lysis buffer containing 25 mM HEPES (pH 7.7), 
400 mM NaCl, 1.5 mM MgCl2, 2 mM EDTA, 0.5% Triton X-100, 0.1 mM PMSF, 2 mM 
DTT, and phosphatase and protease inhibitor cocktails (Thermo Scientific, Rockford, IL). 
Protein concentrations were measured using the Bio-Rad protein assay, and optical density 
values were obtained using an ELISA plate reader (Bio-Tek Instruments, Winooski, VT). 
Proteins (50 μg) were resolved by electrophoresis on 8% SDS-PAGE and then transferred to 
PVDF membranes and probed with specific primary antibodies and then with appropriate 
horseradish peroxidase-conjugated secondary antibodies (GE Healthcare, Waukesha, WI). 
Proteins were detected using a chemiluminescence-based kit (Amersham Life Sciences, 
Arlington Heights, IL).  
In addition, a commercially available kit (Qproteome Tissue Kit, Qiagen, Valencia, CA) 
was used to perform Western blot assay to measure Ik-1 and MZF1 protein levels in 
formalin-fixed and paraffin-embedded (FFPE) tissue sections from NPM-ALK+ ALCL 
patients (approval of the Institutional Review Board was obtained prior to performing human 
tissue analysis). Briefly, tissue sections mounted on glass slides were examined and tumor 
areas were identified and marked. Next, sections were deparaffinized, and tumor areas were 
excised from the slides and transferred into 1.5-mL collection tubes. β-Mercaptoethanol (6 
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µL) was admixed with the provided Extraction Buffer EXB Plus (94 μL) and then added to 
the excised tissues. Tissue tubes were incubated on ice for 5 min and then the contents were 
mixed by vortexing and incubated on a heating block at 100°C for 20 min. Using an oven 
with rotators, samples were incubated at 80°C for 2 h with agitation at 750 rpm. After 
incubation, tubes were cooled at 4°C for 1 min. The samples were centrifuged for 15 min at 
14,000 g at 4°C. The supernatant containing the extracted proteins was collected. For 
quantification of protein yield, the Bio-Rad assay was used as described above.  
RNA extraction, cDNA synthesis, and relative quantitative PCR (qPCR) – Total RNA was 
isolated and purified using the RNAeasy Mini Kit (Qiagen). Briefly, 1 × 106 cells were 
collected by centrifugation at 200 g for 5 min, washed twice in phosphate-buffered saline 
(PBS), and subjected to lysis and homogenization with Buffer RLT using QiaShredder spin 
columns (Qiagen). Homogenized cells were re-suspended in an equal volume of 70% ethanol 
and passed through the spin columns. Cells were then washed once using Buffer RW1 and 
twice using Buffer RPE (Qiagen). Total RNA was collected upon elution with RNase-free 
water. Optical density was detected using spectrophotometry (NanoDrop 2000, Thermo 
Fisher Scientific, Waltham, MA). 
cDNA synthesis was performed using the Superscript III RT protocol (Invitrogen, 
Carlsbad, CA). Approximately 0.3 μg total RNA was used for reverse transcription. Briefly, 
total RNA, oligo deoxy-thymine (dT), and deoxytrinucleotide triphosphate (dNTP) were 
admixed, and the final volume was adjusted to 10 μL using RNase-free water. The RNA 
mixture and primer were denatured at 65°C for 5 min and then placed on ice. The master 
reaction mixture consisting of 10× cDNA synthesis buffer, 0.1 M DTT, RNaseOUT, 
SuperscriptIII RT, MgCl2, and RNase-free H2O was prepared on ice and vortexed gently. 
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Then, 10 μL of the reaction mixture was pipetted into each reaction tube on ice. Samples 
were transferred to a thermal cycler preheated to the appropriate cDNA synthesis temperature 
and incubated at 50°C for 60 min and then at 85°C for 5 min. Finally, 1.0 μL RNase H was 
added and the samples were incubated at 37°C for 20 min to remove template RNA.  
Relative qPCR was used to measure the levels of IGF-IR mRNA in NPM-ALK+ ALCL 
cell lines after transfection with Ik-1 or MZF1 expression vectors (Open Biosystems, 
Pittsburgh, PA) using reactions containing reverse-transcribed cDNA, IGF-IR primer/probe, 
and Taqman Mastermix (Applied Biosystems, Grand Island, NY). 18S ribosomal RNA was 
used as the endogenous control. 
Transfection – Cells were transfected with Ik-1 or MZF1 expression plasmids using 
electroporation and the Amaxa 4D Nucleofector System (solution SF, program CA-150; 
Lonza, Walkersville, MD) and then incubated for 48 h. In some experiments, scrambled or 
ALK siRNA (Dharmacon, Pittsburgh, PA) was transfected into NPM-ALK+ ALCL cell lines 
by using the same approach.  
Construction of the human IGF-IR gene promoter – Three different fragments of the 
human IGF-IR gene promoter were amplified using genomic DNA (Promega, Madison, WI). 
Briefly, 500 ng of genomic DNA was added to HotStarTaq plus Q solution additive mixture 
(Qiagen) and subjected to Touchdown PCR. The PCR primers and amplification conditions 
are shown in Table 1 and Table 2, respectively.  
TABLE 1. Sequence of the primers used to construct the 3 fragments (F1, F2, and F3) of the human 
IGF-IR gene promoter. 
Primer Name  Sequence 
F1 (Forward)  5’-CTC TCC TCG AGC CAC TCT GGG C-3’ 
F1 (Reverse)  5’-CAA GAC GTG CGG AGC GGA GC-3’ 
F2 (Forward)  5’-TCC GCA CGT CTT GGG GAA CC-3’ 
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F2 (Reverse)  5’-GCC CCG AAG TCC GGG TCA CA-3’  
F3 (Forward)  5’-GAC TCC GCG TTT CTG CCC CTC-3’ 
F3 (Reverse)  5’-CTC CAC TCG TCG GCC AGA GC-3’ 
TABLE 2. The amplification conditions used in Touchdown PCR for the construction of 3 fragments 
of the human IGF-IR gene promoter (∞: hold). 
Phase 1 Step  Temperature Time 
1  Denature 95°C  15 min 
2  Denature 95°C  30 sec 
3  Anneal              70°C  45 sec 
    -1.0°C*  
4  Elongate 72°C  1 min 
Repeat steps 2-4 (15 times) 
Phase 2 Step  Temperature Time 
5  Denature 95°C  30 sec 
6  Anneal               60°C  45 sec 
7  Elongate 72°C  1 min 
Repeat steps 5-7 (25 times) 
Termination Step  Temperature Time 
8  Elongate 72°C  5 min 
9  Halt reaction 4°C  15 min 
10  Hold  4°C  ∞ 
*Every time steps 2-4 were repeated, the annealing temperature was decreased by 1.0°C/cycle until 
the estimated melting temperature was reached. 
PCR products were run on 1.5% agarose gel, excised, and purified using the Qiaquick 
Gel Extraction Kit (Qiagen). The PCR products were then subcloned at a 1:5 molar ratio into 
the pGEM vector using the TA cloning system (Promega). The ligated products were 
transformed using MaxEfficiency DH5α-competent cells (Invitrogen) overnight at 37°C, and 
positive clones were selected and verified by PCR and direct DNA sequencing. Clones 
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containing the correct insert were amplified in ampicillin containing Luria-Bertani (LB) 
broth (Corning Costar, Corning, NY). Plasmids were isolated and purified using the Purelink 
Quick Plasmid Miniprep Kit (Invitrogen). To construct reporter plasmids containing the 
human IGF-IR gene promoter fragments, the pGEM plasmids and the PGL4.17 luciferase 
vector (Promega) were subjected to restriction enzyme digestion using ZraI/SpeI (Promega) 
and EcoICRI/NheI (New England Biolabs, Ipswich, MA). After digestion, DNA was ligated 
at room temperature using T4 DNA ligase (Promega) and the PCR conditions shown in Table 
3.  
TABLE 3. PCR conditions used for DNA ligation for the construction of the human IGF-IR gene 
promoter (∞: hold). 
Temperature  Time 
22°C   30 min 
20°C    30 min 
18°C    30 min 
16°C    30 min 
14°C    30 min 
12°C   30 min 
10°C   30 min 
8°C    30 min 
6°C   30 min 
4°C   30 min 
4°C   ∞ 
Ligated products were confirmed by agarose gel electrophoresis and transformed using 
DH5α-competent cells. Positive clones were selected, subjected to plasmid isolation and 
purification using the Miniprep Kit, and verified by PCR and direct DNA sequencing. 
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Site-directed mutagenesis and luciferase assay – Mutated human IGF-IR luciferase reporter 
constructs were generated using the QuickChange II XL Site Directed Mutagenesis Kit 
(Agilent Technologies, Santa Clara, CA) and a set of primers depicted in Table 4. 
TABLE 4. Sequences of the primers used to construct the 3 mutated fragments of human IGF-IR 
luciferase reporter (F1, F2, and F3). 
Primer Name  Sequence 
F1 (Forward)  5’-CAA GAG CCC CAG CCG GGA GAA AGG GGA C-3’ 
F1 (Reverse)  5’-GTC CCC TTT CTC CCG GCT GGG GCT CTT G-3’ 
F2 (Forward)  5’-CAG AAA CGC GGA GCG CCG GCC ACC-3’ 
F2 (Reverse)  5’-GGT GGC CGG CGC TCC GCG TTT CTG-3’ 
F3 (Forward)  5’-GCC AGA GCG AGA GCG CCA AAT CCA GGA CAC-3’ 
F3 (Reverse)  5’-GTG TCC TGG ATT TGG CGC TCT CGC TCT GGC-3’ 
Luciferase assay –  For luciferase assays, R- cells were transfected using Lipofectamine 2000 
reagent. Briefly, 1 x 106 R- cells were seeded in 6-well plates. The following day, plasmids 
were incubated in 100 µL OptiMEM media for 5 min at room temperature. Simultaneously, 7 
µL lipofectamine was incubated in a separate tube. Then, the contents of the plasmid tubes 
were added to the lipofectamine and incubated for 20 min at room temperature. Finally, the 
plasmid mixtures were added to the corresponding plate wells containing the R- cells.  
Luciferase assay was performed with the Dual Glo Luciferase Kit (Promega) after co-
transfecting the R- cells with the reporter plasmids containing the wild-type or mutated IGF-
IR promoter fragments or NPM promoter (kind gift from Dr. Qishen Pang, Cincinnati 
Children’s Hospital, Cincinnati, OH) along with Ik-1 or MZF1 expression plasmids using 
Lipofectamine 2000 (Invitrogen) for 48 h. Cells were trypsinized, washed twice with sterile 
PBS, and plated in a 96-well luminometer plate. An equal volume of Dual-Glo reagent was 
added and incubated for 10 min for cell lysis to occur. Firefly luminescence readings were 
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obtained using a plate reader (PolarStar Omega, BMGLabTech, Cary, NC). Finally, the 
Dual-Glo Stop & Glo reagent was added and incubated for 10 min. Renilla luminescence 
readings were obtained using the above methods.  
Chromatin immunoprecipitation (ChIP) assay – Because NPM-ALK+ ALCL cells contain 
low levels of endogenous Ik-1 and MZF1, expression plasmids containing full-length Ik-1 or 
MZF1 were constructed by transferring the inserts into a c-Myc-tagged expression vector 
(pCMV-Myc-N; Clontech). Briefly, the original expression vectors containing Ik-1 or MZF1 
as well as pCMV-Myc-N were subjected to digestion using the restriction enzymes NotI/SalI 
for Ik-1 or XhoI/ECORI for MZF1 (Promega). Digested products were verified by agarose 
gel electrophoresis and then excised and ligated using the HD InFusion system (Clontech). 
Ligated products were transformed using DH5α-component cells, and positive clones were 
selected and verified by PCR. 
ChIP assays were performed using the Pierce Agarose ChIP Kit (Thermo Scientific). 
Briefly, at 48 h post-transfection, cells were cross-linked using 1% formaldehyde, and cell 
pellets were lysed and re-suspended in a buffer containing 0.6 µL Micrococcal Nuclease 
(ChIP grade) and subjected to sonication on ice (Output 6; six 15 sec pulses, followed by 45 
sec rest periods; Sonic Dismembrator, model 100; Thermo Fisher Scientific). Five microliters 
of digested chromatin was separated for the 10% input. The remaining sonicated samples 
were immunoprecipitated overnight at 4°C on a rocking platform using the c-Myc-Tag 
antibody and the provided plugged spin columns. Following overnight incubation, ChIP-
grade Protein A/G Plus agarose beads were incubated for 2 h with the lysate at 4°C on a 
rocking platform. The samples were then washed and reverse cross-linked at 65°C for 40 
min. The immunoprecipitated samples and input were eluted in a buffer containing 5 M NaCl 
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and 20 mg/mL Proteinase K. Finally, chromatin DNA was recovered and purified using the 
DNA Clean-Up column and subjected to Touchdown PCR using HotStarTaq Master Mix and 
Q solution and a set of primers shown in Table 5. PCR products were run on 1.5% agarose 
gel. 
TABLE 5. Sequences of the primers flanking potential binding sites (BS) of Ik-1 and MZF1 within 
the human IGF-IR promoter used in the RT-PCR reactions following the ChIP assay. 
Primer Name   Sequence 
Ik-1 BS2 (Forward)  5’-CGG GGG CAT TGT TTT TGG AG-3’ 
Ik-1 BS2 (Reverse)  5’-CGG GTT CCC CAA GAC GTG-3’ 
Ik-1 BS3 (Forward)  5’-TCT TGT TTA CCA GC ATTA ACT CGC-3’ 
Ik-1 BS3 (Reverse)  5’-CCT CTC TCG AGT TCG CCT G-3’ 
Ik-1 BS4 (Forward)  5’-CGC CGC TTT GTG TGT GTC-3’ 
Ik-1 BS4 (Reverse)  5’-GCC GCC TCC TCC CTC A-3’ 
MZF1 BS2 (Forward)  5’-GCG GGG GCA TTG TTT TTG GA-3’ 
MZF1 BS2 (Reverse)  5’-CCG GGT TCC CCA AGA CGT G-3’ 
MZF1 BS3 (Forward)  5’-GCG CGT GTC TCT GTG TGC-3’ 
MZF1 BS3 (Reverse)  5’-GCG AGT TAA TGC TGG TAA ACA A-3’ 
MZF1 BS4 (Forward)  5’-GTG TGT GTC CTG GAT TTG GGA-3’ 
MZF1 BS4 (Reverse)  5’-GCA GAA ACG CGG AGT CAA AAT-3’ 
MZF1 BS5 (Forward)  5’-CGG CCC TTC GGA GTA TTG T-3’ 
MZF1 BS5 (Reverse)  5’-CAA GTC TCA AAC TCA GTC TTC G-3’ 
MTS assay – Cell viability was evaluated using a CellTiter 96 AQueous One Solution Cell 
Proliferation 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium (MTS) assay kit (Promega). Cells were seeded in 96-well plates (1.0 × 104 
cells/well) in 100 μL RPMI supplemented with 10% FBS. Twenty microliters of MTS 
reagent were added, and the cells were incubated at 37°C in a humidified 5% CO2 chamber 
for 4 h. Optical density measurements were obtained at 490 nm using an ELISA plate reader. 
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BrdU assay – Cell proliferation was measured using a BrdU assay kit (ExAlpha Biologicals, 
Shirley, MD). Briefly, 2.0 × 105 cells/mL were plated into a 96-well plate. BrdU (1:500 
dilution) was added, and the plate was incubated for 24 h at 37°C. Cells were then fixed for 
30 min at room temperature. After the cells were washed, anti-BrdU antibody was added for 
1 h followed by peroxidase goat anti-mouse IgG conjugate (1:2000 dilution) for 30 min. 
Next, the 3,3’,5,5’-tetramethylbenzidine peroxidase substrate was added, followed by 
incubation for 30 min at room temperature in the dark. The acid Stop Solution was then 
added and the plate was read at 450 nm using an ELISA plate reader. 
Cell migration assay – Cell migration was analyzed using 24-well Transwell plates with 
polycarbonate membranes (Corning Costar). Briefly, cells transfected with Ik-1 or MZF1 in 
serum-free culture medium were loaded into the upper compartment, and 500 ng/mL IGF-I 
(R&D Systems, Minneapolis, MN) in serum-free medium was loaded into the lower 
compartment. As controls, non-transfected cells in serum-free medium were loaded into the 
upper compartment with/without IGF-I added into the lower compartment. Plates were 
incubated for 4 h at 37°C, and cells migrating through the membrane into the lower chamber 
were counted using a particle counter and size analyzer (Beckman Coulter, Brea, CA). 
Anchorage-independent colony formation assay – Methylcellulose (Methocult H4230; 
StemCell Technologies) (3.0 mL) was added to 15-mL tubes. Empty vector- (EV-), Ik-1- or 
MZF1-transfected cells were added in a 1:10 (v/v) ratio to the methylcellulose tubes and 
mixed well by gentle inversion. One milliliter of the mix was divided into 24-well plates in 
triplicate. Plates were placed in a humidified incubator at 37°C in 5% CO2 for 7 days. Then, 
p-iodonitrotetrazolium violet was added for 24 h for staining. Colonies were visualized using 
the AlphaImager system (Alpha Innotech Corporation, San Leandro, CA). In an additional 
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experiment, SUP-M2 cells were incubated for 21 days, and the results were similar to those 
of the shorter incubations.  
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3.1.2.2. Results 
Identification of the transcription factors Ikaros isoform-1 (Ik-1) and myeloid zinc finger 1 
(MZF1) as capable to potentially bind with the IGF-IR gene promoter: The TFSearch, 
MATCH, and Genomatix transcription factor search algorithms identified multiple potential 
transcription factors. We elected to focus on Ik-1 and MZF1 because: their 1) matrix 
similarity thresholds to bind with the IGF-IR gene promoter are > 0.9, which has been 
predicted collectively by the 3 algorithms [the matrix similarity threshold represents the 
quality of the match between the transcription factor binding sequence and arbitrary parts of 
the promoter sequence, and is used to minimize false positive results] (Table 6); 2) 
contribution to the transcriptional regulation of IGF-IR expression has not been previously 
described; 3) role in the pathogenesis of NPM-ALK+ T-cell lymphoma is not known; and 4) 
contribution to normal and abnormal hematopoiesis has been established by the transcription 
factors [141-145]. 
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TABLE 6. Ik-1 and MZF1 can potentially bind with IGF-IR gene promoter. Three 
online-based software search algorithms (Genomatix, MATCH, and TESearch) predicted 
several transcription factors that could potentially bind with IGF-IR gene promoter. Ik-1 and 
MZF1 were predicted by 3 and 2, respectively, of the 3 software algorithms, with the highest 
probability of > 0.09.  
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Expressions of Ik-1 and MZF1 are significantly decreased in NPM-ALK+ ALCL: Western 
blotting was used to first analyze 4 NPM-ALK+ ALCL cell lines (Karpas 299, SR-786, SUP-
M2, and DEL) and normal human T lymphocytes for the expression of Ik-1 and MZF1. The 
expression levels of Ik-1 and MZF1 were significantly decreased in the 4 cell lines compared 
to the normal T lymphocytes (Figure 11A and 11B). Jurkat cells were used as positive 
controls for the expression of Ik-1 and MZF1. Densitometric analysis of the expression of Ik-
1 and MZF1 relative to β-actin is shown (Figure 11C). In addition, examination of the 
expression levels of Ik-1 and MZF1 in protein lysates extracted from 15 FFPE patient tissues 
showed patterns of expression similar to cell lines. Ik-1 and MZF1 expressions were 
decreased in 87% and 100% of the patient’s samples, respectively, compared to normal T 
lymphocytes (Figure 11D). Densitometric analysis of the expression of Ik-1 and MZF1 
relative to β-actin is shown (Figure 11E).  
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FIGURE 11. The expression of Ik-1 and MZF1 is decreased in NPM-ALK+ ALCL cell 
lines and human primary tumors. (A) WB shows that Ik-1 levels were lower in 4 NPM-
ALK+ ALCL cell lines than in T lymphocytes. Jurkat cells were used as a positive control. β-
actin represents the level of proteins loaded in each lane. (B) Similarly, MZF1 levels were 
lower in the lymphoma cell lines than in normal human T-cells. Jurkat cells served as a 
positive control. β-actin reflects the level of proteins loaded in each lane. (C) Densitometric 
analysis of the Ik-1/MZF1 Western blotting bands relative to the β-actin bands depicted in 
(A) and (B) further demonstrated that the expression of these two transcription factors is 
decreased in NPM-ALK+ ALCL cell lines vs. T-cells and positive control cell lines. (D) 
Western blotting assay showing that the expression of Ik-1 and MZF1 were lower in ALK+ 
ALCL specimens from patients than in T lymphocytes. β-actin reflects the level of total 
proteins loaded in each lane. Variability in β-actin levels is due to the poor quality of some of 
the FFPE tumor sections. (E) Densitometric studies analyzing the Ik-1/MZF1:β-actin ratio of 
the Western blotting bands shown in (D).  
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Ik-1 and MZF1 bind the IGF-IR promoter and regulate its activity: To elucidate whether 
Ik-1 and MZF1 can bind and regulate the IGF-IR gene promoter, a luciferase assay was 
performed using 3 different fragments of the human IGF-IR promoter construct (F1: -682/-
137, F2: -137/+583, F3; +530/+1137; illustrated in Figure 12A and 12B) along with either 
EV, Ik-1 or MZF1 expression plasmids. In addition, a second luciferase assay was performed 
simultaneously using mutated versions of the promoter fragments that were sequentially 
deleted at the corresponding binding sites. Ik-1 and MZF1 significantly decreased the 
luciferase activity of the F1 and F2, but not the F3, regions of the human IGF-IR promoter 
(Figure 12C). In contrast, Ik-1 and MZF1 did not decrease the luciferase activity of the 
mutated forms of the IGF-IR promoter (Figure 12C). These results suggest that each of these 
transcription factors can interact with binding sites located within the F1 and F2 regions, but 
not the F3 region. 
The 3 web-based transcription factor search algorithms also predicted 5 potential binding 
sites for Ik-1 and 6 potential binding sites for MZF1 within the IGF-IR promoter (Figure 
12A and 12B). To determine which of these sites is responsible for Ik-1 or MZF1 
interactions with the IGF-IR promoter, a ChIP assay was performed. Because there are low 
levels of endogenous Ik-1 and MZF1 in the cells, Karpas 299 and SR-786 cells were 
transfected with Myc-tagged Ik-1 or MZF1 (c-Myc-Ik-1 or c-Myc-MZF1) expression 
constructs or with empty vector (EV). Using a c-Myc antibody, the transcription factors were 
immunoprecipitated and the sonicated chromatin was used to perform an RT-PCR analysis 
using primers flanking the potential binding sites for Ik-1 and MZF1 within the human IGF-
IR promoter. The ChIP assay identified 2 binding sites (BS2 and BS4) for Ik-1 and 3 binding 
sites for MZF1 (BS2, BS3, and BS4) (Figure 12D, 12E; the sites are depicted in 11A and 
11B). The RT-PCR (2 different sets of primers were tried) showed nonspecific binding in the 
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ChIP assay for Ik-1 BS1 and BS5, and for MZF1 BS1 and BS6 (data not shown). This 
nonspecific binding could possibly be due to the instability of the primers to bind to and 
amplify the extreme beginning and end of the IGF-IR gene promoter. 
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FIGURE 12. Ik-1 and MZF1 interact with and bind to the IGF-IR gene promoter. (A) 
The general structure of the IGF-IR gene promoter, including the transcription and 
translation start sites is shown. The 3 PCR fragments used to perform the luciferase assay 
(F1: -682/-137, F2: -137/+583, F3: +530/+1137) as well as 5 sites that could potentially bind 
with Ik-1 are shown. *: 2 sites that were shown to bind with Ik-1 by the ChIP assay. (B) The 
3 PCR fragments used to perform the luciferase assay and 6 sites that could potentially bind 
with MZF1 are depicted. *: 3 sites that were confirmed by the ChIP assay as binding sites for 
MZF1. (C) Luciferase assay performed in R- cells, which lack endogenous IGF-IR 
expression, demonstrates that transfection of Ik-1 or MZF1 induced a marked decrease in 
IGF-IR promoter activity at concomitantly transfected F1 and F2, but not at F3, of the IGF-
IR gene promoter (*: P < 0.05; **: P < 0.01; ***: P < 0.001 compared with EV). 
Importantly, Ik-1 and MZF1 failed to induce their effects when F1 and F2 were mutated 
(MT) at their potential binding sites. The results are shown as means ± SE of 3 consistent 
experiments. (D) ChIP assay shows that Ik-1 binds with binding site 2 (BS2) and BS4 of the 
IGF-IR gene promoter. As shown, controls including EV, IgG, input, and H2O worked 
properly. The 2 binding sites are identified by an (*) in (A). (E) ChIP assay confirms that 
MZF1 is capable of binding with the IGF-IR gene promoter at BS2, BS3, and BS4, which are 
marked by an (*) in (B). Positive and negative controls worked properly. 
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Ik-1 and MZF1 decrease IGF-IR mRNA and protein levels in NPM-ALK+ ALCL cells:  
Next, we sought to explore the effects of up-regulating the expression of Ik-1 and MZF1 in 
NPM-ALK+ ALCL cells. Sufficient transfection of Karpas 299, SUP-M2, and SR-786 cells 
with Ik-1 or MZF1 expression plasmids resulted in a significant decrease in IGF-IR mRNA 
expression (Figure 13A and 13B; Figure 13Cand 13D). In contrast, EV failed to elicit 
similar effects. These effects resulted in significant decrease in IGF-IR protein levels, and 
subsequently, its activated/phosphorylated form, pIGF-IR. Furthermore, Ik-1- and MZF1-
induced downregulation of IGF-IR was followed by decreases in several downstream 
signaling proteins that are important for the IGF-IR signaling axis, such as pAKTSer437 and 
pIRS-1Ser639 (Figure 13E). No significant changes were detected in total AKT levels, but 
unexpectedly Ik-1 and MZF1 decreased total IRS-1 levels. When the IRS-1 gene promoter 
sequence was analyzed using the 3 web-based transcription factor search algorithms, we 
discovered that Ik-1 and MZF1 have the potential to bind to the IRS-1 gene promoter, which 
may explain this unexpected finding.  
The ectopic expression of Ik-1 and MZF1 resulted in significant decrease in NPM-ALK 
and pNPM-ALK levels (Figure 13E). When we entered the NPM-ALK sequence into the 
three web-based algorithms, we found that neither of these transcription factors have 
potential binding sites within the NPM gene, which is where the promoter for NPM-ALK 
resides. In addition, WB analysis failed to demonstrate changes in wild type NPM protein 
after transfection of Ik-1 or MZF1, providing evidence that Ik-1 and MZF1 are not directly 
regulating NPM-ALK (Figure 13E). Moreover, the luciferase activity of the full length NPM 
promoter remained unchanged after transfection with Ik-1 or MZF1 (Figure 13F). These 
observations allude to the possibility that the decrease NPM-ALK protein levels is most 
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likely the result of decreases in IGF-IR, which is consistent with our previous results 
showing that IGF-IR sustains the stability of NPM-ALK protein.   
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FIGURE 13. Ik-1 and MZF1 decrease IGF-IR mRNA and protein expression and the 
phosphorylation of downstream targets. (A) WB demonstrates increased expression levels 
of Ik-1 and MZF1 proteins at 48 h after transfection into 3 NPM-ALK+ ALCL cell lines. β-
actin shows equal protein loading. (B) Densitometric studies illustrate the ratio of the Ik-1 or 
MZF1 protein to β-actin. The ratios support increased expression of the corresponding 
transfection factor after transfection. (C) Transfection of Ik-1 remarkably decreased IGF-IR 
mRNA levels in Karpas 299, SUP-M2, and SR-786 cell lines (*: < 0.0001 compared with 
EV). (D) Similarly, transfection of MZF1 induced a significant decrease in IGF-IR mRNA 
levels (*: < 0.0001 compared with EV). The results depicted in (C) and (D) represent the 
means ± SE of 3 experiments. (E) WB shows that transfection of Ik-1 and MZF1 into Karpas 
299, SUP-M2, and SR-786 cell lines induced marked downregulation of IGF-IR protein, 
which was also associated with decreased pIGF-IR levels. Moreover, the decrease in IGF-
IR/pIGF-IR expression levels was associated with decreased phosphorylation of important 
IGF-IR targets including IRS-1, AKT, and NPM-ALK. Whereas the basal levels of AKT 
remained unchanged, notable decrease in IRS-1 protein was observed. The 3 web-based 
transcription factor search algorithms showed that Ik-1 and MZF1 could potentially bind with 
the IRS-1 gene promoter. In contrast, searching these algorithms did not support potential 
binding of Ik-1 or MZF1 and the NPM gene promoter, where the expression of NPM-ALK 
protein is regulated at the transcriptional level. (F) In line with lack of potential 
binding/interaction between Ik-1 or MZF1 and the NPM gene promoter, a luciferase assay 
performed in R- cells shows that transfection of Ik-1 and MZF1 does not decrease the NPM 
promoter activity. The results represent means ± SE of 3 consistent experiments. 
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Ik-1 and MZF1 decrease the viability, proliferation, migration, and anchorage-
independent colony formation of NPM-ALK+ ALCL cells: A series of cellular assays were 
performed to test the biological impact of forced expression of Ik-1 and MZF1 in NPM-
ALK+ ALCL. Transfection of Karpas 299, SUP-M2, and SR7-86 with Ik-1 or MZF1, but not 
EV, decreased the cell viability of the NPM-ALK+ ALCL cells (Figure 14A and 14B). In 
addition, cell proliferation was significantly reduced by the two transcription factors (Figure 
14C and 14D). Furthermore, migration in response to IGF-I was significantly hindered in the 
three cell lines (Figure 14E). Finally, Ik-1 and MZF1 abrogated the potential of NPM-ALK+ 
ALCL cells to form colonies in methylcellulose (Figure 14F and 14G).  
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FIGURE 14. Transfection of Ik-1 and MZF1 decreases the viability, proliferation, 
migration, and anchorage-independent colony formation of NPM-ALK+ ALCL cells. 
(A) Compared with EV, transfection of Ik-1 was associated with significant decreases in the 
viability of the NPM-ALK+ ALCL cells Karpas 299, SUP-M2, and SR-786 at 48 h after 
transfection (*: P < 0.0001). (B) In a similar fashion, transfection of MZF1 into these cells 
induced marked decreases in their viability (*: P < 0.0001). (C) Ik-1 significantly decreases 
the proliferation of the NPM-ALK+ ALCL cell lines (*: P < 0.05; **: P < 0.01). (D) In 
addition, transfection of MZF1 reduced the proliferation of these cells (*: P < 0.05; **: P < 
0.01). (E) IGF-I stimulated the migration of Karpas 299, SUP-M2, and SR-786 cells. 
Whereas this effect was profoundly reduced when cells were treated with IGF-I and 
simultaneously transfected with Ik-1 or MZF1; transfection of EV failed to induce similar 
effects (for Karpas 299, *: P < 0.0001 in IGF-I vs. IGF-I+Ik-1 and IGF-I+MZF1, †: P < 0.01 
in IGF-I+EV [Ik-1] vs. IGF-I+Ik-1, ‡: P < 0.001 in IGF-I+EV [MZF1] vs. IGF-I+MZF1; for 
SUP-M2, §: P < 0.05 in IGF-I vs. IGF-I+Ik-1, IGF-I+EV [Ik-1] vs. IGF-I+Ik-1 and IGF-
I+EV [MZF1] vs. IGF-I+MZF1, †: P < 0.01 in IGF-I vs. IGF-I+MZF1; for SR-786, *: P < 
0.0001 in IGF-I vs. IGF-I+MZF1, IGF-I+EV [Ik-1] vs. IGF-I+Ik-1, and IGF-I+EV [MZF1] 
vs. IGF-I+MZF1, ‡: P < 0.001 in IGF-I vs. IGF-I+Ik-1). (F) Ik-1 abrogated anchorage-
independent colony formation of Karpas 299, SUP-M2, and SR-786 cells at 7 days after 
transfection (*: P < 0.05; **: P < 0.01; ***: P < 0.001 compared with EV). The numbers of 
the colonies are shown in the left panel, and representative examples from cells transfected 
with EV or Ik-1 are shown in the right panel. (G) Furthermore, MZF1 halted NPM-ALK+ 
ALCL cells’ anchorage-independent colony formation in methylcellulose at 7 days after 
transfection (*: P < 0.05; **: P < 0.01 compared with EV). The numbers of the colonies are 
shown in the left panel, and representative examples from cells transfected with EV or MZF1 
are shown in the right panel. Results illustrated in Fig. 14 are means ± SE of at least 3 
consistent experiments. 
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3.1.3. Transcriptional Regulation of IGF-IR: Gene Amplification 
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3.1.3.1. Materials and Methods 
Cell Lines – Five characterized NPM-ALK+ ALCL cell lines were used in this study 
including Karpas 299, DEL, SUP-M2, SR-786, and SU-DHL-1. Normal T lymphocytes were 
purchased from StemCell Technologies (Catalog # 70024, Vancouver, British Columbia). 
Lymphoma cell lines and T lymphocytes were maintained in RPMI 1640 medium (HyClone, 
South Logan, Utah) supplemented with 10% FBS, glutamine (2 mM), penicillin (100 U/ml), 
and streptomycin (100 μg/ml) at 37°C in a humidified 5% CO2 in air chamber.  
Cytospins – Cytospins were prepared from NPM-ALK+ ALCL cell lines and normal T 
lymphocytes. Approximately 100,000 cells were suspended in RPMI medium and pipetted 
into cytospin chambers. Cells were suspended onto slides using the following conditions: 700 
rpm, high acceleration, for 5 min. Once completed, the slides were allowed to dry and fixed 
immediately in ice cold 100% methanol (-20°C) for 5 min. Thereafter, slides were air dried 
and stored in -20°C until FISH was performed. 
Fluorescent in situ hybridization (FISH) – Human T lymphocytes and NPM-ALK+ T-cell 
lymphoma cells (1 × 105 cells) suspended in RPMI were pipetted into cytospin chambers. 
Cytospin slides were prepared (700 rpm at high 25 acceleration for 5 min). The cytospin 
slides were fixed in ice cold 100% methanol, and stored at -20°C until FISH was performed. 
We adopted a previously described approach to perform FISH assay and analysis [136]. The 
SureFish probes and kit from Agilent Technologies were used. Briefly, 1.0 μL of IGF-IR 
FISH probe (G100168R) and 1.0 μL of chromosome enumeration probe 15 (CEP15; 
G100543G), which identify centromere 15, were mixed gently in Agilent FISH hybridization 
buffer. Cytospin slides were prepared and placed in gradually increasing concentrations of 
ethanol (70%, 85%, and 100%), each for 1 min at room temperature. After allowing the 
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slides to dry, 5.0 μL of probe/hybridization buffer mixture were added to the slides, and 
cover slips were applied. Hybridization was then accomplished by using the ThermoBrite 
system (Abbott Molecular, Abbott Park, IL). The slides were first incubated at 78°C for 5 
min to denature the DNA, and then incubated at 37°C for 24 h. Thereafter, cover slips were 
removed and slides were placed and agitated in Wash buffer 1 (73°C) for 2 min. 
Subsequently, slides were transferred and agitated at room temperature for 2 min in Wash 
Buffer 2. The slides were air dried in the dark at room temperature, followed by pipetting 
DAPI (1.0 μg/mL in PBS). DAPI was then removed, and slides were mounted with 
ProlongGold antifade media (P36934, Invitrogen, Grand Island, NY) and viewed using the 
FV1000 confocal microscope (Olympus America, Center Valley, PA).  
FISH scoring was performed in 55 nonoverlapping nuclei per slide. The means of the 
IGF1R gene and CEP15 copy numbers per cell, number of cells with two or fewer, three, and 
four or more copies of IGF1R and CEP15 signals, and IGF1R-to-CEP15 ratio were obtained. 
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3.1.3.2. Results 
IGF-IR is not amplified in NPM-ALK+ ALCL cell lines: We analyzed IGF-IR gene probe 
signal (red) and the chromosome 15 pericentromeric (CEP) probe signal (green) in 
approximately 55 nonoverlapping nuclei in 5 NPM-ALK+ ALCL cell lines (Karpas 299, SR-
786, SUP-M2, SU-DHL-1, and DEL) and normal T lymphocytes prepared on cytospins by 
FISH (Figure 15). Also, we measured the additional parameters that are listed in Figure 15. 
While normal T lymphocytes IGF-IR copy number was approximately 2 copies/cell, the 
median IGF-IR gene copy number in the cell lines was 3 copies/cell. However, the median 
CEP15 gene copy number in the cell lines analyzed by FISH was 2.5 copies/cell. 
Considering that the ratio between IGF-IR gene copy number-to-CEP15 gene copy number is 
1.1, we conclude that there is no apparent IGF-IR gene amplification in NPM-ALK+ ALCL 
cells.    
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FIGURE 15. FISH analysis of IGF-IR gene (red signal) and chromosome enumeration 
15 (green signal; CEP15), which detects centromere 15, copy numbers in normal human 
T lymphocytes and NPM-ALK+ ALCL cell lines. FISH studies show no evidence to 
support amplification of IGF-IR gene in NPM-ALK+ ALCL cells. As shown in the table, the 
IGF-IR-to-CEP15 ratio was consistently < 2.0 in the T lymphocytes as well as in the NPM-
ALK+ T-cell lymphoma cells. 
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3.2. Discussion for Aim 1 
In this aim, we show that previously unidentified defects in transcriptional machinery 
contribute to the pathogenesis of NPM-ALK+ ALCL. Firstly, we found that, compared with 
their expression in normal human T lymphocytes, the transcription factors Ik-1 and MZF1 
are markedly decreased in NPM-ALK+ALCL cell lines and lymphoma tumors from patients. 
Substantial evidence is provided to support that Ik-1 and MZF1 possess the ability to bind 
specific sites residing within the IGF-IR gene promoter and inhibit its activity. In agreement 
with these observations, ectopic expression of Ik-1 and MZF1 in NPM-ALK+ ALCL cells 
causes remarkable downregulation of the expression of IGF-IR mRNA and protein. Also, 
transfection of Ik-1 and MZF1 was associated with decreased cell viability, proliferation, 
migration, and anchorage independent colony formation of NPM-ALK+ ALCL cells, 
asserting the tumor suppressing impact of Ik-1 and MZF1 in this lymphoma. Secondly, we 
failed to identify IGF-IR gene amplification in the lymphoma cells after measuring IGF-IR 
gene and CEP15 pericentromeric gene copy numbers.  
It has been previously shown that Ik-1 induces tumor-suppressing effects primarily in 
hematopoietic cellular elements [146-148]; nonetheless, the contribution of MZF1 to 
tumorigenesis is more diverse as it may induce oncogenic or tumor suppressor effects in 
hematopoietic and non-hematopoietic cells [149-154]. The IGF-IR gene promoter is tightly 
regulated during mammalian development, and during the embryonic and early postnatal 
stages it induces the transcription of high levels of IGF-IR mRNA, which decreases to much 
lower levels during growth [155]. The IGF-IR gene promoter is a TATA-less and CAAT-less 
promoter, and like other structurally similar promoters, the IGF-IR promoter is GC-rich [156-
158]. The transcription of the IGF-IR gene is therefore initiated from an 11 basepair unique 
site contained within an “initiator” motif similar to the ones present in the terminal 
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deoxynucleotidyl transferase and adenovirus middle late gene promoters [157, 159, 160]. 
Although levels of expression of IGF-IR during physiological and pathological conditions 
can be rigorously determined at the transcriptional level [161], relatively few transcription 
factors have been shown to be capable of binding with and regulating the expression of the 
IGF-IR gene promoter. The multiple GC boxes present in this promoter form potential 
binding sites for members of the zinc-finger transcription factor family. In line with this 
possibility, earlier studies using rat IGF-IR gene promoter showed that Sp1, a zinc-finger 
transcription factor, binds with GC boxes located within the 5’-flanking region and one 
homopurine/homopyrimidine motif (CT element) in the 5’-untranslated region of IGF-IR 
gene promoter to enhance its activity [159, 162]. 
The IGF-IR gene promoter also includes cis-elements for members of the early growth 
response family of zinc-finger proteins including the WT1 Wilms tumor suppressor, which, 
in contrast with Sp1, downregulates the expression of IGF-IR [163, 164]. Indeed, increased 
expression of WT1 protein was associated with a reciprocal decrease in the expression of 
IGF-IR protein and receptor number in prostate cancer cells, and downregulation of WT1 
increased IGF-IR expression in glioblastoma [165, 166]. Albeit less extensively studied, 
E2F1 and EGR-1 are also implicated in the positive regulation, and STAT1 in the negative 
regulation of IGF-IR gene expression [167-169]. In addition to the direct regulatory effects of 
Sp1 and WT1, several studies have elucidated indirect contributions of oncogenic and tumor 
suppressor proteins to the regulation of the IGF-IR gene expression through interactions with 
these two transcription factors. In breast cancer, BRCA1 appears to suppress the IGF-IR 
promoter activity, but there is no evidence to support BRCA1 binding and direct interactions 
with the IGF-IR promoter. Instead, BRCA1 most likely suppresses the activity of the IGF-IR 
promoter through the sequestration of Sp1 [170, 171]. 
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Similarly, in breast cancer cells, the estrogen receptor enhances IGF-IR gene promoter 
activity via interactions with Sp1 and WT1 [172, 173]. Also, MCF7 breast cancer cells that 
express caveolin-1 demonstrate much higher levels of IGF-IR gene promoter activity, and the 
effects of caveolin-1 on the IGF-IR gene promoter were mediated through Sp1 [174]. 
Furthermore, the tumor suppressor transcription factor, Kruppel-like factor 6 (KLF6), 
activates IGF-IR gene transcription through synergy with Sp1 [175]. Moreover, it was found 
that wild-type p53 downregulates IGF-IR gene expression and mutated p53 enhances this 
expression [176-178]. The regulatory mechanisms conferred by p53 also do not involve 
specific binding with the IGF-IR gene promoter but seem to be mediated, at least partially, 
by protein-protein interactions between p53 and Sp1. 
We have also previously demonstrated that NPM-ALK and IGF-IR are physically 
associated, and it appears that this physical association, through interactions with Hsp90, 
enhances the stability of NPM-ALK protein [127]. In the current study, the decrease in IGF-
IR expression after Ik-1 and MZF1 transfection was also associated with pronounced 
decrease in NPM-ALK basal protein levels. Although these results agree with our previous 
observations, we sought to investigate whether Ik-1 or MZF1 is capable of regulating the 
expression of NPM-ALK directly at the transcriptional level. The web-based transcription 
factor search algorithms failed to predict potential binding sites between the NPM gene 
promoter, where the transcription of the NPM-ALK chimeric oncogene is driven [34], and 
either Ik-1 or MZF1. Furthermore, a luciferase assay using an NPM reporter construct 
showed that transfection of Ik-1 and MZF1 does not affect NPM promoter activity or protein 
levels. Therefore, our current results indicate that the decrease in NPM-ALK protein levels 
occurs secondarily to Ik-1- and MZF-1-induced downregulation of IGF-IR protein 
expression. 
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The Ik-1 and MZF1 transcription factors play physiological roles in the development of 
normal hematopoiesis [142-145]. In the present work we describe for the first time in any 
type of cancer cell the negative regulation of IGF-IR gene expression by Ik-1 and MZF1 
transcription factors. Ik-1 regulates transcription by binding to specific consensus binding 
sites (C/TGGGAA/T) within target promoters [179]. Similarly, MZF1’s 13 zinc fingers are 
separated into 2 arms, and each arm has the ability to independently bind to specific binding 
sites within the promoters of target genes: the first domain of fingers 1-4 (ZN 1-4) binds to 
the sequence 5'-AGTGGGGA-3', and the second domain of fingers 5-13 (ZN 5-13) binds the 
core sequence 5'-CGGGnGAGGGGGAA-3' [144]. Similar to other transcription factors that 
bind with IGF-IR gene promoter, we found that Ik-1 and MZF1 possess the potential to bind 
with sequences located both upstream and downstream of the transcription start site within 
the 5'-flanking region as well as within the 5'-untranslated region. Specifically, potential 
binding sites for Ik-1 are located at nucleotides -504/-491, -138/-125, +77/+90, +427/+440, 
and +1011/+1024, and potential binding sites for MZF1 are located at nucleotides -504/-496, 
-299/-291, -138/-130, +501/+514, +919/+928, and +1011/+1019 (binding sites confirmed by 
ChIP are underlined). To our knowledge, these binding sites have not been previously 
described to bind with any of the transcription factors that are known to regulate IGF-IR 
gene. Among the previously described transcription factors, Sp1, E2F1, and EGR-1 showed a 
greater net change in promoter activity at binding sites located downstream of the 
transcription start site [162, 168, 169]. While this pattern was similar to Ik-1, MZF1 
demonstrated a greater net change in IGF-IR promoter activity at binding sites located 
upstream of the transcription start site, which resembles the inhibitory effects induced by 
WT1 [163]. 
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Ik-1- and MZF1-induced downregulation of IGF-IR was associated with decreased levels 
of its activated/phosphorylated form, pIGF-IR. These effects induced downregulation of the 
phosphorylation levels of the molecular targets of IGF-IR including IRS-1, AKT, and 
NPMALK. Whereas basal levels of AKT remained unchanged, the basal levels of IRS-1 
decreased after transfection of Ik-1 and MZF1. To further analyze this unexpected finding, 
we searched the web-based transcription factor algorithms and found that the IRS-1 gene 
promoter contains sites that could potentially function as targets for Ik-1 and MZF1 
transcriptional activity. It is important to mention that IRS-1 is also a downstream target of 
NPM-ALK phosphorylation activity [52]. Although further analysis is required to support 
this idea, we cannot completely rule out that Ik-1 and MZF1 act as tumor suppressors in this 
lymphoma through targeting the expression of IGF-IR and IRS-1. 
It is important, however, to emphasize that deregulated systems underlying the 
pathogenesis of NPM-ALK+ ALCL are complex owing to the fact that they originate from 
more than one defective regulatory mechanism [131]. Although our results provide strong 
evidence that the aberrant decrease in the expression of Ik-1 and MZF1 transcription factors 
contributes to upregulation of an important oncogenic protein, i.e., IGF-IR, we elected to 
investigate whether other transcriptional mechanisms exist to further enhance IGF-IR 
expression. Our experiments failed to support the presence of IGF-IR gene amplification, an 
aberrant transcriptional mechanism, in NPM-ALK+ ALCL. IGF-IR gene amplification has 
been previously reported in small subgroups of patients with solid tumors such as lung cancer 
[136, 138]. To this end, our data suggest a model in which upregulation of IGF-IR in NPM-
ALK+ ALCL results from defects in transcriptional mechanisms, which reflects the 
complexity of survival signaling in this lymphoma. 
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3.3. Posttranscriptional Regulation of IGF-IR 
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3.3.1. Introduction 
Modifications of mRNA stability and/or translational efficiency through the 
posttranscriptional regulation of mRNAs are increasingly reported in cancer. MicroRNAs 
(miRs) constitute a family of 19- to 24- noncoding nucleotide RNAs that regulate gene 
expression posttranscriptionally through direct targeting of the 3’-UTR of the mRNA. There 
has been substantial evidence indicating that miRs are aberrantly expressed in many human 
cancers and may function as oncogenes or tumor suppressors; thus contributing significantly 
to cancer development and progression [180, 181]. Recently, there have been a few studies 
examining miRs that play a role in the pathogenesis of NPM-ALK+ ALCL [182-185]. In our 
lab, we identified substantial decrease in basal expression levels of miR-96 and miR-26a in 
NPM-ALK+ ALCL than normal human T lymphocytes [61, 132]. Importantly, we found that 
miR-96 induces negative regulatory effects on the expression of NPM-ALK protein, and 
miR-26a downregulates the expression of iNOS protein. However, the regulation of IGF-IR 
by miRs in NPM-ALK+ ALCL has not been studied previously. 
Another mechanism in which oncogenes, growth factors, cytokines, and cell-cycle 
regulatory genes are regulated posttranscriptionally is by controlling the rate of their mRNA 
turnover. In support of this view, mRNA turnover directly impacts signaling pathways that 
are often overactive in cancer, suggesting an important posttranscriptional component in 
regulating the expression of target mRNAs. In this aim, we hypothesized whether increased 
IGF-IR expression may be explained by posttranscriptional aberrancies, such as deregulated 
miRs and delayed mRNA turnover.  
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3.3.2. Posttranscriptional Regulation of IGF-IR: MicroRNA 
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3.3.2.1. Materials and Methods 
Microarray analysis – Total RNA isolation was performed using the Trizol reagent 
(Invitrogen, Grand Island, NY). RNA labeling and hybridization on miR array chips were 
performed as previously described [186]. Briefly, 5 μg of total RNA from each sample was 
biotin-labeled by reverse transcription using 5′ biotin end-labeled random octomer oligo 
primer. Hybridization of biotin-labeled cDNA was carried out on a miR array chip (MD 
Anderson Cancer Center, Version 5.0), which contains 678 human miR genes in duplicate. 
Hybridization signals were detected by biotin binding of a streptavidin–Alexa647 conjugate 
by using an Axon GenePix 4000B scanner and the images were quantified by GenePix 6.0 
software (Axon Instruments, Union City, CA). 
Web-based software – In order to identify potential binding sites for miR-30a or miR-30d in 
the IGF-IR-3’-UTR, 3 web-based algorithms were used: MiRANDA 
(http://www.microrna.org/microrna/home.do), PicTar (http://pictar.mdc-berlin.de), and 
TargetScan (http://www.targetscan.org). 
Cell lines – Five NPM-ALK+ ALCL cell lines were used in this study including Karpas 299, 
DEL, SUP-M2, SR-786, and SU-DHL-1 (DSMZ, Germany). Normal T lymphocytes were 
purchased from StemCell Technologies (Catalog # 70024, Vancouver, British Columbia). 
The R- cells (mouse 3T3-like fibroblasts with targeted ablation of Igf1r) were a generous gift 
from Dr. R. Baserga (Thomas Jefferson University, Philadelphia, PA) and were used as the 
host cell line for luciferase assay studies [100]. The lymphoma cell lines and normal T 
lymphocytes were maintained in RPMI 1640 medium (HyClone, South Logan, Utah) 
supplemented with 10% FBS (Sigma, St. Louis, MO), glutamine (2 mM), penicillin (100 
U/ml), and streptomycin (100 μg/ml) at 37°C in a humidified 5% CO2 in air chamber. 
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Dulbecco’s Modified Eagle Medium (DMEM), supplemented with 10% FBS was used to 
culture the R- cells under the same above conditions.  
MiR isolation from formalin-fixed and paraffin embedded (FFPE) – miRs were extracted 
from formalin-fixed, paraffin-embedded tissue sections prepared from tumor samples using 
the High Pure FFPE RNA Micro Kit (Roche Applied Science, Indianapolis, IN). First, FFPE 
tissue sections were marked for areas of interest and subjected to the following 
deparaffinization conditions: xylene (2 changes, 10 min each), 100% ethanol (2 changes, 10 
min each), and deionized water (1 change, until ready for tissue excision). Tissue areas were 
excised using a blade and placed in microcentrifuge tubes. Tubes were spun to bring contents 
to the bottom of the tube. To each sample, 100 µL Paraffin Tissue Lysis Buffer (provided in 
kit), 16 µL 10% SDS, and 40 µL Proteinase K working solution were added. Samples were 
vortexed and incubated in a 55°C water bath for 3 h. Next, 325 µL binding buffer was added 
to each sample and transferred into the High Pure Filter tube attached to a 2mL collection 
tube (provided in kit). Tubes were centrifuged 30 sec at 10,000 × g. Following centrifugation, 
the flow through was discarded and samples were washed 2 times with 500 µL Wash buffer 
working solution, then once again with 300 µL Wash buffer working solution. Finally, the 
tubes were centrifuged at 13,000 × g for 1 min to dry the filter. The High Pure Tube was 
placed in a clean 1.5 mL microcentrifuge tube and solution containing miRs were eluted 2 
times with 20 µL nuclease-free water.  
RNA extraction, cDNA synthesis, and quantitative real time PCR (qPCR) – Total RNA was 
isolated and purified using RNAeasy Mini Kit (Qiagen, Valencia, CA). Briefly, 1-2 × 106 
cells were collected by centrifugation at 200× g for 5 min, washed twice in sterile PBS, and 
subjected to lysis and homogenization by RNA Lysis (RLT) buffer using QiaShredder spin 
columns. Homogenized cells were resuspended in an equal volume of 70% ethanol and 
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passed through provided spin columns. Two additional washing steps were performed with 
appropriate buffers: Buffer RW1 and Buffer RPE. Total RNA was collected upon elution 
with nuclease-free water. Optical density readings were read using DNA/Protein Analyzer 
(Beckman Coulter, Fullerton, CA)  
cDNA synthesis for IGF-IR was performed through a two-step procedure using 
Superscript III RT protocol (Invitrogen, Carlsbad, CA). Approximately 0.3 μg total RNA was 
used for reverse transcription. First, total RNA, oligo (dT), and dNTP mix were added to a 
mixture that was adjusted to a final volume of 10 μL with nuclease-free water. This mixture 
was denatured by incubating at 65°C for 5 min and then placed on ice. Second, a master 
reaction mix consisting of 10× cDNA synthesis buffer, 0.1 DTT, RNaseOUT, SuperscriptIII 
RT, MgCl2 and nuclease-free water was prepared on ice and vortexed gently. Approximately 
10 μL of master mix was pipetted into each sample tube on ice bringing the final volume to 
20 μL. The samples were then transferred to a thermal cycler preheated to the appropriate 
cDNA synthesis temperature and incubated for 60 min at 50°C, then terminated at 85°C for 5 
min. 1 μL of RNase H was added and samples were incubated at 37°C for 20 min to remove 
template RNA. 
 cDNA synthesis for miR-30a and miR-30d was performed using the TaqMan MicroRNA 
Reverse Transcription Kit (Applied Biosystems). Briefly, 100 mM dNTPs (with dTTP), 
MultiScribe™ Reverse Transcriptase (50 U/µL), 10× Reverse Transcription (RT) Buffer, 
RNase Inhibitor (20 U/µL), and nuclease-free water was combined with total RNA in the 
ratio of 7 µL RT master mix: 5 µL total RNA (300 ng/reaction). Samples were mixed gently 
and centrifuged to bring the solution to the bottom of the tube. To each sample, 12 µL of the 
master mix prepared above containing total RNA and 3 µL of 5× RT primer from each assay 
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set was added into the corresponding RT reaction tube for a final volume of 15 μL/reaction. 
The samples were vortexed, centrifuged briefly, and transcribed using the following PCR 
conditions: 
Table 7. PCR conditions for miRNA reverse transcription 
Steps  Time  Temperature 
Hold  30 min  16°C 
Hold  30 min  42°C 
Hold  5 min  85°C 
Hold  ∞   4°C 
qPCR was used to quantitate the levels of IGF-IR mRNA in NPM-ALK+ ALCL cell lines 
after transfection with miR-30a and miR-30d using the reverse transcribed cDNA, IGF-IR 
gene expression assay primer/probe, and Taqman Mastermix (Applied Biosystems). The 
primer/probe sets used were obtained from Applied Biosystems (sequences not provided by 
the manufacturer). 18S ribosomal RNA was used as the endogenous control.  
qPCR was used to examine the expression levels for miR-30a and miR-30d using the 
reverse transcribed cDNA, miR-30a, miR-30d or RNU48 gene expression assay 
primer/probe, and Taqman Mastermix (no AmpErase UNG) (Applied Biosystems). The 
primer/probe sets used were obtained from Applied Biosystems (sequences not provided). 
RNU48 was used as the endogenous control. 
Transfection – Transfection of NPM-ALK, control mimic, miR-30a, miR-30d (Dharmacon) 
or with vectors used to create stable cell lines was performed by electroporation using Amaxa 
nucleofection system in 100 µL cuvettes (Lonza; Solution V, Program A-023) and thereafter, 
cells were incubated for 48 h. For luciferase assays, R- cells were transfected using 
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Lipofectamine 2000 reagent. Briefly, 1 × 106 R- cells were seeded in 6 well plates overnight. 
The following day, plasmids were incubated in 100 μL Optimem media for 5 min at room 
temperature. Simultaneously, 7 μL of Lipofectamine reagent was incubated in a separate 
tube. Thereafter, the tubes containing plasmids and the tubes containing Lipofectamine 
reagent were combined and incubated for a further 20 min at room temperature. Finally, the 
mixture was added to the corresponding well in the 6 well plates containing R- cells and 
incubated for 48 h. 
Cloning of IGF-IR 3’-UTR – IGF-IR 3’-UTR luciferase plasmid containing miR-30 binding 
site was constructed by the following approach: IGF-IR was amplified from genomic DNA 
(50 ng) using the HotStar Taq Mastermix, primers and PCR conditions listed in Table 2. 
Table 8. PCR conditions for WT IGF-IR 3’-UTR construction 
Primer Name      Sequence 
WT IGF-IR 3’-UTR Forward 5’-GTGTCCGCATCTTTCTGGTC-3’ 
WT IGF-IR 3’-UTR Reverse 5’-GGATCACAAACACACATTTGC-3’ 
Step    Temperature Time 
1. Initial activation step 95°C   15 min  
2. 3-step cycling (35 cycles) 
Denaturation:   94°C   1 min  
Annealing:  55°C   1 min 
Extension:   72°C   1 min  
3. Final extension: 10 min 72°C 
The PCR products were run on 1.5% agarose gel, excised, and purified using the 
QIAquick gel extraction kit (Qiagen). Subsequently, DNA was ligated into pCR 2.1-TOPO 
vector using the TOPO TA cloning system (catalog # 451641; Invitrogen). Briefly, 4 µL of 
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fresh PCR product, 1 µL of Salt Solution, 1 µL of pCR 2.1-TOPO vector, and 5 µL of 
nuclease-free water were admixed and incubated for 5 min at room temperature. Thereafter, 
ligated products were immediately transformed using DH5α competent cells and plated on 
ampicillin resistant agar plates coated with 40 mg/mL X-gal overnight at 37°C. White 
colonies were picked and amplified using ampicillin containing LB broth overnight at 37°C 
with shaking at 225 rpm and subjected to miniprep using QIAprep Miniprep kit (Qiagen). 
Plasmid sequence was confirmed using direct sequencing. In order to create the luciferase 
reporter plasmid containing the IGF-IR 3’-UTR, the pCR 2.1-TOPO-IGF-IR-3’-UTR 
plasmid and the pGL4.17 luciferase vector (Promega) were subjected to restriction enzyme 
digest using Hind III and Eco RV restriction enzymes (New England Biolabs, Ipswich, MA). 
Restriction enzyme digested products were run on a 1.5% agarose gel and purified using the 
QIAquick gel extraction kit. Resulting DNA was ligated using the Quick Ligation kit 
(Catalog # M2200S; New England Biolabs) and the following PCR conditions in Table 3: 
Table 9. PCR conditions for Quick Ligation 
Temperature  Time 
22°C   30 min 
20°C   30 min 
18°C   30 min 
16°C   30 min 
14°C   30 min 
12°C   30 min 
10°C   30 min 
8°C   30 min 
6°C  30 min 
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4°C  30 min 
4°C   ∞ 
Ligated products were subjected to transformation as described above. The WT IGF-IR 
3’-UTR luciferase vector was used as a template to create mutated (MUT) IGF-IR 3’-UTR 
luciferase constructs using the Quickchange II XL site-directed mutagenesis kit (Agilent 
Technologies), primers and PCR conditions listed in Table 4. 
Table 10. PCR conditions for mutated IGF-IR 3’-UTR construction  
MUT IGF-IR 3’-UTR Forward  
5’-TAGTCAGTTGACGAAGATCTGGTCAAGAACTAATTAAATGTTTCATT-3’ 
MUT IGF-IR 3’-UTR Reverse  
5’-AATGAAACATTTAATTAGTTCTTGACCAGATCTTCGTCAACTGACTA-3’ 
Step Temperature Time 
1.  95°C   1 min 
2.*   95°C   50 sec 
60°C   50 sec 
68°C   6 min 
3.  68°C   7 min 
*Step 2 is repeated for a total of 18 cycles 
MUT IGF-IR 3’-UTR luciferase plasmids were transformed, purified, and verified using 
the above procedures. 
Luciferase assay – Luciferase assay was performed with the Dual Glo Luciferase kit 
(Promega) after cotransfecting R- cells with the reporter plasmids containing the wild type or 
mutated IGF-IR 3’-UTR constructs along with control mimic, miR-30a or miR-30d. Cells 
were washed with sterile PBS, scraped, and plated in a 96 well luminometer plate. 
Thereafter, the Dual-Glo Reagent (75 μL) was added and incubated for 10 min at room 
temperature for cell lysis to occur. Firefly luminescence readings were obtained using a 
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luminometer. Finally, the Dual-Glo Stop & Glo reagent was added in equal volume to 
original culture media volume and incubated for 10 min at room temperature. Renilla 
luminescence readings were obtained using the above methods.  
Western blotting – Cells were collected and lysed using lysis buffer containing 25 mM 
HEPES (pH 7.7), 400 mM NaCl, 1.5 mM MgCl2, 2 mM EDTA, 0.5% Triton X-100, 0.1 mM 
PMSF, 2 mM DTT, phosphatase inhibitor, and protease inhibitor cocktails (Thermo 
Scientific). Protein concentrations were measured using Bio-Rad protein assay and OD 
values were obtained using an ELISA plate reader (Bio-Tek Instruments, Winooski, VT). 
Proteins (50 μg) were electrophoresed on 8% SDS-PAGE. The proteins were transferred to 
PVDF membranes and probed with specific primary antibodies and then with appropriate 
horseradish peroxidase-conjugated secondary antibodies (GE Healthcare, Cardiff, UK). 
Proteins were detected using chemiluminescence-based kit (Amersham Life Sciences, 
Arlington Heights, IL).  
Antibodies – The following antibodies were used: pIGF-IRY1131 (3021), pALKY1604 (Y664 in 
NPM-ALK; 3341), pAKTS473 (4051), integrin α5 (4705), and integrin β1 (9699) (all from 
Cell Signaling Technology, Danvers, MA); IRS-1 (ab40777) and AKT (ab8805) (Abcam, 
Cambridge, MA); IGF-IR (396700, Life Technologies, Grand Island, NY); pIRS-1S639 (sc-
22300, Santa Cruz Biotechnology, Santa Cruz, CA); ALK (M719501-2, Dako, Carpinteria, 
CA); and β-actin (A-5316, Sigma). 
Colony formation assay – Transfected cells were resuspended to eliminate clumping and 
then added in a 1:10 (v/v) ratio to 3 mL methylcellulose (MethoCult H4230 (NPM-ALK+ 
ALCL cells) or MammoCult 04100 (for MCF-7); Stemcell Technologies) in 15 mL tubes. 
Tubes were tightly capped, and the mix was gently inverted several times. Then, 1.0 mL of 
the mix was divided into 24-well plates in triplicates. Plates were placed in a humidified 
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incubator at 37°C in 5% CO2 for 7 days and then p-iodonitrotetrazolium violet was added for 
24 h for staining. Colonies were visualized using AlphaImager system (Santa Clara, CA). 
Cell proliferation assay – Cell proliferation was measured using the 5-bromo-2′-
deoxyuridine (BrdU) assay kit (ExAlpha, Shirley, MA). Briefly, 2 × 105 cells/mL was plated 
into a 96-well plate. The BrdU label (1:500 dilution) was added, and the plate was incubated 
for 24 h at 37°C. Cells were fixed for 30 min at room temperature, incubated with anti-BrdU 
antibody for 1 h after washing, followed by peroxidase goat anti-mouse IgG conjugate 
(1:2000 dilution) for 30 min. Thereafter, the 3,3’,5,5’-tetramethylbenzidine peroxidase 
substrate was added and incubated for 30 min at room temperature in the dark. Thereafter, 
the acid Stop Solution was used to stop the reaction and the plate was read at 450 nm using 
an ELISA plate reader. 
Cell migration assay – Cell migration was studied using 24-well transwell plates with 
polycarbonate membranes (Corning Costar, Tewksbury, MA). Briefly, treated NPM-ALK+ 
ALCL cells were serum-starved for 24 hours, then loaded in serum-free RPMI 1640 medium 
onto the upper compartment. Simultaneously, 500 ng/mL insulin-like growth factor I (IGF-I) 
(R&D Systems, Minneapolis, MN) was loaded in serum free culture medium onto the lower 
compartment. For control cells, untransfected cells were incubated with or without IGF-I in 
the lower compartment. Plates were incubated for 4 h at 37°C, and cells migrating through 
the membrane into the lower chamber were counted using a particle counter and size 
analyzer (Coulter). 
5’aza-cytidine treatment – 1 × 106 NPM-ALK+ ALCL cells were plated in 24 well plates. 5 
μM 5’-aza-cytidine (Catalog # A2385; Sigma Aldrich) was added to the wells and the plate 
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was incubated for 5 h. Thereafter, cells were collected by centrifugation (200× g for 5 min), 
washed once with PBS, and subjected to RNA extraction. 
Stable cell lines – To generate Karpas 299 tamoxifen-inducible stable cells, vectors 
containing miR-30a (pEGFP/RFP-miR-30a) or miR-30d (pEGFP/RFP-miR-30d) were used 
(catalog # v-0923, CelluTron, Baltimore, MD). The vector expressing Cre recombinase 
(pCreER-IRES-Puro) was also used (catalog # v-0924, CelluTron). Karpas 299 cells were 
transfected with empty vector or miR-30a or miR-30d expression vectors by electroporation 
(as described above). Forty-eight hours post transfection, 2.5 µg/mL blasticidin was added to 
culture media and the cells were incubated for 2 weeks. Thereafter, sorting by flow 
cytometry was performed to isolate the GFP+ cells, which indicate that the miR vector of 
interest is present. Furthermore, sorted cells were collected and expanded to become the 
subsequent “host cell line.” The “host cell lines” were then transfected with the second vector 
expressing Cre recombinase by electroporation. After 48 h, 0.1 µg/mL puromycin was added 
for 1 week. Subsequently, stable cells expressing either empty vector or miR along with the 
Cre recombinase vector were expanded and maintained in media containing 1.5 µg/mL 
blasticidin and 0.05 µg/mL puromycin. Stable cell lines were first tested in vitro using 2 µM 
4-hydroxytamoxifen (4-OHT; Sigma Aldrich). Images were obtained using Olympus IX70 
microscope (Center Valley, PA).  
In vivo studies – Mice (SCID/beige, female, 8 weeks old) were purchased from Taconic 
Biosciences, Inc. (CBSCBG-F, Hudson, NY). Karpas 299 cells (2.0 × 106) expressing either 
empty vector miR-30a or miR-30d were subcutaneously injected into the left flank. On the 
day of injection, 2 mg/mL 4-OHT (dissolved in ethanol and corn oil in 1:9 ratio) was 
administered for 21 days by i.p. injection. Tumor size was measured every 3 days using 
Vernier calipers, and tumor burden was calculated using the formula: 3.14 × long axis × short 
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axis2 × 0.6 cm3. Mice were euthanized when tumors reached 1.5 cm. To measure miRNA 
levels, some were sacrificed at day 21. 
Statistical analysis – Statistical analysis was performed using GraphPad Prism software. The 
student’s t-test, Tukey’s multiple comparisons test, Log Rank Mantel-Cox test, and 2-way 
ANOVA were used for statistical comparison, whenever appropriate. P < 0.05 was 
considered statistically significant. 
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3.3.2.2. Results 
MiR-30a and miR-30d are downregulated in NPM-ALK+ ALCL cells: To examine whether 
deregulated miRs exist in NPM-ALK+ ALCL cells, an miR array analysis was performed 
using 5 NPM-ALK+ ALCL cell lines (Karpas 299, SR-786, SUP-M2, SU-DHL-1, DEL) 
compared to normal human T lymphocytes (Figure 1A). The array generated a list of 
potentially downregulated or upregulated miRs in NPM-ALK+ ALCL cells. Because of our 
interest in IGF-IR, 3 web-based algorithms, TargetScan, PicTar, and miRANDA, were 
utilized to explore whether any of the highly ranked miRs have potential binding sites with 
the IGF-IR 3’-UTR. We identified that members of the miR-30 family of miRNAs could 
potentially bind the IGF-IR 3’-UTR (Figure 16A). Although several members of this family 
appeared to be deregulated based on the heat map, two of these miRs, miR-30a and miR-30d, 
appeared with the highest binding probability. The low expression levels of miR-30a and 
miR-30d, relative to human T lymphocytes, were confirmed by qPCR (Figure 16A). 
Examination of miR-30a and miR-30d expression levels in lymphoid tumors from patients 
revealed that these miRs were significantly decreased in these tissues compared to normal 
lymph nodes (P<0.0001, Figure 16B).  
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FIGURE 16. Array analysis of differential expression of miR in NPM-ALK+ ALCL cell 
lines vs. normal human T lymphocytes. (A) MicroRNA array analysis identified numerous 
miR to be downregulated (green/blue) or upregulated (yellow/orange/red) in NPM-ALK+ 
ALCL cell lines vs. normal human T lymphocytes. Because of our interest in whether any of 
these miRs is involved in the regulation of IGF-IR expression, we used the web based 
algorithms, TargetScan, MiRanda, and PicTar, to identify miRs with the potential to bind the 
3’-UTR of IGF-IR. These algorithms predicted members of miR-30 family to bind with 3’-
UTR-IGF-IR (> 0.9). We focused on miR-30a and miR-30d because they demonstrated the 
highest differential expression. The algorithms also proposed the potential binding sites of 
miR-30a and miR-30d within the IGF-IR 3’-UTR (bottom panel). According to the miR 
array, these miR are markedly downregulated in the lymphoma cell lines than the normal 
human T-cell (upper left panel). Decreased expression of these miR was further confirmed by 
qPCR (upper right panel) (T lymphocytes vs. NPM-ALK+ ALCL cell lines: * = p<0.00005). 
(B) qPCR also shows that miR-30a and miR-30d are significantly downregulated in FFPE 
tumor tissues from ALK+ ALCL patients compared to normal lymph nodes (* = p<0.05). 
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MiR-30a and miR-30d bind IGF-IR 3’-UTR and decrease IGF-IR protein, but not IGF-IR 
mRNA levels: We explored whether miR-30a and miR-30d possess the ability to bind and 
regulate IGF-IR 3’-UTR by performing a luciferase assay using a wild type IGF-IR 3’-UTR 
luciferase construct along with control, miR-30a or miR-30d mimics transfected into R- cells, 
which lack the expression of IGF-IR. Simultaneously, a luciferase assay using mutated IGF-
IR 3’-UTR luciferase construct lacking binding domains to miR-30a and miR-30d was 
performed after transfection of control or miR mimics. MiR-30a and miR-30d, but not the 
control mimic, decreased the luciferase activity of wild type IGF-IR 3’-UTR. Furthermore, 
changes were not observed in the luciferase activity of the mutated IGF-IR 3’-UTR. These 
findings suggest that miR-30a and miR-30d bind and negatively regulate IGF-IR 3’-UTR 
(Figure 17). Next, the effects of miR-30a and miR-30d on endogenously expressed IGF-IR 
were examined by transfecting Karpas 299 and DEL cells with either control, miR-30a or 
miR-30d mimic and then measuring IGF-IR protein and mRNA levels by Western blotting 
and qPCR, respectively (Figure 18). Although miR-30a and miR-30d significantly decreased 
IGF-IR protein, they failed to decrease IGF-IR mRNA, suggesting that these miRs induce 
negative regulation of IGF-IR expression posttranscriptionally (Figure 18). We further 
examined the phosphorylation levels of IGF-IR and its important downstream signaling 
targets. Transfection of miR-30a and miR-30d was associated with decreased pIGF-IRTyr1131, 
and also decreased pIRS-1Ser639 and pAKTSer473 levels, with no changes in total IRS-1 and 
AKT. It has been previously demonstrated that IRS-1 and AKT are downstream targets of 
IGF-IR signaling. MiR-30a and miR-30d also decreased pNPM-ALKTyr664 expression levels. 
This finding is consistent with our previous observations that IGF-IR functions to maintain 
the phosphorylation of NPM-ALK [128]. In addition, miR-30a and miR-30d also decreased 
total NPM-ALK protein expression. We have previously demonstrated that IGF-IR is able to 
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maintain NPM-ALK protein stability [127]. However, to rule out that these 2 miRs have 
direct inhibitory effects on NPM-ALK, we searched the web-based miR target prediction 
algorithms, and found that NPM-ALK does not represent a target of miR-30a or miR-30d. 
These findings provide strong evidence to support that the decrease in total NPM-ALK 
expression levels resulted from the decrease in IGF-IR and its effects on promoting the 
stability of NPM-ALK protein. Finally, miR-30a and miR-30d decreased the expression of 
important proteins involved in cell migration and adhesion and known to contribute to IGF-
IR oncogenic effects, namely integrin α5/β1. 
 
 
 
 
 
 
 
 
 
 
 
 
106 
 
** 
* 
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
IGF-IR 3'UTR+control mimic IGF-IR 3'UTR+miR-30a
IGF-IR 3'UTR+miR-30d IGF-IR 3'UTR[MT]+control mimic
IGF-IR 3'UTR[MT]+miR-30a IGF-IR 3'UTR[MT]+miR-30d
R
el
at
iv
e 
lig
ht
 u
ni
t 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
107 
 
 
 
 
 
 
 
 
 
FIGURE 17. MiR-30a and miR-30d decrease IGF-IR-3’-UTR activity. A luciferase assay 
in R- cells transfected with wild type IGF-IR 3’-UTR luciferase reporter construct along with 
control mimic, miR-30a or miR-30d mimics revealed that miR-30a and miR-30d can bind 
and regulate IGF-IR 3’-UTR. In contrast, R- cells transfected with control mimic or mutated 
[MT] IGF-IR 3’-UTR failed to show similar decrease in IGF-IR 3’-UTR activity (*: p<0.05; 
**: p<0.001). The results are shown as means ± SD of 3 consistent experiments. 
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FIGURE 18. MiR-30a and miR-30d decrease IGF-IR protein expression, but not IGF-
IR mRNA expression. Forced expression of control mimic, miR-30a or miR-30d mimics in 
Karpas 299 and DEL cell lines induced marked downregulation of IGF-IR protein (upper 
panel), but not IGF-IR mRNA (lower panel), indicating that these miRs regulate IGF-IR 
expression posttranscriptionally. The results are shown as means ± SD of 3 consistent 
experiments. In addition, there were significant decreases in pIGF-IRTyr1131, pNPM-
ALKTyr664, pIRS-1Ser639, and pAKTSer473 without any changes in total IRS-1 or total AKT. In 
contrast, the basal levels of NPM-ALK were significantly reduced, which is in agreement 
with our previous findings that IGF-IR sustains the stability of NPM-ALK protein. 
Furthermore, there was significant decrease in the tumor cell invasion-related proteins, 
integrins α5/β1. To our knowledge, which was further supported by searching the web-based 
miR prediction search algorithms, integrins α5/β1 are not potential direct targets of miR-30a 
or miR-30d, and therefore their downregulation most likely resulted from IGF-IR 
downregulation.  
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MiR-30a and miR-30d decrease cell proliferation, migration, and anchorage-independent 
colony formation potential of NPM-ALK+ ALCL cells: Thereafter, we proceeded to test the 
impact of miR-30a and miR-30d-mediated downregulation of IGF-IR on the neoplastic 
potential of NPM-ALK+ ALCL. Transfection of Karpas 299 and DEL with either miR-30a or 
miR-30d significantly decreased lymphoma cell proliferation (Figure 19A), migration in 
response to IGF-I (Figure 19B), and anchorage-independent colony formation potential. 
Similar effects were not observed in control cells transfected with control mimic (Figure 
19C). 
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FIGURE 4. MiR-30a and miR-30d decrease cell proliferation, migration, and colony 
formation potential in NPM-ALK+ ALCL cells. (A) Transfection of Karpas 299 and DEL 
cells with miR-30a or miR-30d, but not control mimic, resulted in significant decrease in the 
proliferation of these cells after 48 h. (B) In addition, miR-30a and miR-30d decreased 
significantly the migration of the lymphoma cells in response to IGF-I (500 ng/mL). (C)  The 
2 miRs abrogated Karpas 299 and DEL cell colony forming potential. The number of 
colonies is shown on the left and representative images are shown on the right. *: p<0.05; **: 
p<0.001; §: control mimic vs. miR-30a [p<0.05]; ¥: control mimic vs. miR-30d (p<0.05); †: 
control mimic vs. miR-30d (p<0.001). The results are shown as means ± SD of 3 consistent 
experiments. 
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Methylation contributes to downregulation of miR-30a and miR-30d expression in NPM-
ALK+ ALCL: At this point, we sought to define the mechanisms that could lead to 
downregulation of miR-30a and miR-30d expression in NPM-ALK+ ALCL. To determine 
whether the decrease in miR-30a and miR-30d was due to effects elicited by NPM-ALK, 
Karpas 299 and DEL cells were transfected with scrambled siRNA or ALK siRNA for 
various time points, and miR-30a and miR-30d levels were measured by qPCR. Even after 
sufficient knockdown of NPM-ALK, there were no significant changes in miR expression, 
suggesting that NPM-ALK most likely does not induce the decrease in miR-30a and miR-
30d (data not shown). 
Several miRs have been previously shown to be decreased in cancer cells due to 
epigenetic events, such as methylation of their gene promoters [187]. To test whether 
methylation is suppressing expression of miR-30a and miR-30d in NPM-ALK+ ALCL, 
Karpas 299 and SUP-M2 cells were treated with the demethylating agent 5’-azacytidine (5’-
aza) for 48 h and levels of miR-30a and miR-30d were measured by qPCR (Figure 20). 5’-
aza significantly increased miR-30a by 2, 2, and 3-fold in Karpas 299, DEL, and SUP-M2, 
respectively. In addition, 5’-aza increased miR-30d by 2.5, 2, and 4-fold in Karpas 299, DEL, 
and SUP-M2, respectively. These results suggest that methylation could represent one 
possible mechanism underlying decreased expression of miR-30a and miR-30d in NPM-
ALK+ ALCL. 
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FIGURE 20. 5’-aza increases miR-30a and miR-30d expression in NPM-ALK+ ALCL 
cells. Treatment of Karpas 299, DEL, and SUP-M2 with the demethylating agent 5’-aza-
cytidine (5 µM for 48 h) resulted in increased miR-30a (2 fold, 2 fold, and 3 fold for Karpas 
299, DEL, and SUP-M2, respectively) and miR-30d expression (2.5 fold, 2 fold, and 4 fold 
for Karpas 299, DEL, and SUP-M2, respectively) (* = p<0.05, ** = p<0.001). The results are 
shown as means ± SE of 3 consistent experiments. 
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MiR-30a and miR-30d suppress NPM-ALK+ ALCL tumor progression in mice: Tamoxifen-
inducible stable cell line variants of Karpas 299 cells that express EV, miR-30a or miR-30d 
were developed to test the effect of miR-30a and miR-30d on NPM-ALK+ ALCL in vivo. To 
create these cell lines, a vector containing miR-30a or miR-30d juxtaposed to a red 
fluorescent protein (RFP) coding sequence, was obtained. The vector also contained a green 
fluorescent protein (GFP), which is flanked by lox P sites. The miR expressing vectors were 
sequentially transfected with a second plasmid encoding Cre recombinase. With the 
treatment of 4-hydroxy tamoxifen (4-OHT), the Cre recombinase was activated, which 
resulted in excision of "floxed" GFP and the termination sequence allowing RFP and miR to 
be expressed. Ex vivo analysis revealed that miR-30a and miR-30d were stably expressed, as 
indicated by expression of RFP after the cells were treated with 4-OHT for 48 h, compared to 
untreated cells that still showed GFP expression (Figure 21). In addition, cells transfected 
with EV showed only GFP expression. 
Stable cell lines expressing EV, miR-30a or miR-30d were subcutaneously injected into 3 
different groups of SCID/beige mice. On the day of injection, 2 mg/mL 4-OHT was 
administered i.p. to induce the expression of the miRs, and thereafter was administered daily 
for 21 days to maintain the expression of miRs (Figure 22). Importantly, during the course of 
administration of 4-OHT, mice in which miRs were induced displayed much slower tumor 
establishment rate compared to control mice. By day 21, all of the mice in the control group 
had already been euthanized, whereas all of the mice from the miR-30a and miR-30d groups 
were alive. To measure miR levels after induction, some mice from the miR groups were 
sacrificed at day 21. The level of expression of miR-30a and miR-30d were also measured in 
tumors from control mice with lack of induction of miR. The remaining mice in were 
monitored past day 21 without 4-OHT administration. After cessation of miR induction at 
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day 21, tumors present in mice with activated miR-30a and miR-30d slowly began to 
increase in size, although never reached the size of the control group. Furthermore, we 
noticed that miR-30a and miR-30d groups of mice had much smaller tumors that were more 
localized to the injection site relative to the control group (Figure 22A). Control mice, in 
contrast, displayed larger tumors that were sometimes disseminated and spread to the dorsal 
areas away from the injection site (Figure 22B). Measurement of miR-30a and miR-30d in 
mouse tumors revealed both miRs to be decreased in control mice, but demonstrated high 
expression in tumors from miR-induced mice. Furthermore, miR seemed to be continually 
expressed at low levels after stopping 4-OHT treatment, which may account for the fact that 
these tumors only gradually increased in size after 4-OHT cessation (Figure 23).  
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FIGURE 21. Inducible miR-30a and miR-30d mouse model. (A) Stable Karpas 299 cell 
lines were tested ex vivo before utilizing in mice. 4-OHT was added to Karpas 299 cells 
expressing EV, miR-30a (pEGFP/RFP-miR-30a/pCreER-IRES-Puro) or miR-30d 
(pEGFP/RFP-miR-30d/pCreER-IRES-Puro) for 48 h. Fluorescent microscopy revealed 
conversion of GFP to RFP in cells transfected with miR-30a or miR-30d, indicating 
expression of miRs, whereas cells expressing EV had no RFP signal, and thereby lack miR. 
(B) Mice experiments scheme illustrating that 8-week old female SCID/beige mice were 
injected s.c. with 2 × 106 Karpas 299 cells expressing EV, miR-30a or miR-30d. In miR-30a 
and miR-30d groups, 4-OHT (2 mg/mL) was administered i.p. once daily and tumor burden 
was measured every 3 days up to 21 days. After stopping 4-OHT at 21 days, some mice were 
scarified to measure miRs levels in the tumors and the remainder observed until euthanized.  
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FIGURE 22. MiR-30a and miR-30d suppress NPM-ALK+ ALCL tumor growth in vivo. 
(A) Upper left panel; during administration of 4-OHT, mice in which miR-30a or miR-30d 
was activated developed tumors substantially slower than the control mice. More 
importantly, all control mice had been euthanized due to excessive tumor burden at day 21 or 
before, whereas no mice from the miR-30a or miR-30d groups required to be euthanized 
during this period. By day 29, tumor burden in miR-30a or miR-30d groups began to 
gradually increase although for most of the tumors over 50 days their size was still 
considerably less than control group tumors (overall tumor volume significance over 50 days: 
control vs. miR-30; p=0.0004) Upper right panel; day 21 tumor volume only (*= p< 0.05); 
Lower panel; survival for miR-30a and miR-30d groups of mice was significantly longer 
relative to control groups (***= p=0.0006). (B) Representative images at day 21 (with 4-
OHT) or > day 21 (no 4-OHT). Control mice displayed larger tumors, including one mouse 
that displayed disseminated tumors (example shown; all tumors from this example are shown 
as tumor aggregate below image), whereas mice from miR-30a and miR-30d groups at 21 
days displayed tumors that were smaller and localized to the site of injection. Although the 
mice in the miR-30 groups in which 4-OHT treatment was stopped displayed slightly larger 
tumors after 21 days, the tumor volume was still considerable less compared to controls.  
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FIGURE 23. Adequate induction of miR-30a and miR-30d expression by 
administration of 4-OHT in mice. miR-30a and miR-30d expression levels increased in 
tumors from mice administrated 4-OHT for 21 days. High levels of miRs expression 
continued even after cessation of 4-OHT, perhaps indicating that induction of miRs led to 
persistent expression in the system.  
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3.3.3. Posttranscriptional Regulation of IGF-IR: mRNA Stability 
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3.3.3.1 Materials and Methods 
Cell lines – Five NPM-ALK+ ALCL cell lines were used: Karpas 299, DEL, SUP-M2, SR-
786, and SU-DHL-1 (DSMZ, Germany). Normal T lymphocytes were purchased from 
StemCell Technologies (Catalog # 70024, Vancouver, British Columbia). Lymphoma cell 
lines and normal T lymphocytes were maintained in RPMI 1640 medium (HyClone, South 
Logan, UT) supplemented with 10% FBS (Sigma, St. Louis, MO), glutamine (2 mM), 
penicillin (100 U/ml), and streptomycin (100 μg/ml) at 37°C in a humidified 5% CO2 in air 
chamber.  
Actinomycin D treatment – Briefly, actinomycin D (Sigma) was dissolved in DMSO (final 
concentration: 1 mg/mL). Human T lymphocytes or NPM-ALK+ ALCL cell lines were 
treated with 1 µM actinomycin D and samples were collected at 0, 0.5, 1, 2, 4, and 8 h.  
RNA extraction, cDNA synthesis and absolute quantitative real time PCR (qPCR) – Total 
RNA was isolated and purified using RNAeasy Mini Kit (Qiagen, Valencia, CA). Briefly, 1-
2 × 106 cells were collected by centrifugation at 200× g for 5 min, washed twice in sterile 
PBS, and subjected to lysis and homogenization in RLT buffer using QiaShredder spin 
columns. Homogenized cells were resuspended in an equal volume of 70% ethanol and 
passed through provided spin columns. Two additional washing steps were performed with 
appropriate buffers: Buffer RW1 and Buffer RPE. Total RNA was collected upon elution 
with RNAse-free water. Optical density readings were detected using Nanodrop (Thermo 
Scientific). 
cDNA synthesis was performed through a two-step procedure using Superscript III RT 
protocol (Invitrogen, Carlsbad, CA). Approximately 0.3 μg total RNA was used for reverse 
transcription. First, total RNA, oligo (dT), and dNTP mix were added to a mixture that was 
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adjusted to a final volume of 10 μL with Rnase-free water. RNA mixture and primer was 
denatured by incubating at 65°C for 5 min and then placed on ice. Second, a master reaction 
mix consisting of 10× cDNA synthesis buffer, 0.1 DTT, RNaseOUT, SuperscriptIII RT, 
MgCl2, and RNAse-free water was prepared on ice and vortexed gently. Approximately 10 
μL of reaction mix was pipetted into each reaction tube on ice bringing the final volume to 20 
μL. The samples were then transferred to a thermal cycler preheated to the appropriate cDNA 
synthesis temperature and incubated for 60 min at 50°C, then terminated at 85°C for 5 min. 1 
μL of RNase H was added and samples were incubated at 37°C for 20 min to remove 
template RNA.  
Absolute Quantitation real-time PCR was used to examine levels of IGF-IR mRNA in 
NPM-ALK+ ALCL cell lines and normal T lymphocytes in a 25 µL reaction using 1 µL of 
the reverse transcribed cDNA, 20× IGF-IR copy number primer/probe, and Taqman 
Genotyping Mastermix (Applied Biosystems). The primer/probe sets used were obtained 
from Applied Biosystems (sequences not provided). To create a standard curve, serial ten-
fold dilutions (30, 300, 3000, 30,000, 300,000 copies) of an IGF-IR plasmid [128] were used. 
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3.3.3.2. Results 
Rate of IGF-IR mRNA decay in ALK+ ALCL cell lines and normal human T lymphocytes: 
Consistent with our previously published results [128], basal levels of IGF-IR were much 
higher in the NPM-ALK+ ALCL cell lines than in the normal human T lymphocytes (Figure 
24A, 24B). In T lymphocytes, IGF-IR mRNA decreased to 50% of its basal levels at 0.8 h 
(Fig. 1A). The decay of IGF-IR mRNA varied among the 5 different NPM-ALK+ ALCL cell 
lines, yet it consistently occurred at a more prolonged rate than T lymphocytes (Figure 24B), 
decreasing to 50% of the basal IGF-IR mRNA at 2.62 ± 0.4 h (mean ± SE). 
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FIGURE 24. IGF-IR mRNA expressed in NPM-ALK+ ALCL cells exhibits prolonged 
decay time compared with IGF-IR mRNA from normal human T lymphocytes. (A) The 
50% level of IGF-IR mRNA was detected at 0.8 h in normal human T lymphocytes. (B) In 
contrast with T lymphocytes, the NPM-ALK+ ALCL cell lines expressed remarkably higher 
basal levels of IGF-IR mRNA, with DEL and SUP-M2 cells demonstrating the highest and 
lowest levels, respectively. The 50% IGF-IR mRNA level was achieved after longer periods 
of time in the lymphoma cells than in normal T lymphocytes (SU-DHL-1: 3.7 h, Karpas 299: 
3.4 h, SR-786: 2.6 h, SUP-M2: 1.9 h, DEL: 1.5 h). The mean of the IGF-IR mRNA decay 
time in the lymphoma cells was 2.62 ± 0.4 h (SE). Results shown represent the means ± SE 
of 3 experiments. 
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3.4. Discussion for Aim 2 
In this aim, we identified deregulated posttranscriptional mechanisms that could contribute to 
the pathogenesis of NPM-ALK+ ALCL. First, we identified miR-30a and miR-30d as 
potential regulators of IGF-IR expression at the posttranscriptional stage. Relative to normal 
T lymphocytes and reactive human lymphoid tissues,, miR-30a and miR-30d were 
significantly decreased in the NPM-ALK+ ALCL cell lines and tissues from lymphoma 
patients. Binding of miR-30a and miR-30d to respective binding sites located within the IGF-
IR 3’-UTR decreased substantially the activity of the IGF-IR 3’-UTR. Furthermore, both 
miRs decreased IGF-IR protein levels but not IGF-IR mRNA levels, suggesting that these 
miRs do not cleave IGF-IR mRNA, but inhibit IGF-IR translation. Downregulation of IGF-
IR by miR-30a and miR-30d resulted in decreased phosphorylation of several important IGF-
IR interacting proteins and induced reduction in cell proliferation, migration, and colony 
formation. Treatment with the demethylating agent, 5’-aza-cytidine, was associated with 
increased miR-30a and miR-30d levels in NPM-ALK+ ALCL cell lines, alluding to the 
possibility that these miRs are suppressed by epigenetic silencing. Importantly, the 2 miRs 
hindered NPM-ALK+ ALCL tumor growth in immune-compromised mice. These results 
suggest that miR-30a and miR-30d can negatively regulate the progression of NPM-ALK+ 
ALCL. At the posttranscriptional level, we also determined that IGF-IR mRNA turnover was 
considerably slower in the NPM-ALK+ ALCL cells compared with normal T lymphocytes.  
When we measured the expression levels of miR-30a and miR-30d, both miRNAs were 
significantly decreased in the NPM-ALK+ ALCL cell lines and patient tumors compared to 
normal T lymphocytes and reactive lymph nodes. To the best of our knowledge, the gene 
from which miR-30a and miR-30d are transcribed has not been identified, and therefore, this 
proved to be a limitation for us to further investigate how the expression of these miRs is 
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negatively regulated. Nonetheless, there have been reports showing that certain oncogenes 
can directly inhibit the expression of miRs [188-192]. Thus, we sought to examine whether 
the key oncogene in NPM-ALK+ ALCL, namely NPM-ALK, is involved in the suppression 
of miR-30a and miR-30d. Effective targeting NPM-ALK by siRNA did not result in 
increased expression of either miR-30a or miR-30d, suggesting that NPM-ALK is not 
contributing to downregulation of miR-30a and miR-30d expression (data not shown). 
However, there have been a variety of other mechanisms proposed for the deregulation of 
miRs in cancer such as epigenetic silencing [187]. A large proportion of tumor suppressor 
miRs are located within CpG islands, and therefore, are prone to DNA hypermethylation, as 
in the case of miR-127, miR-9-1, miR-34b/c cluster, and the DNMT1-derived miR-124a 
[193-196]. In our study, treating the NPM-ALK+ ALCL cell lines with demethylating agent 
5-aza-cytidine increased the expression of miR-30a and miR-30d, suggesting that the gene 
promoter from which miR-30a and miR-30d are transcribed is methylated.  
Although there are few studies that have shown that some members of the miR-30 family 
possess oncogenic potential, the majority of these studies have described these miRs as tumor 
suppressors [197-201]. In line with these studies, our data show that miR-30a and miR-30d 
induced significant posttranscriptional decrease in IGF-IR protein expression,. To further 
support this notion, both miR-30a and miR-30d decreased significantly the activity of the 
IGF-IR 3’-UTR, which resulted in decreased cell proliferation, migration, and colony 
formation potential of NPM-ALK+ ALCL cell lines, testifying to the tumor suppressor 
properties of these miRs.  
Exogenous expression of miR-30a and miR-30d in the NPM-ALK+ ALCL cells 
decreased the phosphorylation of NPM-ALK as well as its basal protein levels. We have 
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recently demonstrated that IGF-IR and NPM-ALK are physically associated via the Y646 
and Y664 residues of NPM-ALK and Y950 residue of IGF-IR, which are located within their 
respective C-terminus. Through this association, a positive feedback loop appears to sustain 
their activation/phosphorylation [127, 128]. We also previously found that specific 
abrogation of IGF-IR by siRNA significantly decreased NPM-ALK protein levels, further 
attesting to the contribution of IGF-IR to sustaining NPM-ALK protein stability [127]. Using 
the 3 web-based miR prediction algorithms, we found that miR-30a and miR-30d do not have 
potential binding sites within NPM-ALK, implying that the decrease seen in NPM-ALK 
protein expression levels most likely resulted from IGF-IR downregulation. 
Decreased IGF-IR level after transfection with miR-30a and miR-30d was associated 
with decreased phosphorylation of important IGF-IR downstream signaling partners, 
including pIRS-1 and pAKT, with no changes in total IRS-1 or AKT, which further 
demonstrates that miR-30a and miR-30d possess tumor suppressor properties in this 
lymphoma. Previous in vitro and in vivo studies showed that members of the miR-30 family 
are involved in the regulation of migration, invasion, and adhesion in a variety of cancer cells 
including those of the prostate, pancreas, and breast. These effects occur through modulating 
key proteins such as Ets-related gene (ERG), vimentin, integrin β3, and other epithelial-to-
mesenchymal transition molecules [199, 202, 203]. In the NPM-ALK+ ALCL cells, another 
cellular protein involved in cell adhesion and migration, integrin α5/β1, significantly 
decreased after miR-30-induced downregulation of IGF-IR. There have been previous reports 
indicating that IGF-IR or its primary ligand IGF-I can promote the stability and expression of 
α5/β1 to support the progression of different carcinomas, such as plasma cell myeloma, 
prostate cancer, and chondosarcoma by enhancing cell motility, migration, adhesion of the 
malignant cells, and contributes to therapeutic resistance [204-208]. Because α5/β1 is not a 
133 
 
direct target of miR-30a or miR-30d, as indicated by the three online algorithms, 
downregulation of IGF-IR by miR-30a and miR-30d most likely caused the decrease in α5/β1 
and thus contributed to the inhibition of the migratory potential of the NPM-ALK+ ALCL 
cells.  
MiR-30a and miR-30d were able to inhibit the NPM-ALK+ ALCL tumor growth in 
SCID/beige mice. Even after withdrawing the administration of 4-OHT at 21 days, miR 
expression remained elevated in the mice, suggesting that although the tumor growth in some 
of these mice increased gradually, the overall average of the tumors in miR-30-induced group 
of mice never reached the overall average of tumor growth in control mice, perhaps due to 
the persistent effects of miR-30, which continuously slowed the progression of the tumors. In 
addition, some control mice displayed disseminated tumors, whereas all the miR-30a and 
miR-30d groups displayed smaller tumors that were confined to site of injection. Although 
these miRs can regulate different proteins involved in migration and invastion, it is possible 
that in our system, this effect was due to downregulation of integrin α5/β1 and thereby 
limiting the migration of these cells to other sites.  
Because we found that the lack of expression of miR-30a and miR-30d is independent 
from NPM-ALK, we decided to study whether these miRs are also capable of regulating the 
expression of IGF-IR in other cancer types that are known to have high expression of IGF-IR 
such as breast cancer and colon cancer [209, 210]. Similar to the NPM-ALK+ ALCL, miR-
30a and miR-30d were significantly decreased in the MCF-7 and SW480 breast cancer and 
colon cancer cell lines, respectively, as well as primary tissue specimens from patients 
(Figure S1). Ectopic expression of miR-30a and miR-30d in MCF-7 and SW-480 cells 
induced remarkable downregulation of IGF-IR protein, but not IGF-IR mRNA (Figure S2). 
Downregulation of IGF-IR decreased pIGF-IR, pAKT, pIRS-1, integrin α5/β1, and led to 
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significant reduction in cell proliferation, migration, and anchorage-independent colony 
formation potential (Figures S2 and S3). It has been previously shown that upregulation of 
integrin α5/β1 in MCF-7 cells contribute to multidrug resistance (MDR) [205]. 
Downregulation of integrin α5/β1 through reduction in IGF-IR protein by miR-30a and miR-
30d may provide a mechanism to overcome MDR in these cells. Furthermore, both miR-30a 
and miR-30d significantly hindered progression of mammary tumors in female Balb/c nude 
mice (Figures S5 and S6). Recently, it has been shown that IRS-2 is a target for miR-30a in 
colon cancer [211]. In addition, miR-30a has been previously documented to reduce breast 
cancer by targeting vimentin, AVEN, metadherin, and Eya2 [212-215]. This further stresses 
the importance of these miRs for the survival of these cancers. In our study, we provide 
substantial evidence demonstrating IGF-IR as a novel target for miR-30a and miR-30d in 
these cancers. 
Our data also show that the posttranscriptional decay of IGF-IR mRNA in NPM-ALK+ 
ALCL occurs over a remarkably prolonged time compared with the decay of IGF-IR mRNA 
that is physiologically expressed in human T lymphocytes, suggesting an additional 
deregulated mechanism in which IGF-IR is upregulated posttranscriptionally. Very few 
studies have examined the rate of IGF-IR mRNA decay in other types of cancer, but these 
few studies support our findings [216-218]. For instance, when we treated the NPM-ALK+ 
ALCL cells with actinomycin D, the average half-life for the lymphoma cells was around 3 
h. This is similar to what was observed in other types of cancer, such as in the pancreatic 
cells MIA-PaCa-2 in which the half-life of IGF-IR mRNA was 4 h, compared to control cells 
in which 50% of IGF-IR mRNA was decayed in as little as 20 min after actinomycin D 
treatment [218]. Similar rates of decay were observed in breast cancer cells after treatment 
with antiestrogen ICI 182780 in a separate study [219]. Some mechanisms have been 
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proposed to explain the sustained stability of IGF-IR mRNA. For example, in one study, 
treatment of the osteogenic sarcoma-derived cell line Saos-2 with TNFα, decreased 
substantially IGF-IR mRNA stability relative to untreated cells [220]. It has been previously 
reported that NPM-ALK+ ALCL cells lack the expression of TNFα due to DNA methylation 
of the TNFα promoter [221]. Furthermore, TNFα is highly expressed in normal activated T 
lymphocytes, where it is frequently involved in immune responses, especially in regards to 
inflammatory and immunomodulatory processes [222-225]. The lack of expression of this 
cytokine in the NPM-ALK+ ALCL cells may be one possibility why IGF-IR mRNA is able 
to remain stable for longer periods of time compared to the normal T lymphocytes. In two 
other separate studies, IGF-IR mRNA stability was greatly influenced by the expression of 
HuR, an mRNA-binding protein involved in regulating the stability of a variety of mRNAs 
[216, 217]. Whether either of these mechanisms plays a role in NPM-ALK+ ALCL is a 
direction of future study. 
Overall, in this aim, we have determined the tumor suppressing properties of miR-30a 
and miR-30d in NPM-ALK+ ALCL through targeting IGF-IR. Negative regulation of IGF-IR 
by miR-30a and miR-30d significantly reduces the oncogenic potential of these cells. In 
addition, the delay in IGF-IR mRNA decay further contributes to the upregulation of IGF-IR. 
Our results provide novel mechanisms in which IGF-IR is posttranscriptionally deregulated 
in this lymphoma, which may be beneficial to develop new therapeutic approaches to treat 
and ultimately eliminate the aggressive NPM-ALK+ ALCL. 
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3.4.1. Supplemental  
Stable cell lines – For MCF-7 Tet-inducible stable cell lines, miR-30a and miR-30d 
sequences were first subcloned into pmRi-mCherry vector (Clontech, catalog # 631119). 
Next, the pmRi-mCherry vectors expressing miR-30a or miR-30d were transfected into 
MCF-7 Tet-On Advanced cell line (catalog # 631153, Clontech) along with hygromycin B 
linear marker (200 ng; catalog# 631118, Clontech). Cells were cultured in DMEM media 
containing 100 µg/mL hygromycin B and 200 µg/mL G418 antibiotics for 2 weeks. Positive 
clones were expanded and maintained in DMEM media containing 50 µg/mL hygromycin B 
and 100 µg/mL G418.  
In vivo studies – For MCF-7 Tet-inducible miR in vivo experiments, mice (Balb/c nude, 
catalog # BALBNU-F, 6-weeks old, female) were first primed with 2.5 µg/50 µL 17-
estradiol (E2) diluted in peanut oil and injected s.c. for 1 week to assist MCF-7 cell 
proliferation. Then, mice were injected s.c. in the left mammary fat pad with 2 × 106 cells 
expressing MCF-7 Tet-ON, pmRi-mCherry-miR-30a or pmRi-mCherry-miR-30d. 
Doxycycline (2 mg/mL) plus 5% sucrose and 2.5 µg of E2 was administered starting on the 
day of cell injection in the drinking water that was changed every 3 days in order to activate 
the miR. Once tumors developed, tumor burden was measured every 3 days for 100 days 
after cell injection. Tumor burden was calculated using the formula 3.14 × long axis × short 
axis2 × 0.6. Doxycycline was administered during the entire 100 days, until mice were 
sacrificed.  
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FIGURE S1. MiR-30a and miR-30d are downregulated in MCF-7 and SW480 cells. (A) 
qPCR analysis identified the expression of miR-30a and miR-30d to be remarkably 
downregulated in MCF-7 and SW480 cells compared with normal epithelial cells (MCF-
10a). (B) A similar pattern of expression was identified in breast cancer patients and colon 
cancer patients compared to their respective normal counterparts (* = p<0.05). 
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FIGURE S2. MiR-30a and miR-30d decrease IGF-IR protein expression, but not IGF-
IR mRNA expression in MCF-7 and SW480 cells. Forced expression of control mimic, 
miR-30a mimic or miR-30d mimic in MCF-7 and SW480 cell lines induced marked 
downregulation of IGF-IR protein levels (upper panel), but not of IGF-IR mRNA levels 
(lower panel). The results are shown as means ± SD of 3 consistent experiments. In addition, 
as shown in upper panel, there were significant decreases in downstream signaling proteins 
such as pIGF-IR1131, p-IRS-1Ser605, and pAKTSer445 without notable changes in total IRS-1 
and AKT. Furthermore, miR-30a and miR-30d decreased the expression of integrin α5/β1.  
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FIGURE S3. MiR-30a and miR-30d decrease cell proliferation, migration, and colony 
formation potential in MCF-7 and SW480 cells. (A) Transfection of MCF-7 and SW480 
cells with miR-30a and miR-30d, but not control mimic, resulted in significant decrease in 
their proliferation after 48 h. (B) In addition, miR-30a and miR-30d decreased significantly 
the migration of the cells in response to IGF-I (500 ng/mL). (C) The two miRs decreased 
colony formation potential of MCF-7 and SW480 cells. Numbers of colonies are shown on 
the left and representative images are shown on the right. *: p<0.05; **: p<0.001; §: control 
mimic vs. miR-30a [p<0.05]; ¥: control mimic vs. miR-30d [p<0.05]. The results are shown 
as means ± SD of 3 consistent experiments. 
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FIGURE S4. Breast cancer mouse model with inducible expression of miR-30a or miR-
30d. Six-weeks old female Balb/c nude mice were first primed with s.c. injection of 2.5 
µg/50 µL 17-estradiol (E2) diluted in peanut oil subcutaneously for 1 week before cell 
injection in order to assist MCF-7 cell proliferation. Then, mice were injected s.c. in the left 
mammary fat pad with 2 × 106 cells expressing MCF-7 Tet-ON, pmRi-mCherry-miR-30a or 
pmRi-mCherry-miR-30d. Doxycycline (2 mg/mL) plus 5% sucrose and 2.5 µg of E2 was 
administered on the day of cell implantation in the drinking water that was changed every 3 
days for entire 100 days in order to activate the miR. Once tumors developed, tumor burden 
was measured every 3 days for 100 days total from time of cell implantation.  
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FIGURE S5. Inducible expression of miR-30a and miR-30d suppresses breast cancer 
tumor growth in vivo. (A) Right panel; tumors developed in all control mice at 62 days after 
MCF-7 cell s.c. implantation. In miR-30a and miR-30d groups, only 2/5 mice developed 
tumors. Tumors in control mice grew significantly faster, and the average tumor volume was 
greater than the miR-30a and miR-30d groups of mice, whose sizes were smaller and 
stabilized over the course of the study (100 days). Left panel; at day 100, control and miR-30 
groups were euthanized to collect tumors [tumor burden significance at day 100 only, ***= p 
<0.0001; overall tumor burden significance: control vs. miR-30; p<0.0001]. (B) At day 100, 
control mice displayed tumors of variable sizes but were generally larger with greater 
average tumor volume than mice from miR-30a and miR-30d groups that displayed smaller 
average tumor sizes.  
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FIGURE S6. Doxycyclin increased efficiently the levels of miR-30a and miR-30d in vivo. 
MiR-30a and miR-30d expression levels increased in tumors that miRs were activated by 
doxycycline treatment at 100 days. 
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3.5. Posttranslational Regulation of NPM-ALK & IGF-IR  
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3.5.1. Introduction 
Posttranslational modifications contribute to critical signaling events that occur during 
neoplastic transformation. SUMOylation is a posttranslational modification that is 
characterized by the covalent and reversible binding of small ubiquitin-like modifiers 
(SUMO), including SUMO-1, SUMO-2/3, and SUMO-4, with their target proteins [226-
228]. Although SUMOylation has some similarities with ubiquitination [229, 230], it has 
been shown that SUMO proteins compete with ubiquitin for substrate binding and thus 
SUMOylation appears to protect target proteins from proteasomal degradation [231, 232]. In 
addition to enhancing protein stability, SUMO proteins are involved in nuclear translocation 
of target proteins, which affects processes essential for cellular homeostasis [233, 234]. The 
SUMO family also includes the sentrin-specific proteases (SENPs): SENP1-3 and SENP5-7 
[226, 235]. The roles of SENPs encompass removal of SUMO from target proteins; thus 
suppressing protein stabilization induced by SUMOylation. It has been recently demonstrated 
that SUMOylation plays a key role in the progression of cancer by stabilizing oncoproteins or 
targeting tumor suppressors to proteosomal degradation [236-240]. SUMOylation in NPM-
ALK+ ALCL has not been previously studied; therefore, one of our goals in this aim is to 
analyze SUMOylation in this aggressive lymphoma. 
Posttranslational modifications also include ligand-mediated activation of target proteins. 
It has been previously shown that chimeric oncogenes, e.g., the Ewing sarcoma fusion 
proteins, transcriptionally induce the expression of IGF-I [68]. The increase in secreted IGF-
I, as we have previously demonstrated in this lymphoma, leads to phosphorylation and 
activation of IGF-IR protein through dimerization. Whether NPM-ALK upregulates IGF-I 
expression and, as a result, promotes IGF-I-induced activation of IGF-IR is not known. In 
this aim, we also examined the potential role of NPM-ALK in regulating IGF-I expression.  
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3.5.2. Aberrant Posttranslational Mechanisms: SUMOylation 
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3.5.2.1. Materials and Methods 
Web-based search – To identify potential SUMOylation consensus binding sites within 
NPM-ALK and IGF-IR amino acid sequences, the online algorithm SUMOplot was used: 
http://www.abgent.com/SUMOplot. 
Cell lines – Five characterized NPM-ALK+ ALCL cell lines were used, including Karpas 
299, DEL, SUP-M2, SR-786, and SU-DHL-1 (DSMZ, Germany). The 786-O (renal 
adenocarcinoma cell line; CRL-1932, ATCC) was used as a negative control for SUMO 
proteins. Jurkat cells (T lymphoblastic leukemia/lymphoma; ATCC) were used as host cells 
in protein degradation experiments and as a positive control. The normal human CD3+ pan-T 
cells were purchased (Catalog number: 70024, StemCell Technologies, Vancouver, British 
Columbia, Canada). Cells were maintained in RPMI 1640 medium (HyClone, South Logan, 
UT) supplemented with 10% FBS (Sigma, St. Louis, MO), glutamine (2 mM), penicillin (100 
U/mL), and streptomycin (100 μg/mL) at 37°C in a chamber containing humidified air with 
5% CO2.  
Western blotting – Western blotting was used to analyze the expression of various proteins. 
Cells were collected and subjected to lysis using lysis buffer as previously described [128]. 
Concentrations were measured using a Bio-Rad protein assay (Bio-Rad, Hercules, CA), and 
OD values were obtained using an ELISA plate reader (Bio-Tek Instruments, Winooski, VT). 
Proteins (50 μg) were subjected to electrophoresis with sodium dodecyl sulfate on 8% SDS-
PAGE. Proteins were transferred to polyvinylidene fluoride (PVDF) membranes and probed 
with specific primary antibodies and then with appropriate horseradish peroxidase–
conjugated secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, and GE 
Healthcare, Cardiff, UK). Proteins detection was performed using chemiluminescence 
(Amersham Life Sciences, Arlington Heights, IL).  
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Antibodies – Antibodies included SUMO-1 (4940), SUMO-2/3 (4971), Ubc9 (4786), SENP1 
(11929), Ubiquitin (3933), Myc-tag (2276) (Cell Signaling Technology, Danvers, MA), ALK 
(M7195; DAKO, Carpenteria, CA), and β-actin (a5316; Sigma, St. Louis, MO). 
Immunoprecipitation – Cells were lysed using lysis buffer containing 25 mM HEPES (pH 
7.7), 400 mM NaCl, 1.5 mM MgCl2, 2 mM EDTA, 0.5% Triton X-100, 0.1 mM 
phenylmethylsulfonyl fluoride (PMSF), 2 mM dithiothreitol (DTT), Halt protease and 
phosphatase inhibitor cocktails 100× (Thermo Scientific), and N-Ethylmaleimide (NEM; 10 
mM) (Thermo Scientific) to inhibit deSUMOylation [241]. For immunoprecipitation, protein 
A/G agarose beads (Millipore, Billerca, MA) were blocked with 5% bovine serum albumin 
(BSA) overnight in order to reduce non-specific binding. In addition, lysates were pre-
cleared using 2.5 µg normal IgG with rocking for 1 h at 4°C, followed by centrifugation for 1 
min at 13,000 rpm and removal of supernatant. Thereafter, 800 µg of lysate was incubated 
with 2.5 µg of primary antibody or mouse IgG control antibody along with the blocked 
protein A/G agarose beads overnight at 4°C. The next day, immunocomplexes were spun and 
supernatant was removed. The beads were washed 3 times with cold phosphate-buffered 
saline solution (PBS) for 15 min each at 13,000 rpm and once with lysis buffer, and then 
resuspended with 2× sample buffer (Bio-Rad). The samples were then subjected to SDS-
PAGE. 
Recombinant proteins – The NPM-ALK recombinant protein was constructed using the TnT 
T7/SP6 Coupled Rabbit Reticulocyte Lysate System (Promega, Fitchburg, WI). The template 
for the TnT reaction was a plasmid previously described [128]. The following reaction 
components were assembled in a 1.5 mL microcentrifuge tube: TNT Rabbit Reticulocyte 
Lysate (25 µL), TNT Reaction Buffer (2 µL), TNT T7 RNA Polymerase (1 µL), Amino Acid 
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Mixture Minus Leucine 1 mM (0.5 µL), Amino Acid Mixture Minus Methionine 1 mM (0.5 
μl), RNasin Ribonuclease Inhibitor, 40 u/µl (1 μL), NPM-ALK plasmid template (2 µL), 
Transcend Biotin-Lysyl-tRNA (1 μl), and nuclease-free water to a final volume of 50 μL. 
Thereafter, the reactions were incubated at 30°C for 90 min. Aliquots of these reactions (5 
µL) were analyzed by Western blotting to confirm the translation of NPM-ALK. 
SUMOylation assay – The in vitro SUMOylation assay was performed by using the SUMO-
1 and SUMO-2/3 SUMOlink Kits (Active Motif, Carlsbad, CA). Briefly, the following 
reaction components were assembled in a 1.5 mL microcentrifuge tube: protein buffer (1 
µL), 5× SUMOylation buffer (1 µL), NPM-ALK recombinant protein (4 µL), E1 activating 
enzyme (1 µL), E2 conjugating enzyme (1 µL), SUMO-1, -2 or -3 protein (1 µL), and 
nuclease-free water to a final volume of 20 μL. For baseline mutated reactions, the SUMO 
proteins were substituted with their corresponding mutated proteins, provided in the kit. The 
reactions were mixed gently and incubated at 30°C for 3 h. Thereafter, the reactions were 
stopped by adding an equal volume of 2× SDS-PAGE loading buffer and analyzed by 
Western blotting. 
Site-directed mutagenesis – NPM-ALKK24R and NPM-ALKK32R constructs were created by 
using the QuickChange II XL Site-Directed Mutagenesis kit (Agilent Technologies, Santa 
Clara, CA) and the following set of primers according to the manufacturer’s instructions: 
Table 11. Primers used to create NPM-ALKK24R and NPM-ALKK32R constructs by site-
directed mutagenesis. 
 
NPM-ALKK24R Forward 5’-TTTTCGGTTGTGAACTACGGGCCGACAAAGATTATC-3’ 
NPM-ALKK24R Reverse 5’-GATAATCTTTGTCGGCCCGTAGTTCACAACCGAAAAG-3’ 
NPM-ALKK32R Forward 5’-GCCGACAAAGATTATCACTITCGCGTGGATAATGATGAAAATGAG -3’ 
NPM-ALKK32R Reverse 5’-CTCATTTTCATCATTATCCACGCGAAAGTGATAATCTTTGTCGGC-3’ 
The polymerase chain reaction (PCR) products (5 µL) were transformed using 
MaxEfficiency DH5alpha competent cells (Invitrogen), and the transformation reactions 
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were plated on ampicillin-resistant plates. Colonies containing the correct insert were 
confirmed by direct sequencing and amplified in ampicillin-containing LB broth overnight at 
37°C with shaking at 225 rpm. The following day, the colonies were processed with the 
QiaPrep Spin Miniprep Kit (Qiagen, Germantown, MD) to isolate plasmids. For in vitro 
SUMOylation assays, the mutated plasmids were used as templates for the TnT reactions to 
create mutated recombinant proteins. 
Transfection – Transfection of NPM-ALK+ ALCL cells with the SENP1 expression plasmid 
(Origene, Rockville, MD) was performed by electroporation using the Amaxa 4D 
nucleofection system in 100 µL cuvettes (Solution SF, Program CA-150; Lonza, Houston, 
TX); Transfection of Jurkat cells using the wild-type NPM-ALK, NPM-ALKK24R or NPM-
ALKK32R plasmid was performed using the Nucleofector System (Solution V, Program X-
001; Lonza, Houston, TX); thereafter, cells were incubated for 48 h. 
Protein degradation assay – Cells were transfected, using the conditions described in the 
previous section, with either wild type or mutated NPM-ALK constructs for 48 h. The cells 
were then treated with cyclohexamide (CHX, Sigma-Aldrich; 100 µg/mL) for another 24 or 
48 h, then harvested and subjected to lysis and Western blotting.  
Immunofluorescence – Cytospins were prepared from EV or myc-tagged SENP1 transfected 
cells, followed by fixation with 4% paraformaldehyde (PFA) at the following timepoints: 0 
min, 15 min, 30 min, 1 h, 3h, 6 h, 12 h, 24 h, and 48 h. After fixation, cells were subjected to 
permeabilization with 0.2% Triton-X in PBS for 30 min at room temperature. Subsequently, 
cells were blocked with 0.3% Triton-X/2% BSA in PBS solution for 1 h at room temperature. 
Thereafter, Myc-tag primary antibody was added at 1:2000 dilution in order to detect 
exogenous SENP1 and slides were incubated at 4°C overnight. The following day, slides 
were washed 3 times in PBS and Alexa 647 fluorochrome-conjugated secondary antibody 
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was added at 1:200 dilution for 1.5 h at room temperature. Thereafter, slides were washed 3 
times in PBS and counterstained with DAPI. Prolong Gold Antifade Mountant (catalog # 
P36934; Invitrogen) was added, slides were coverslipped, and sealed with nail polish to 
prevent dehydration.  Images were captured using Deltavision Image Restoration microscope 
(Olympus IX71; GE Healthcare; total magnification is ×400). 
Cell fractionation – Cell fractionation was performed using the Nuclear/Cytosol 
Fractionation kit (BioVision, Milipitas, CA). For expression of cytoplasmic and nuclear 
proteins at baseline levels as well as after transfection with EV or SENP1 expression 
plasmids, cells were collected by centriguging at 600 × g for 5 min at 4°C. CEB-A buffer 
(0.2 mL) containing DTT and protease inhibitors (provided in the kit) was added and samples 
were spun at 500 × g for 3 min at 4°C. The supernatant was removed and the pellet was 
resuspended in 0.2 mL of the CEB-A mix and subjected to vigorous vortexing at the highest 
setting for 15 sec to fully resuspend the pellet. Thereafter, the samples were incubated on ice 
for 10 min. Ice-cold CEB-B buffer (11 µL) was added to the tube, which was subjected to 
vortexing and placed on ice for 1 min, and then spun at maximum speed for 5 min. 
Immediately, the supernatant (containing the cytoplasmic extract) was transferred into a 
clean, pre-chilled tube. The remaining pellet was washed 5 times in ice-cold PBS by 
centrifugation at maximum speed for 1 min. Then, the pellet was resuspended in 30 µL of 
ice-cold NEB buffer and subjected to vortexing for 15 sec and returned to ice for 10 min. 
This step was repeated 4 times. Finally, the samples were subjected to centrifugation at 
maximum speed for 15 min, and the supernatant (containing nuclear extract) was transferred 
into a clean, pre-chilled tube. 
Colony formation assay – Methylcellulose (3 mL; Methocult H4230) was added to 15 mL 
tubes. Transfected cells were resuspended to eliminate clumping and then added in a 1:10 
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(v/v) ratio to the methylcellulose. Tubes were tightly capped, and the mixtures were gently 
inverted several times. Then, 1.0 mL of the mix was dispensed into 24-well plates in 
triplicate. Plates were placed in a humidified incubator at 37°C in 5% CO2 for 7 days and 
then p-iodonitrotetrazolium violet was added for 24 hours for staining. Colonies were 
visualized using the AlphaImager system (ProteinSimple, San Jose, CA). 
Cell viability assay – Cell viability was evaluated by the CellTiter 96 AQueous One Solution 
Cell Proliferation Assay (MTS) kit (Promega). Cells were seeded in 96-well plates at a 
concentration of 10,000 cells/well in 100 μL of RPMI medium supplemented with 10% FBS. 
MTS reagent (20 μL) was added and then incubated at 37°C in a humidified chamber 
containing 5% CO2 in air for approximately 4 hours. OD measurements were obtained by 
using an ELISA plate reader. 
BrdU assay – Cell proliferation was measured by using the 5-bromo-2′-deoxyuridine (BrdU) 
assay kit (ExAlpha, Shirley, MA). Briefly, 2 × 105 cells/mL were plated into a 96-well plate. 
The BrdU label (1:500 dilution) was added, and the plate was incubated at 37°C for 24 h. 
Cells were fixed for 30 min at room temperature. The anti-BrdU antibody was added for 1 h 
after washing, followed by peroxidase goat anti-mouse IgG conjugate (1:2000 dilution) for 
30 min. Thereafter, the 3,3’,5,5’-tetramethylbenzidine peroxidase substrate was added to the 
cells and the plate incubated for 30 min at room temperature in the dark. The acid Stop 
Solution was then added and the plate was read at 450 nm by using an ELISA plate reader. 
Protein extraction from FFPE tissues – Proteins were recovered from these sections by 
using the Qiagen Qproteome FFPE Tissue Kit (Catalog # 37623). Briefly, 2 µM tissue 
sections were subjected to the following sequence of deparaffinization conditions: (1) xylene 
(2 × 5 min); (2) 100% ethanol (3 × 5 min); (3) 95% ethanol (3 × 5 min); and (4) 80% ethanol 
(3 × 5 min). Areas of interest were excised from the slide with a needle and transferred to a 
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1.5 mL collection tube. The supplied Extraction Buffer EXB Plus without β-mercaptoethanol 
was provided with the kit. For each extraction procedure, 6 μL of β-mercaptoethanol was 
first added to 94 μL of Extraction Buffer EXB Plus to obtain a working solution. Extraction 
Buffer EXB Plus supplemented with β-mercaptoethanol (100 µL) was added into the tube 
containing the excised tissue and mixed by vortexing. Each tube was sealed with a Collection 
Tube Sealing Clip (supplied) and incubated on ice for 5 min, then mixed again by vortexing. 
The samples were incubated on a heating block at 100°C for 20 min, and then incubated in an 
oven with rotators at 80°C for 2 h with agitation at 750 rpm. Thereafter, the tubes were held 
at 4°C for 1 min and the Collection Tube Sealing Clips were removed. The samples were 
subjected to centrifugation for 15 min at 14,000 × g at 4°C. The supernatant containing the 
extracted proteins was transferred to a new 1.5 mL tube. For quantification of protein yield, 
the Bio-Rad assay was used. 
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3.5.2.2. Results 
SUMOylation pathway is upregulated in NPM-ALK+ ALCL cells: SUMOylation of IGF-IR 
has been previously characterized in other types of cancers. In addition, we found 
SUMOylation of IGF-IR in NPM-ALK+ ALCL cells (Supplemental Figures), which 
supports previously published literature [238, 242-244]. Nonetheless, we decided to focus on 
whether SUMOylation also contributes to NPM-ALK protein stability, which has not been 
previously studied. To determine whether there are SUMO consensus motifs located within 
the NPM-ALK amino acid sequence, we searched the online algorithm SUMOPlot and 
identified several potential SUMO consensus motifs (Figure 25). Screening of the 5 NPM-
ALK+ ALCL cell lines relative to normal human T lymphocytes revealed Ubc9 and SUMO-1 
to be moderately overexpressed in 3/5 cell lines, whereas SUMO-2/3 demonstrated 
significant overexpression in all cell lines. In contrast, SENP1 protein was substantially 
decreased in all cell lines, suggesting that the SUMOylation pathway is deregulated in NPM-
ALK+ ALCL cells (Figure 26A). A similar pattern was observed in patient samples extracted 
from FFPE lymphoma tumor sections (Figure 26B). 
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FIGURE 25. SUMO consensus motifs within NPM-ALK amino acid sequence. The 
online software SUMOplot revealed several SUMO consensus motifs within the NPM-ALK 
amino acid sequence, two of which appeared with the highest probability of conjugation with 
the SUMO proteins (>0.80). Red: motifs with high probability; Green: motifs with low 
probability; Blue: overlapping motifs. 
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FIGURE 26. SUMO is upregulated in NPM-ALK+ ALCL. (A) Upper panel; screening of 
the NPM-ALK+ ALCL cells lines Karpas 299, SR-786, DEL, SUP-M2, and SU-DHL-1 by 
Western blotting revealed overexpression of Ubc9 and SUMO-1 in the majority of the cell 
lines (4/5 and 3/5 cell lines, respectively) relative to normal T lymphocytes (TL). SUMO-2/3 
was upregulated in the lymphoma cell lines, relative to TL. In contrast, SENP1 protease was 
decreased in the lymphoma cell lines compared to TL. β-actin was used as a loading control. 
Jurkat and 786-O cells were used as positive and negative controls, respectively. Lower 
panel; densitometry of SUMO proteins relative to β-actin is shown. (B) Upper panel; 
Western blot performed on protein extracted from FFPE tissue sections of patient specimens 
(1-15) revealed a similar pattern of expression: Ubc9 and SUMO-1 was overexpressed in 
7/15 and 9/15 patients, whereas SUMO-2/3 was overexpressed in all patients. In contrast, 
SENP1 was decreased in 13/15 patients. β-actin was used as loading control. Lower panel; 
densitometry of SUMO proteins relative to β-actin is shown. Variability in β-actin levels was 
due to the poor quality of some of the FFPE tumor sections.   
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SUMO proteins physically associate with NPM-ALK: To test whether the SUMO proteins 
can physically associate with NPM-ALK, NPM-ALK protein was immunoprecipitated in the 
Karpas 299 and SR786 cell lines and the expression of SUMO-1, SUMO-2/3, and Ubc9 was 
analyzed by Western blotting. We found that all 3 of the SUMO proteins can interact with 
NPM-ALK (Figure 27A). Furthermore, an in vitro SUMOylation assay showed that all 
SUMO modifiers are capable of SUMOylating NPM-ALK in vitro, as indicated by the 
presence of the higher molecular weight band above the baseline NPM-ALK protein levels. 
In contrast, mutated SUMO-1 and SUMO-2/3 proteins failed to SUMOylate NPM-ALK 
(Figure 27B).  
SUMOplot showed several potential SUMO consensus motifs for NPM-ALK: K24 and 
K32 were identified as having the highest probability of conjugation with SUMO proteins. 
To determine whether these potential sites are indeed capable of binding the SUMO 
modifiers, a second in vitro SUMOylation assay was performed using either the wild-type 
NPM-ALK protein or NPM-ALK protein mutated at either K24 or K32 (Figure 28A). 
SUMOylation was abolished with NPM-ALKK24R for both SUMO-1 and SUMO-3 and with 
NPM-ALKK32R for SUMO-3 only (Figure 28B). This suggests that SUMO-1 and SUMO-3 
are most likely the primary SUMO modifiers for NPM-ALK at K24 and K32. In contrast, 
mutations at K24 and K32 failed to prevent SUMO-2 from conjugating to NPM-ALK; 
SUMO-2 most likely conjugates to lysine residues found within other consensus motifs in 
NPM-ALK.  
Next, we sought to determine the effects of K24 and K32 mutations on NPM-ALK 
protein stability. Jurkat cells, which lack NPM-ALK but contain high levels of SUMO 
modifiers and Ubc9 proteins, were transfected with wild-type NPM-ALK, NPM-ALKK24R, 
NPM-ALKK32R or the NPM-ALKK24R/K32R construct, and then treated with the protein 
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synthesis inhibitor CHX for 24 or 48 h. While degradation of NPM-ALK protein was 
minimal at 24 h, CHX inhibited protein synthesis significantly in cells expressing NPM-
ALKK24R, NPM-ALKK32R, and most with the NPM-ALKK24R/K32R combination at 48 h. NPM-
ALK mutated at K24 induced an increase in degradation by 42% compared to wild type 
NPM-ALK. Similarly, NPM-ALK mutated at K32 led to an increase of its degradation level 
by 56% vs. wild type NPM-ALK. Notably, NPM-ALK dual mutation at K24 and K32 was 
associated with more pronounced increase in degradation; 67% in comparision with wild 
type NPM-ALK. In contrast, CHX did not inhibit wild-type NPM-ALK at either time point 
(Figure 29). These findings suggest that SUMOylation contributes to the stability of NPM-
ALK in NPM-ALK+ ALCL cells.   
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FIGURE 27. NPM-ALK is SUMOylated. (A) NPM-ALK was immunoprecipitated in 
Karpas 299 and SR-786 cells, and the expression of SUMO proteins was detected by 
Western blotting. These studies showed that SUMO-1 and SUMO-2/3 can interact with 
NPM-ALK, as indicated by bands present in lane 1 (NPM-ALK immunoprecipition) but not 
in lanes 2 and 3, where normal mouse IgG was immunoprecipitated or beads alone were used 
in the IP reaction, respectively. (B) Upper panel; NPM-ALK recombinant protein was 
created using the TnT coupled rabbit reticulocyte kit. Western blotting was performed to test 
the expression of the NPM-ALK recombinant protein (entire membrane shown): no 
expression of NPM-ALK in rabbit reticuloycte lysate only (lane 1), positive band 
corresponding to NPM-ALK in the NPM-ALK recombinant protein at 80 kDa (lane 2), and 
in the positive control Karpas 299 cell line (lane 3). Lower panel; recombinant NPM-ALK 
protein was subjected to in vitro SUMOylation assay. Presence of a band with a molecular 
weight that is ~20 kDa higher than baseline NPM-ALK molecular weight was detected in 
lanes incubated with wild type SUMO-1 (lane 1), SUMO-2 (lane 3), or SUMO-3 (lane 5); 
incubation with mutated SUMO forms (lanes 2, 4, and 6) did not show higher molecular 
weight band.   
 
 
 
 
 
 
 
 
 
169 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. 
B. 
170 
 
 
 
 
 
 
 
 
 
FIGURE 28. NPM-ALK is SUMOylated at Lys24 and Lys32. (A) Mutated NPM-ALK 
recombinant proteins (NPM-ALKK24R and NPM-ALKK32R) were created using the TnT 
coupled rabbit reticulocyte kit. Western blotting was performed to test NPM-ALK protein 
expression of recombinant proteins: wild-type (WT) NPM-ALK recombinant protein (lane 
1), NPM-ALKK24R recombinant protein (lane 2), and NPM-ALKK32R recombinant protein 
(lane 3). (B) Wild type and mutated recombinant NPM-ALK proteins were subjected to an in 
vitro SUMOylation assay. SUMOylation was abolished with the K24R mutation for SUMO-
1 and SUMO-3 and with the K32R mutation for SUMO-3. These two mutations failed to 
deSUMOylate SUMO-2. 
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FIGURE 29. SUMOylation promotes the stability of NPM-ALK protein. Upper panel; 
Jurkat cells were transfected with wild type NPM-ALK, NPM-ALKK24R, NPM-ALKK32R or 
NPM-ALKK24R/K32R for 48 h and then treated with the protein synthesis inhibitor 
cyclohexamide (CHX) for an additional 0, 24, or 48 h. NPM-ALKK24R and NPM-ALKK32R 
substantially decreased NPM-ALK protein expression at 48 h (42% and 50% protein 
reduction, respectively), which was further enhanced with NPM-ALKK24R/K32R (67% protein 
reduction). In contrast, wild type NPM-ALK protein expression did not decrease even after 
48 h. Lower panel; densitometry of NPM-ALK compared to β-actin. β-actin loading was 
unequal due to limited amount of protein available in some samples for Western blot after 
prolonged transfection.  
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Abolishment of SUMOylation prevents nuclear NPM-ALK accumulation in NPM-ALK+ 
ALCL cells: It is well established that NPM-ALK gains the ability to translocate to the 
nucleus through the process of heterodimerization between wild type NPM and NPM-ALK 
[50]. Whether other unidentified factors contribute to this phenomenon remain unclear. 
SUMOylation has been shown to play important roles in the translocation of target proteins 
into the nucleus [233]. We set to study whether SUMOylation contributes to the translocation 
of NPM-ALK and its accumulation in the nucleus. To elucidate whether there is abundance 
of NPM-ALK inside the nucleus in NPM-ALK+ ALCL cells, we fractionated Karpas 299 and 
SR-786 (2 cell lines showing low expression levels of endogenous SENP1, but higher 
expression of SUMO modifiers). As previously described [47], there was significantly higher 
expression of NPM-ALK in the nuclear extracts than in the cytoplasmic extracts, as well as 
higher expression of SUMO proteins in the nucleus (Figure 30). The strong presence of 
NPM-ALK inside the nucleus may be due to the enhanced SUMOylation process in NPM-
ALK+ ALCL cells. To further investigate this interesting observation, Karpas 299 and SR-
786 cells were transfected with SENP1, one of the proteases responsible for removing the 
SUMO modifier from the target and thereby destabilizing the target, and cell fractionation 
was performed again. Consistent with previous studies [245, 246], we found that SENP1 is 
able to rapidly shuttle between the nucleus and cytoplasm in NPM-ALK+ ALCL cells 
(Figure 31; upper panel). Importantly, SENP1 decreased the expression of SUMO proteins 
in the nucleus. This decrease was associated with reduction of nuclear NPM-ALK levels in 
both cell lines. This event further led to a decrease in the cytoplasmic expression of NPM-
ALK, suggesting that SUMOylation contributes to the accumulation of NPM-ALK in the 
nucleus in NPM-ALK+ ALCL cells, which appears to hinder its export from the nucleus to 
the cytoplasm (Figure 31; lower panel). 
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FIGURE 30. NPM-ALK is predominantly expressed in the nucleus. Cell fractionation 
experiments in Karpas 299 and SR-786 revealed higher expression of NPM-ALK protein in 
the nucleus, relative to cytoplasm. In addition, SUMO proteins were mainly nuclear. Lamin 
A/C and β-actin were used as nuclear and cytoplasmic loading controls, respectively. 
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FIGURE 31. SENP1 decreases NPM-ALK expression. Upper panel; Karpas 299 and SR-
786 cells were transfected with EV or SENP1 expression plasmid. Then, 
immunofluorescence staining for the detection of SENP1 was performed at various time 
points. Up to 1 h, SENP1 was predominantly localized in the cytoplasm, and then it became 
predominantly nuclear at 3 to 6 h. At 24 h most of SENP1 appeared to be shuttling back to 
the cytoplasm, whereas at 48 h strong levels of expression of SENP1 were detected in the 
nucleus and cytoplasm. Lower panel; cellular fractionation shows that transfection of SENP1 
in Karpas 299 and SR-786 cells resulted in decreased expression of SUMO-1 and SUMO-2/3 
proteins at 48 h after transfection. The decrease in SUMO was associated with decreased 
NPM-ALK protein expression in the nucleus and cytoplasm at 48 h after transfection. The 
decrease in NPM-ALK levels appears to be more pronounced in the nucleus. Lamin A/C and 
β-actin were used as nuclear and cytoplasmic loading controls, respectively. 
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Downregulation of the SUMOylation pathway decreases cell proliferation, viability, and 
colony formation potential in NPM-ALK+ ALCL cells, and enhances the ubiquitination of 
NPM-ALK: To test the biological impact of overexpressing SENP1, we transfected DEL, 
SR-786, and SU-DHL-1 (3 cell lines showing low expression levels of endogenous SENP1), 
with either empty vector or SENP1 full-length expression plasmid for 48 h. SENP1 
significantly decreased cell viability, cell proliferation, and colony formation potential of 
lymphoma cells (Figure 32A, 32B, 32C). In addition, SENP1 increased the covalent 
modification of ubiquitin on NPM-ALK, suggesting that deSUMOylation by SENP1 
switches target proteins to the ubiquitination pathway (Figure 32D). 
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FIGURE 32. SENP1 decreases cell viability, proliferation, and colony formation 
potential in NPM-ALK+ ALCL cells. (A) Transfection of DEL, SR-786, and SU-DHL-1 
cells with EV or the SENP1 protease expression plasmid in resulted in a significant decrease 
in their viability after 48 h. (B) In addition, SENP1 decreased significantly the proliferation 
of these cells, and (C) decreased their colony formation potential. Numbers of colonies are 
shown on the left and representative images are shown on the right (*: p<0.05; **: p<0.001). 
(D) SENP1 decreased NPM-ALK expression, which was simultaneously associated with 
increased binding between ubiquitin and NPM-ALK, suggesting that deSUMOylation directs 
NPM-ALK to the ubiquitination pathway.  
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FIGURE 33. Schematic model illustrating the SUMOylation of NPM-ALK. We have 
identified that SUMOylation plays an important role in stabilizing NPM-ALK protein. NPM-
ALK is able to form heterodimers with wild type NPM, which facilitates shuttling of NPM-
ALK between the cytoplasm and nucleus. Left panel; SUMOylation of NPM-ALK at Lys24/32 
results in its stabilization in the nucleus, which leads to efficient shuttling of NPM-ALK into 
the cytoplasm. Right panel; in the presence of deSUMOylating protease SENP1, the SUMO 
modifier is removed from the NPM-ALK heterodimer in the nucleus which allows the 
binding of ubiquitin, which mediates its degradation via 26s proteasome, as has been 
previously demonstrated [247]. Degradation of the NPM-ALK heterodimer in the nucleus 
decreases its nuclear accumulation and subsequently reduces its translocation and expression 
in the cytoplasmic compartment.   
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3.5.3. Aberrant Posttranslational Mechanisms: IGF-I 
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3.5.3.1. Materials and Methods 
Cell lines – Three NPM-ALK+ ALCL cell lines were used in this study: DEL, SUP-M2, and 
SR-786. The cell lines were maintained in RPMI 1640 medium (HyClone, South Logan, 
Utah) supplemented with 10% FBS (Sigma, St. Louis, MO), glutamine (2 mM), penicillin 
(100 U/ml), and streptomycin (100 μg/ml) at 37°C in a humidified 5% CO2 in air chamber.  
Transfection – Transfection of the cells with scrambled or NPM-ALK siRNA (Dharmacon) 
was performed by electroporation using Amaxa 4D nucleofection system in 100 µL cuvettes 
(Lonza; Solution SF, Program CA-150) and, thereafter, cells were incubated for 48 h.  
Western blotting – Western blotting was used to analyze the expression of IGF-I and NPM-
ALK proteins. Cells were collected and lysed using lysis buffer containing 25 mM HEPES 
(pH 7.7), 400 mM NaCl, 1.5 mM MgCl2, 2 mM EDTA, 0.5% Triton X-100, 0.1 mM PMSF, 
2 mM DTT, phosphatase inhibitor (20 mM B-GP, 1 mM Na3VO4, Roche), and protease 
inhibitor cocktails (10 μg/ml leupeptine, 2 μg/ml pepstatin, 50 μg/ml antipain, 1x 
benzamidine, 2 μg/ml chymostatin; Roche). Concentrations were measured using Bio-Rad 
protein assay and OD values were obtained using an ELISA plate reader (Bio-Tek 
Instruments, Winooski, VT). Proteins (50 μg) were electrophoresed on 8% SDS-PAGE. The 
proteins were transferred to PVDF membranes and probed with specific primary antibodies 
and then with appropriate horseradish peroxidase-conjugated secondary antibodies (Santa 
Cruz; and GE Healthcare, Cardiff, UK). Proteins were detected using chemiluminescence-
based kit (Amersham Life Sciences, Arlington Heights, IL).  
Antibodies – Antibodies used were ALK (M719501-2; Dako, Carpinteria, CA); IGF-I (05-
172; Millipore, Billerica, MA); and β-actin (A-5316; Sigma). 
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ELISA – To measure the levels of IGF-I secreted in cell culture supernatant, a standard 
ELISA-based approach was used. Briefly, cells were transfected with scrambled or ALK 
siRNA for 48 h. Thereafter, cells were switched to serum free media for 24 h. The medium 
was then collected and concentrated using Amicon Ultra-15 centrifugal tubes (UFC900308; 
Millipore). ELISA assay was performed using the IGF-I cytokine kit (R&D Systems). 
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3.5.3.2. Results 
NPM-ALK does not affect the levels of expression of IGF-IR or IGF-I: Previous studies in 
our lab demonstrated that the levels of IGF-IR as well as endogenous IGF-I and secreted 
IGF-I were increased in NPM-ALK+ ALCL [128] (Figure 34). To explore whether NPM-
ALK plays a role in the increased levels of expression of IGF-IR and IGF-I, we transfected 
SR-786, DEL, and SU-DHL-1 cells with ALK siRNA for extended periods of time. Although 
siRNA effectively decreased NPM-ALK levels, the levels of IGF-IR protein (Figure 35A) 
and mRNA (Figure 35B) remained unchanged. In addition, decreased levels of NPM-ALK 
by siRNA were not associated with decreased levels of endogenous pro-IGF-I or IGF-I 
proteins (Figure 35A) or levels of secreted IGF-I (Figure 35C). 
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FIGURE 34. Expression of IGF-I in NPM-ALK+ ALCL cell lines. (A) Western blotting 
shows overexpression of endogenous IGF-I in 4/5 NPM-ALK+ ALCL cell lines. EJM 
(plasma cell myeloma) and RSC96 (Schwann cells) cell lines were used as positive and 
negative controls, respectively. (B) RT-PCR shows the presence of IGF-I mRNA in SUP-
M2, SR-786, DEL (low level), and EJM, and its absence in Karpas 299, SU-DHL-1, and 
RSC96. (C) SUP-M2, SR-786, and DEL cell lines demonstrate the presence of secreted IGF-
I in cell culture supernatants. The EJM cell line was included because it expresses IGF-I 
protein and mRNA. IGF-I is almost undetectable in cell culture supernatants from Karpas 
299 and RSC96 cells. The experiment was repeated 3 times, and the results shown are the 
mean ± SD. P<0.01 for SUP-M2, SR-786, and DEL compared with other cell lines. Adapted 
by direct permission from BLOOD (Shi P, Lai R, Lin Q, Iqbal AS, Young LC, Kwak 
LW, Ford RJ, Amin HM. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to 
induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells. Blood. 2009 Jul 
9;114(2):360-70.), copyright 2009. 
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FIGURE 35. NPM-ALK does not affect the levels of expression of IGF-IR and IGF-I. 
(A) Western blotting shows that at 48 h, downregulation of NPM-ALK by ALK siRNA was 
not associated with decreased expression of IGF-IR, pro-IGF-I or IGF-I proteins in SUP-M2, 
SR-786, and DEL cell lines. Analysis of IGF-IR levels after transfection of the cells with 
ALK siRNA was performed at extended time points (12, 24, 48, 72, and 96 h), and also in 
other cell lines including Karpas 299 and SU-DHL-1, with similar results (data not shown). 
β-Actin shows equal protein loading. (B) Downregulation of NPM-ALK in the 3 cell lines 
did not decrease the levels of IGF-IR mRNA. The example shown is at 48 h after transfection 
of the cells with ALK siRNA. The results are shown as means ± SE of 4 consistent 
experiments. In addition, analysis of IGF-IR mRNA was performed at other time points and 
cell lines as described in Fig. 6A. Changes in IGF-IR mRNA levels were not detected at any 
time point (data not shown). (C) An ELISA assay showing that specific downregulation of 
NPM-ALK did not decrease the levels of secreted IGF-I in the 3 NPM-ALK+ ALCL cell 
lines SUP-M2, SR-786, and DEL. The results represent means ± SE of 3 experiments. 
 
 
 
 
 
 
192 
 
3.6. Discussion for Aim 3 
In this aim we show that posttranslational defects exist and contribute to the pathogenesis of 
NPM-ALK+ ALCL. Firstly, we found that there was an overall upregulation of SUMO 
proteins expression in 5 NPM-ALK+ ALCL cell lines as well as in ALK+ ALCL patients’ 
specimens compared to normal human T lymphocytes. Specifically, the expression of 
SUMO-2/3 was increased in the lymphoma cell lines and patients’ tumor samples. In 
addition, the expression of SUMO-1 was increased in majority of cell lines and patients’ 
tumors. In contrast, expression of the SUMOylation inhibitor SENP1 was decreased in the 
cell lines and patients’ tumors than the T lymphocytes. We also showed that NPM-ALK is 
SUMOylated via covalent modification by SUMO proteins, which protects it from 
degradation. In support of this idea, inhibition of SUMOylation through restoration of the 
deSUMOylating SENP1 protease decreased SUMO protein expression, and induced a 
substantial decrease in NPM-ALK protein expression in the cytoplasm and nucleus. Our data 
provide strong evidence that SUMOylation contributes to the stability of NPM-ALK protein 
in NPM-ALK+ ALCL. Downregulation of SUMOylation by SENP1 resulted in decreased 
viability, proliferation, and colony formation potential of the lymphoma cells, suggesting that 
disruption of the SUMOylation pathway induces tumor-suppressing effects in this type of 
cancer. Secondly, we found that NPM-ALK does not regulate the expression of IGF-I and 
IGF-IR proteins. IGF-I is the main ligand for IGF-IR and causes posttranslational 
modifications of IGF-IR thorough phosphorylation and subsequent activation. 
SUMOylation is a dynamic process that induces major impact on target proteins 
including changing their stability, localization, and activity. Whereas SUMOylation is 
important for physiological processes, it is deregulated in cancer cells [248]. In line with this 
possibility, our data showed that the SUMO proteins were aberrantly overexpressed and 
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SENP1 protease was decreased in NPM-ALK+ ALCL compared to normal T lymphocytes. It 
has been established that an important outcome of SUMOylation is the maintenance of 
protein stability by protecting targets from proteosomal degradation [237, 249-254]. We were 
able to identify K24 and K32 within the NPM domain as targets for SUMOylation in NPM-
ALK oncogenic protein. Indeed, all SUMO modifiers were capable of modifying NPM-ALK 
at these lysine residues. Mutations induced at K24 and K32 in the SUMO consensus motifs 
of NPM-ALK prevented SUMO-1 and SUMO-3 from modifying NPM-ALK as well as 
resulted in significant degradation of NPM-ALK protein, testifying to the stabilizing effect of 
SUMOylation on NPM-ALK. Moreover, both SUMO-1 and SUMO-3 were required to 
induce substantial degradation, in contrast to the level of degradation achieved individually 
by these modifiers. This observation suggests that this dual mutation that prevents both 
SUMO modifiers from modifying NPM-ALK is required for NPM-ALK to undergo 
degradation. Also, the finding that NPM-ALK double mutant was not degraded entirely 
because NPM-ALK double mutant maintained its ability to bind with SUMO-2. Therefore, 
we cannot completely exclude that other SUMO binding motifs may encompass potential 
binding sites for other SUMO modifiers, such as SUMO-2, which also conveys protection of 
NPM-ALK from degradation.  
We elected to study SENP1 because of its ability to deSUMOylate all 3 SUMO modifiers, 
unlike other SENPs that have preferential deSUMOylation activities [255-257]. SENPs have 
2 primary functions: 1) the conversion of SUMO precursors to mature SUMO via removal of 
a portion of the C-terminus; and 2) the removal of SUMO from target proteins. These SENP-
controlled processes contribute to the dynamic nature of SUMOylation. In fact, using 
immunofluorescence staining we found that SENP1 moves from the nucleus to cytoplasm in 
only 15 min. This is in line with previous studies which showed the very short time required 
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by SENP1 to shuttle between the nucleus and cytoplasm, and how this mechanism allows 
SENP1 to elicit different functions in multiple compartments within the cell [245, 246, 258-
260]. It has been shown that amino acid residues located at positions 171-177, within the N-
terminal region of SENP1, are essential for SENP1 nuclear targeting. This was directly 
demonstrated through substitution experiments in which the basic residues within this short 
motif hindered significantly SENP1 nuclear accumulation and restricted its expression in the 
cytoplasm. Although this motif is does not fit the classical consensus NLS sequence, these 
results provided evidence that this region can be classified as a nonconesus NLS and more 
importantly, is required for SENP1 nuclear import as well as modulating SENP1 activity 
[260]. Reestablishment of SENP1 in NPM-ALK+ ALCL cells resulted in increased 
deSUMOylation activity, which was associated with decreased expression of the SUMO 
proteins and NPM-ALK protein levels. As a result, downregulation of the SUMOylation 
pathway by SENP1 decreased cell viability, proliferation, and colony formation.  
NPM is inherently capable of moving between the nucleus and cytoplasm [50]. The 
nuclear localization signal (NLS) of NPM is present within its C-terminus [17]. Nonetheless, 
the NPM segment that associates with ALK to form the NPM-ALK chimera is derived from 
the more proximal N-terminus that lacks the NLS, explaining why NPM-ALK lacks the 
ability to move to the nucleus [50]. However, nuclear translocation of NPM-ALK still occurs 
primarily because of the formation of heterodimers between wild type NPM and NPM-ALK. 
Our experiments showed that the expression of NPM-ALK in the nucleus, as well as 
cytoplasm, was significantly reduced after SENP1 transfection. This may be explained by: 1) 
SENP1 activity increased in the nucleus upon transfection with SENP1 plasmid, allowing for 
deSUMOylation to simultaneously increase in the nucleus leading to NPM-ALK 
destabilization; and 2) SENP1-mediated degradation of NPM-ALK heterodimers in the 
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nucleus makes them less available for nuclear export into the cytoplasm. Our results suggest 
a model in which SUMOylation provides stabilization of NPM-ALK protein, which appears 
to further sustain NPM-ALK expression and accumulation in the nucleus and cytoplasm.  
SUMOylation can lead to alteration of protein surfaces, which greatly affects interactions 
of the target protein with other molecules that can also indirectly influence the target’s 
stability. For instance, it has been shown that SUMOylation can promote protein-protein 
interactions [261-265]; however, in many cases, SUMOylation leads to protein-protein 
interaction interference [266-268]. For instance, SUMOylated E2-25K prevents interaction 
with the ubiquitin E1 activating enzyme [268]. Similarly, there have been studies indicating 
that disruption of SUMOylation reveals ubiquitin-acceptor lysine residues located elsewhere 
in the protein, whose subsequent ubiquitination will promote protein degradation [250, 251, 
269]. In NPM-ALK+ ALCL cells, deSUMOylation of NPM-ALK by SENP1 led to an 
increase in the association of ubiquitin and NPM-ALK, suggesting that SUMOylation may 
be able to prevent NPM-ALK from entering the proteosomal degradation pathway. NPM-
ALK has been previously shown to be ubiquitinated through hsp70-mediated proteosomal 
degradation, although a specific lysine residue for ubiquitination has not been identified 
[247]. Our data suggest that transfection of SENP1 resulted in the removal of the SUMO 
modifiers, which unmasked lysine residues in NPM-ALK and made them available for 
modification by ubiquitin for proteosomal degradation. To this end, there is no direct 
evidence that ubiquitin binds to and modifies K24 and K32 that we identified as sites of 
modification by SUMO proteins, however, we cannot completely rule out that at least one of 
these residues possess ability to modified by ubiquitin. Indeed, entering the amino acid 
sequence in a web-based ubiquitination prediction search algorithm (UbPred; 
www.ubpred.org) revealed that NPM-ALK contains potential ubiquitination site at K32  
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(intermediate statistical confidence of p=0.71). Importantly, we have provided evidence that 
ubiquitin and NPM-ALK are physically associated after SENP1 transfection, and it is likely 
that deSUMOyaltion triggers the ubiquitination pathway.  
It has been previously shown that IGF-IR undergoes ligand-dependent SUMOylation, 
which appears to be a prerequisite for its nuclear translocation [238, 270]. It has also been 
shown that this nuclear translocation requires the phosphorylation of IGF-IR [271]. In our 
lymphoma cells, IGF-I stimulation induced nuclear expression of pIGF-IR (Figure S7). We 
also determined that IGF-IR is capable of interacting with SUMO proteins in NPM-ALK+ 
ALCL cells (Figure S8), and that transfection of SENP1 leads to decreased expression of 
IGF-IR in the cytoplasm as well as decreased pIGF-IR nuclear expression (Figure S9). We 
have recently demonstrated that the physical association between NPM-ALK and IGF-IR 
proteins enhances the stability of NPM-ALK [127]. In support of this idea, specific targeting 
of IGF-IR by siRNA significantly decreased NPM-ALK protein levels, attesting to the 
contribution of IGF-IR to maintaining NPM-ALK protein stability [127]. In contrast, NPM-
ALK has no effect on IGF-IR protein stability (Figure 35 in section 3.5.3.2.). Therefore, it 
can be postulated that deSUMOylation of IGF-IR by SENP1 perhaps causes interference of 
its association with NPM-ALK, which would lead to NPM-ALK protein instability. 
However, futher studies need to be performed to establish such a claim. Jointly, these 
alternative mechanisms also provide novel evidence in which SUMOylation contributes to 
NPM-ALK protein stability.  
It was previously demonstrated that chimeric oncogenes such as the Ewing sarcoma 
oncogenic fusion proteins induce the expression of IGF-I, the primary ligand of IGF-IR, 
which enhances the phosphorylation/activation of IGF-IR though dimerization [68]. In this 
aim, we tested whether NPM-ALK induces effects similar to Ewing sarcoma fusion proteins 
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on IGF-I levels. Specific abrogation of NPM-ALK by siRNA failed to reduce pro-IGF-I or 
IGF-I protein levels, which suggests that NPM-ALK lacks ability to upregulate IGF-I 
expression, and therefore does not possess a posttranslational effect on IGF-IR, at least from 
this aspect.  
In this aim, we identified for the first time that SUMOylation contributes to maintaining 
NPM-ALK protein stability, and hinders its proteosomal degradation. In contrast, SENP1-
mediated disruption of SUMOylation causes degradation of NPM-ALK, which thereby 
reduces the oncogenic potential of this oncogenic protein. At the other hand, we found that 
NPM-ALK does not regulate IGF-I-mediated posttranslational modulation of IGF-IR. 
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3.6.1. Supplemental 
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FIGURE S7. IGF-IR is SUMOylated. IGF-IR was immunoprecipitated in Karpas 299 and 
SR-786 cells, and expression of SUMO proteins was evaluated by Western blotting.  These 
studies revealed SUMO-1 and SUMO-2/3 are associated with IGF-IR, as indicated by bands 
present in lane 1 (IGF-IR immunoprecipitation) and not in lanes 2 and 3, where mouse IgG 
was immunoprecipitated or beads alone, respectively.  
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FIGURE S8. IGF-IR and pIGF-IR are expressed in the cytoplasm, whereas pIGF-IR is 
expressed in the cytoplasm and nucleus after IGF-I stimulation. Cell fractionation 
experiments in Karpas 299 and SR-786 cells reveals expression of IGF-IR protein in the 
cytoplasm, with no expression in the nucleus with or without IGF-I stimulation. In contrast, 
pIGF-IR is predominantly located in the cytoplasm under non-stimulated conditions. After 
IGF-I stimulation, however, pIGF-IR is expressed in the cytoplasm and nucleus. In addition, 
SUMO proteins predominantly showed nuclear expression. Lamin A/C and β-actin were used 
as nuclear and cytoplasmic loading controls, respectively.  
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FIGURE S9. SENP1 decreases IGF-IR nuclear and cytoplasmic expression. Transfection 
of empty vector or SENP1 expression plasmid in Karpas 299 and SR-786 cells decreased the 
expression of SUMO proteins after 48 h. Subsequently, IGF-IR and pIGF-IR expression 
decreased in the cytoplasm. In addition, pIGF-IR expression decreased significantly in the 
nucleus as well. Lamin A/C and β-actin were used as nuclear and cytoplasmic loading 
controls, respectively. 
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In this work, we identified novel dregulated mechanisms that determine the pathogenic 
expression of IGF-IR and NPM-ALK, two potent oncogenic proteins that play important 
roles in the survival of NPM-ALK+ ALCL; an aggressive type of cancer that predominantly 
affects children and young adults. 
At the transcriptional level, we found that two transcription factors, namely Ik-1 and 
MZF1, are markedly decreased in NPM-ALK+ ALCL cell lines and patients lymphoma 
tissues. Importantly, we provided evidence that Ik-1 and MZF1 negatively regulate the IGF-
IR gene promoter, which leads to a significant decrease in the expression of IGF-IR mRNA 
and protein. We also used FISH analysis and found no evidence to support amplification of 
the IGF-IR gene in this lymphoma. It is important to note that although we performed FISH 
analysis in 5 established NPM-ALK+ ALCL cell lines and obtained consistent findings, it 
cannot be ruled out that if a large cohort of patient samples were analyzed, rare cases with 
IGF-IR gene amplification might have been discovered. 
At the posttranscriptional level, we found that the time required for the decay of IGF-IR 
mRNA is significantly longer in the NPM-ALK+ ALCL cell lines than normal human T 
lymphocytes, which supports the idea that more IGF-IR mRNA transcripts are available for 
translation into IGF-IR protein, resulting in the overexpression of IGF-IR in this lymphoma. 
Also at the posttranscriptional levels, we showed that miR-30a and miR-30d are substantially 
decreased in NPM-ALK+ ALCL cell lines and human lymphoma tissues. Importantly, we 
demonstrated that miR-30a and miR-30d are capable of binding and inhibiting the IGF-IR-
3’UTR to decrease IGF-IR protein expression.  
At the posttranslational level, we identified for the first time that SUMOylation, a 
posttranslational modification mechanism, is deregulated in NPM-ALK+ ALCL. In this 
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regard, SUMOylation appears to sustain the stability of NPM-ALK protein and facilitates its 
nuclear and cytoplasmic accumulation. Although it has been demonstrated in other types of 
cancer, herein our data support that SUMOylation sustains IGF-IR protein stability also in 
NPM-ALK+ ALCL. On the other hand, there was no evidence to support that NPM-ALK is 
involved in the regulation of IGF-I expression, and hence doesn’t impact IGF-I-mediated 
phosphorylation/activation of IGF-IR.  
Intriguingly, our data support that increased expression of IGF-IR protein and decreased 
expression of miR-30a and miR-30d appear not to be directly resulting from the expression 
of NPM-ALK. Although NPM-ALK has significant oncogenic potential and its expression is 
considered the mainstay feature in NPM-ALK+ ALCL, most likely NPM-ALK is not the only 
factor that governs the clinicopathological and the immunophenotypic features of NPM-
ALK+ ALCL as known in human patients. Evidence suggests the oncogenic effects of NPM-
ALK stem from its ability to collaborate with other survival-promoting proteins within the 
lymphoma cells. Although the lymphomagenic potential of NPM-ALK has been 
demonstrated in chimeric as well as transgenic (Tg) mice models, mice typically developed 
significant B-cell lymphoma and plasma cell tumors with a smaller proportion developing T-
cell neoplasms. [272]. For instance, it has been shown that in an NPM-ALK Tg mouse model 
under the control of a murine CD4 promoter, mice developed lymphoma tumors of B-cell 
origin [56]. In addition, the lymphoma tumors found in some these mice were exclusively 
plasmablastic [56]. In another model, NPM-ALK transgenic mice under the control of the 
Vav-promoter also gave rise almost exclusively to tumors of a B-cell origin [273]. This is 
particularly interesting because the Vav-promoter is directly involved in the development and 
expression of all the types of hematopoietic lineages. Furthermore, in a transgenic mouse 
model in which NPM-ALK was under the control of the lck promoter, the developed tumors 
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were of immature T lymphoblastic type [274]. While the lck promoter model is more suitable 
for studying T-cell lineage tumors (lck promoter is active in T cells), the authors concluded 
that this animal model does not reflect the classic human NPM-ALK+ ALCL development. 
Lastly, in a chimeric animal model, irradiated mice transplanted with bone marrow cells 
infected with a retroviral construct, pSRαMSVtkneo–NPM-ALK that contains the 
human NPM-ALK cDNA, developed lymphomas that were composed of immunoblast-like B-
cells [53]. Collectively, these observations indicate that NPM-ALK may be inclined to 
transform B-cell lineages in mice, in contrast to tumors of T-cell origin such as those of 
human NPM-ALK+ ALCL [275]. More importantly, these data are inline with our results that 
failed to show that NPM-ALK, despite being a very important survival molecule in NPM-
ALK+ T-cell lymphoma, does not necessarily regulate all factors contributing to the survival 
of these cells, e.g., the increase in IGF-IR or the decrease in miR-30a/miR-30d expressions.  
The evidence provided by the animal studies supporting how NPM-ALK is very 
important for development of lymphoma tumors yet, these tumors are not necessarily similar 
to NPM-ALK+ ALCL in humans further strengthens the argument that the multilevel 
deregulation identified in our experiments carry important potential in the pathogenesis of 
this aggressive disease. However, there are limitations to in vitro studies including that this 
experimental system lacks essential components that affect the cells under physiological 
conditions such as the microenvironment that includes surrounding stromal tissue and blood 
vessels. These elements are not found in a purely in vitro system, and can influence the 
outcome of the result. In vivo experiments, although more closely related to human 
conditions, also have their limitations. While animal models do contain the 
microenvironment, they do not represent human conditions exactly. Differences in species, 
even subtly, can produce different outcomes. Therefore, perhaps the ideal way to examine if 
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truly a specific oncogenic mechanism is deregulated is by directly analyzing this mechanism 
in a large cohort of patients with correlation to clinicopathological features and response to 
therapy and survival data. In our study, we analyzed  the expression of  Ik-1, MZF1, miR-30, 
and SUMO proteins in relatively small patient populations. Although such analysis supports 
that these aberrancies indeed exist in patients, more extensive analysis in a larger cohort of 
patients is expected to help to provide concrete conclusions.   
It has been shown that NPM-ALK interacts with several molecules known to regulate 
cellular survival. In preliminary studies conducted in our lab, we found that NPM-ALK 
interacts with IGF-IR to maintain the latter’s phosphorylation status. Reciprocally, our data 
suggested that IGF-IR not only maintains NPM-ALK phosphorylation, but also sustains its 
stability. In the current study, we have further demonstrated using several experimental 
approaches in which modifications of transcriptional, posttranscriptional, and 
posttranslational pathways resulted in abrogation of IGF-IR signaling system was associated 
with a remarkable decrease in NPM-ALK protein expression attesting that IGF-IR sustains 
the stability of NPM-ALK. At least from these data, IGF-IR could represent a unique 
oncogenic entity in this lymphoma. 
The aberrant expression/function of key molecules at each regulatory stage, beginning at 
the “gene level” and ending at the “protein level”, allows IGF-IR to escape tight regulatory 
systems in this lymphoma; in contrast to normal human T lymphocytes, in which these 
systems keep IGF-IR expression at low physiologic levels. This observation further 
emphasizes the contributions of every single system. It also suggests that the failure of one 
mechanism to maintain overexpression of IGF-IR might result in alternative pathways that 
rescue IGF-IR expression and maintain it at very high levels for it to continue to elicit 
oncogenic effects. Targeting IGF-IR not only provides opportunities to decrease the 
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oncogenic effects mediated by IGF-IR alone, but could also affect significantly the 
oncogenic potential of NPM-ALK due to IGF-IR’s regulatory effects on the stability of the 
fusion protein. Exploring how these individual mechanisms are themselves deregulated could 
be an important direction for future studies (Figure 36).  
Our model supports the multifaceted nature of NPM-ALK+ lymphoma, and that 
disturbances in more than one regulatory mechanism exist, which reflects the complex 
survival network in these lymphoma cells in particular as well as in cancer cells in general. 
Even though this lymphoma is driven by a major oncogene such as NPM-ALK, our data 
strongly suggest that the regulation of the expression of IGF-I/IGF-IR molecules is largely 
independent from NPM-ALK. Despite the fact that this lymphoma, similar to few other types 
of cancer, is driven by a major oncogene, numerous epithelial, mesenchymal, neural, and 
hematological cancers are instead driven by several oncogenic molecules that work in 
harmony to promote cell survival. Notably, upregulation of IGF-IR is a common feature 
among the majority of these tumors. Thus, the findings in our lymphoma model could be 
applied to other types of cancer. In support of this idea, our data show that miR-30a and miR-
30d can negatively regulate IGF-IR posttranscriptionally; not only in NPM-ALK+ ALCL but 
also in breast and colon cancers as well. Our study also demonstrates that upregulation of 
IGF-IR gene expression results from aberrancies in transcriptional regulatory mechanisms, 
namely Ik-1 and MZF1 transcription factors, resembling what was found before with other 
transcription factors that regulate IGF-IR in epithelial and mesenchymal tumors. In a similar 
fashion, our data support that aberrant SUMOylation of IGF-IR occurs in NPM-ALK+ 
ALCL, and these findings are in line with previously established findings in other types of 
cancer where SUMOylation of IGF-IR plays important roles in their pathogenesis. 
Furthermore, our current study supports that SUMOylation plays an additional important role 
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via maintaining the stability of NPM-ALK. These observations highlight that although 
different types of cancer exhibit remarkably heterogeneous clinical and pathological features, 
certain molecular characteristics are still common among them.  
Overall, we provide novel evidence that multilevel deregulation of survival mechanisms 
contributes to the pathogenesis of NPM-ALK+ ALCL. We hope that our findings will further 
current knowledge of the pathobiology of NPM-ALK+ ALCL and provide a framework for 
the tailoring of novel therapeutic strategies to eradicate this lymphoma.  
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FIGURE 36. Mechanisms contributing to deregulated survival mechanisms in NPM-
ALK+ ALCL. Ik-1 and MZF1 expression levels are significantly decreased, preventing them 
from transcriptionally inhibiting IGF-IR gene expression and allowing IGF-IR mRNA to be 
transcribed. MiR-30a and miR-30d are markedly decreased in NPM-ALK+ ALCL. Lack of 
suppression of the IGF-IR-3’UTR by these miRs allows IGF-IR protein to stabilize. 
Furthermore, slower decay of IGF-IR mRNA increases its bioavailability for protein 
translation. Fully translated IGF-IR is further stabilized by the posttranslational modification 
SUMOylation. SUMOylated IGF-IR can indirectly stabilize NPM-ALK, which is itself is 
capable of being SUMOylated. How these mechanisms are regulated (indicated by “?”) is a 
direction of future study.   
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Future Directions 
Apart from the future studies mentioned in the individual discussion sections, identifying 
whether each of our identified mechanisms have regulatory effects on each other as well as 
determining how these aberrant mechanisms are deregulated would be worth pursuing, as 
illustrated in Figure 36. Some of the important mechanisms that require further analysis 
include: 
1. Determining whether NPM-ALK contributes to the decreased expression levels of Ik-1 
and MZF1 in these lymphoma cells. Preliminary experiment: Transfect NPM-ALK+ 
ALCL cells with scrambled siRNA or ALK siRNA, and check Ik-1 and MZF1 expression 
levels by qPCR and Western blotting.  
2. Identifying the host genes of miR-30a and miR-30d may lead to better understanding of 
how these microRNAs are deregulated, not only in NPM-ALK+ ALCL but also in any 
other type of cancer. It is possible that Ik-1 and MZF1 help support the transcription of 
miR-30 by regulating its host gene. Preliminary experiment: Identify miR-30 genes. In 
addition, overexpression of Ik-1 and MZF1 in NPM-ALK+ ALCL cells by transfection, 
and measure miR-30 expression levels by qPCR.   
3. It has been previously shown that miR-30 directly targets the SUMO conjugating enzyme 
Ubc9, and that restoration of a previously decreased miR-30 expression level inhibits 
Ubc9 expression. Exploring whether the aberrantly decreased expression of miR-30 in 
NPM-ALK+ ALCL cells contributes to upregulation of SUMOylation would also support 
IGF-IR and NPM-ALK protein stability. Preliminary experiment: Overexpress miR-30a 
and miR-30d in NPM-ALK+ ALCL cells, and measure Ubc9 and SUMO expression by 
qPCR and Western blotting.   
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